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Résumé travaux. 
Pendant mes trois ans de thèse, j’ai étudié les mécanismes de régulation génique 
impliqués dans le cancer du sein. Je me suis intéressé en particulier à la régulation 
épigénétique du gène p21 dans les cellules cancéreuses mammaires hormono-
indépendantes, ER-négatives (MDA-MB231).Nous avons démontré que l’activation du 
gène p21 dans ces cellules était p53 indépendante, stimulée en utilisant des inhibiteurs 
des histones deacétylases et contrôlée par l’acétylation du variant d’histone H2A.Z. Mes 
études ont permis la rédaction et publication d’un article (Bellucci et al., 2013 [1]).
Selon les cellules utilisées, l’expression du gène p21 peut toutefois être p53 dépendante 
ou indépendante et le mécanisme d’activation du gène p21, via les HDACi, reste peu 
compris. Par ailleurs, il a été démontré, dans autres systèmes cellulaires, que la 
régulation de p21 dépendait de la localisation du variant d’histone H2A.Z. Nous avons 
montré que dans les cellules MDA-MB231 (p53- négatives), H2A.Z est lié fortement au 
site d’initiation de la transcription du gène p21. Un traitement à la Trichostatin A (TSA), un 
inhibiteur des histone-deacétylases, augmente l’acétylation de H2A.Z favorisant ainsi 
l’expression de p21. A l’opposé, une cellule déplétée en H2A.Z ne répond plus aux 
HDACi. Nous avons démontré que la présence du variant d’histone H2A.Z dans sa forme 
acétylé était importante pour l’expression de p21. 
En utilisant comme gène modèle celui de la Cycline D1, nous avons montré que 
l’acétylation de H2A.Z joue un rôle fondamental dans la régulation de la transcription en 
présence et en absence du récepteur aux œstrogènes. De plus, nous avons identifié des 
enzymes impliqués dans l’acétylation de H2A.Z (Tip60) et dans le remodelage de la 
chromatine (Tip48), nous permettant de proposer un modèle pour l’activation de la 
transcription de ce gène. 
J’ai ainsi participé aux travaux décrits dans deux autres articles (Dalvai et al., 2012 [2] ; 
Dalvai et al., 2013 [3]). 
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Work summary. 
During my PhD, I studied the mechanisms of regulation of gene expression in breast 
cancer. In particular, I was interested in the epigenetic regulation of p21 gene expression 
in an estrogen receptor negative breast cancer cells (MDA-MB231 cells). We found that in 
these cells a TSA treatment stimulated p21 expression and increased acetylation of 
H2A.Z present at the p21 promoter. H2A.Z was strongly associated with the transcription 
start site of p21. Moreover, depleting the cellular pool of H2A.Z compromised p21 
activation and response to HDACi. Acetylation of H2A.Z rather than its association of 
regulatory element per se was important for p21 expression. My studies led to a 
publication (Bellucci et al., 2013 [1]) which shows that p21 gene activation in MDA-MB231 
cells is p53-independent and controlled by the H2A.Z histone variant and its acetylation.
Normally, activation of p21 expression can be p53-independent or dependent, according 
to the cell system used. But the mechanism behind p21 activation, via HDACi, remains 
poorly understood. Moreover, p21 regulation depends on the binding of the histone variant 
H2A.Z.  
Using the Cyclin D1 gene as a model, I also participated in a project, which shows how, in 
this case too, H2A.Z acetylation is critical for gene regulation in estrogen receptor positive 
and negative breast cancer cells. We identified the enzymes involved in H2A.Z acetylation 
(Tip60) and in chromatin remodeling (Tip48), to propose a model for transcription 
activation of this gene.  Results have been described in two other original publications 
(Dalvai et al., 2012 [2]; Dalvai et al., 2013 [2]).
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I. Epigenetics and regulation of gene expression. 
Epigenetics relate to heritable modifications and changes in chromatin composition, which 
occur without DNA sequence modifications. Every cell in an organism has the same 
genome, the same genotype, but at the same time, each cell (or group of cells) maintains 
unique phenotypical characteristics and biological functions. Different states of chromatin 
compaction, conformation and modifications ensure the plasticity of cellular and tissue 
specific gene expression. They are fundamental during differentiation and development of 
an organism and can be heritable from one generation to the next. 
Epigenetic mechanisms play an important role in diseases related to lifestyle, early life 
experience and environmental exposure to toxins. In fact, they are responsible for the 
integration of environmental cues at the cellular level. For these reasons, epigenetics 
have acquired a therapeutic relevance in multiple diseases such as inflammation, 
metabolic diseases and cancer (Arrowsmith, Bountra et al. 2012). 
Since the first data obtained by Barbara McClintock in the 1940s-1960s, in parallel to the 
work of Brink (Mc 1950; Brink 1958; Brink 1958; Brink 1958; Brink 1958; McClintock 
1958), the research about epigenetics has greatly progressed. Looking for an explanation 
for non-Mendelian gene regulation in the past 20 years, many mechanisms, pathways, 
actors, complexes and substrates of epigenetics have been uncovered (Wolffe and 
Matzke 1999). 
The targets of epigenetic regulation are DNA and, especially, nucleosomes. Nucleosomes 
are the basic unit of chromatin and are substrates for the “deposition” of the epigenetic 
marks which, once “read” by specific complexes charged to “interpret” these marks, can 
modulate the transcriptional activity (Egger, Liang et al. 2004; Hake, Xiao et al. 2004). 
Before developing epigenetics and its implication in gene regulation, I will describe 
chromatin and its multiple facets. 
A. Chromatin structure. 
The mechanisms of epigenetic regulation rely on the structure and the composition of 
chromatin. Genomic DNA in eukaryotic cells ranging from yeast to humans is packaged 
into chromatin via DNA –protein interactions. Depending on the compaction state of 
chromatin, two different states of chromatin, heterochromatin and euchromatin, have been 
described.  The heterochromatic state represents a compacted and “closed” form of the 
genetic material. It is observable during the Barr body formation, at centromeres and is, in 
 	
general, correlated to gene silencing. Heterochromatic compaction is achieved by different 
mechanisms such as DNA methylation, histone methylation and other modifications. On 
the opposite, euchromatin is the “open” conformation of the chromatin. Also due to histone 
modifications (acetylation for example), euchromatin supports gene transcription. In fact, 
this low compacted chromatin conformation combined with distinct histone modifications 
allows DNA to be more accessible to the transcriptional machinery. 
DNA is packaged and organized inside the nuclear volume in eucaryotes. The repeating 
unit of chromatin organization is the nucleosome. The nucleosome is an assembly of 147 
base pairs of DNA turned two times around a histone octamer composed of two copies 
each of the histones H2A, H2B, H3 and H4 (Fig.1). Numerous amino acids of the N-
terminal tail of each histone are available for modification. Indeed, post-translational 
modifications of histones are the marks to preserve the balance between hetero- and 
euchromatin, and thus between silencing and transcription (Saha, Wittmeyer et al. 2006; 
Luger, Dechassa et al. 2012). 
Figure 1. Levels of chromatin compaction between double helix DNA and the metaphasic 
chromosome. 
 

B. DNA methylation 
DNA methylation is important during development and adult life, and plays a central role in 
gene expression, parental genomic imprinting or X chromosome inactivation. DNA 
methylation patterns are established very early during embryonic development. Such 
epigenetic modifications characterize extended areas of transcriptionally silent chromatin. 
The four bases of DNA can be methylated, yet only cytosine usually is in eukaryotic cells. 
To perform methylation, a methyl group must be exchanged between S-adenosyl 
methionine (SAM) and the cytosine carbon 5 (Figure 2). This reaction is done by an 
enzyme called DNA Methyl Transferase, or DNMT. Methylated cytosines are preferentially 
found in CpG dinucleotides. The CpG dinucleotides do not have a uniform distribution: 
series of CpGs are found in short regions of the genome, called “CpG islands”, located on 
gene promoters and/or in the first exon of about 60% of human genes (Bird 2002). 
Figure 2 . Schematic representation of DNA methylation. 
1. DNA Methyl Transferases 
There are two classes of DNMTs. The first class, DNMT1 in mammalian cells (Yen, 
Vertino et al. 1992), is involved in the maintenance of methylation patterns during 
replication. DNMT1 recognizes hemi-methylated DNA and ensures that the same 
methylation pattern is conserved between mother and daughter cells.The second class of 
enzymes comprises the mammalian DNMT3a and DNMT3b proteins. These proteins are 
involved in establishing new methylation patterns during early embryonic development 
(Okano, Takebayashi et al. 1999). The deletion of one of these three DNMTs is lethal for 
the organism (Okano, Bell et al. 1999).  
This important modification has a strong impact not only on DNA conformation but also on 
the DNA-protein interactions. In fact, changing DNA structure changes most proteins’ 
 
affinity for DNA, as for example histones and transcription factors. CpG islands are 
recognized by a 70 amino acid domain found in some proteins, called MBD (methyl-CpG 
Binding Domain). This domain is characteristic of a protein family, including for example 
MeCP2, MBD1, MBD2, MBD3 and MBD4.  Not all of these proteins bind methylated DNA 
(Filion and Defossez 2004). Some authors even describe a DNA-demethylase activity for 
MBD2, but this point is not very clear and is still under discussion.  On the other hand, we 
have the example of Kaiso, a transcription factor, which, although it has no MBD, is able 
to bind methylated CpG islands. Another characteristic of these proteins is their capacity 
to recruit other enzymes, in particular histone methyltransferases. These enzymes are for 
example implicated in lysine 9 methylation on histone H3 (Fuks, Hurd et al. 2003; Bowen, 
Palmer et al. 2004). These mechanisms synergize to repress transcription. This 
cooperation is the basis of the maintenance of the X chromosome inactivation for example 
(Heard, Rougeulle et al. 2001).  
Transcription can also be repressed via the interaction between DNMT1 and HDACs 
(histone deacetylases) which act synergistically (Dobosy and Selker 2001; Robertson 
2002), (Rountree, Bachman et al. 2000). MeCP2 is also implicated in the recruitment, on 
DNA methylated promoters, of a corepressor histone methyltransferase complex (mSin3) 
and histone deacetylases (HDAC1) (Figure 3). 
Figure 3. Crosstalk between DNA methylation and histone deacetylation. 
  
This repression is relieved, in vivo, by the deacetylase inhibitor Trichostatin A (see page 
34 for more information), indicating that deacetylation of histones (and/or of other 
proteins) is an essential actor of this repression mechanism. So, two global mechanisms 
of gene regulation, DNA methylation and histone deacetylation, can be linked by MeCP2 
(Jones, Thomas et al. 1998; Nan, Ng et al. 1998; Fuks, Hurd et al. 2003).  
 
2. Hydroxymethylation. 
In addition, another DNA modification has recently been described, 5-
hydroxymethylcytosine (5-hmC). This modification is catalyzed by the ten-eleven 
translocation (TET) family of DNA hydroxylases.  5-hmC, interestingly, seems to be 
associated with gene activation. In fact, recent studies in embryonic stem (ES) cells 
revealed that (i) 5-hmC is enriched in gene bodies where it correlates with gene 
expression levels, (ii) 5-hmC is associated with low gene expression when present at the 
transcription start site (TSS) and (iii) 5-hmC is found at binding sites for pluripotency 
transcription factors in undifferentiated ES cells. Therefore, Tet enzymes could be 
implicated in the initiation of active DNA demethylation. In particular, some links between 
cytosine hydroxymethylation and cancer have been demonstrated. 5-hmC levels are 
greatly reduced in most cultured, immortalized tumor cells (Haffner, Chaux et al. 2011; 
Yang, Liu et al. 2012). TET mutational inactivation has been reported to be associated 
with decreased 5-hmC levels in various myeloid leukemias (Delhommeau, Dupont et al. 
2009). Recently, Lian and collaborators have shown that “loss of 5-hmC” is an epigenetic 
hallmark of melanoma. Genome-wide mapping reveals loss of the 5-hmC landscape in the 
melanoma epigenome (Lian, Xu et al. 2012). In conclusion, DNA methylation, nucleosome 
remodeling and several histone N-terminal tail modifications cooperate to create active or 
inactive chromatin, which is more or less accessible to the transcriptional machinery. 
C. Remodeling complexes 
To change between an open, active and a closed, inactive chromatin state remodeling 
complexes are required. These complexes are responsible for changes in nucleosome 
deposition and chromatin structure in order to facilitate or hinder access to DNA. 
Therefore, gene expression, DNA repair, replication and other biological processes also 
depend on the modulation and recruitment of these complexes. 
Chromatin remodeling complexes use ATP to control nucleosome positioning. They are 
able to evict nucleosomes and are involved in exchanging canonical core histones with 
histone variants (Clapier and Cairns 2009). The ability to reposition nucleosomes play an 
important role in regulating gene expression as well as mediating access to DNA during 
replication and repair (Hartley and Madhani 2009; Jiang and Pugh 2009; Segal and 
Widom 2009). Remodeling complexes typically contain an ATPase domain and can be 
associated with different accessory proteins (Figure 4). The ATPase subunits of these 
enzymes belong to the SNF2 superfamily of helicase-related proteins and contain a 
common core of two RecA helicase domains. These couple ATP hydrolysis to protein 
 
conformational changes. In addition to the helicase domain, proteins of a given family 
share other characteristic domains that define their biological function (Figure 4) (Flaus, 
Martin et al. 2006). SWI/SNF members contain a bromodomain, ISWI members contain a 
HAND-SANT-SLIDE domain, and CHD members contain a double chromodomain. 
ATPase of the INO80 group are characterized by a “split” helicase, which has a long 
insertion separating the DExx and HELICc domain (Flaus, Martin et al. 2006). Using 
ATPase domains and/or associated subunits, these complexes create specific interactions 
with their modified or unmodified nucleosomal substrate (Figure 4). Each domain interacts 
and recognizes specific nucleosome modifications: Bromodomain (BRD/bromo) for 
acetylated histones, chromodomain (CHD/chromo) for methylated histones, the plant 
homeodomain (PHD) for unmodified/acetylated/methylated histone tails and globular 
domain of histones, and finally, HAND/SANT/SLIDE domains recognize nucleosomes and 
nucleosomal DNA. Moreover, these complexes can read DNA sequences, structure or 
methylation, recognize histone modifications, detect the presence of histone variants and 
can interact with chromatin-associated proteins such as transcription factors to identify 
specific target nucleosomes in the nucleus. An additional level of regulation is the 
alternative splicing of remodeling complex components that result in different isoforms 
with distinct properties. Therefore, these complexes contain DNA-binding motifs that are 
present in the ATPase or in accessory subunits (Figure 4) (Fyodorov and Kadonaga 2002; 
Grune, Brzeski et al. 2003). But the direct effects of DNA sequence are difficult to define, 
because their activity (on nucleosomes position) depends on a complex interplay between 
numerous factors: DNA sequence specificity of nucleosomes, competitive binding of 
transcription factors and histone octamer composition (Jiang and Pugh 2009; Bai and 
Morozov 2010). In addition, special conformational features of DNA could play an 
important role. This is the case for the ISWI-type complex ACF, which can be directed by 
an intrinsically curved DNA sequence element (Rippe, Schrader et al. 2007). 
 
Figure 4. Protein domain structure of chromatin remodeling complexes. Chromatin remodeling 
complexes consist of a catalytic ATPase, which belongs to the SF2 helicase superfamily, and 
accessory regulatory subunits. (A) In the CHD, ISWI and SWI/SNF families the ATPase domain (blue 
color) is interrupted by only a small protein sequence, whereas the ATPase domain of the INO80 
family is “split” by a long insertion. In the scheme the ATP binding site is indicated by a star, the DExx 
motif is depicted in dark blue and the helicase C terminal domain (HELICc) in light blue. Although the 
families of ATPases share a common catalytic domain they contain unique flanking regions for 
interactions with (i) DNA via SLIDE, AT hook (AT), DBINO and possibly Myb-like domains, (ii) 
chromatin via SANT, bromo- (bromo) or chromodomains (chromo), and (iii) with other proteins as 
mediated for example by the helicase-SANT-associated (HSA) domain. The interaction domains 
present in all family members are indicated in orange, while those that are present in only a subset of 
the family members are colored in green. (B) Noncatalytic subunits of chromatin remodeling 
complexes can regulate the activity and the substrate recognition of the complex. Via the homeobox 
and DDT domains they interact with the ATPase domain and bind DNA. DNA interaction modules are 
also present in MBDs AT hooks (AT), WAC motifs, Zinc fingers, ARID and high mobility group (HMG) 
domains. Finally, histones or histone modifications are recognized by subunits with bromo, chromo, 
SANT and PHD motifs while interactions with other proteins or protein modifications are mediated by 
WD, SH2, SH3 and ELM2 domains or the LXXLL motif. Moreover, some associated proteins contain 
catalytic activity as for example WSTF, Tip60 and histone deacetylase 1/2 (HDAC1/2). The functions of 
the bromo-associated homology domain (BAH) are currently unknown. (Erdel, Krug et al. 2011) 
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Since a number of subunits of remodeling complexes contain MBD domains capable of 
recognizing methylated DNA, this modification might also play a critical role for targeting 
chromatin remodelers (Zhang, Ng et al. 1999; Feng and Zhang 2001). The DNA-
sequence dependent targeting of remodelers is not necessarily mediated by the 
remodeling complex subunits but can also occur via interaction with other proteins. The 
most interesting is that these complexes can recognize distinct histone modifications (see 
next section), via bromodomain interactions with acetylated histones or chromodomain 
and PHD finger interactions with methylated lysines (Taverna, Li et al. 2007). These 
complexes have both ATPase and interactions domains, as is the case for RSC, Chd1, 
ISWI and Acf1 that contain bromodomains recognizing histone acetylation states to 
promote or inhibit their own activity (Goodwin and Nicolas 2001; Corona, Clapier et al. 
2002; Ferreira, Flaus et al. 2007). For histone methylation, it was found that human Chd1 
binds to H3K4me2/3 stronger than to H3K4me1 via its double chromodomain (Sims, Chen 
et al. 2005). PHD fingers can also recognize methylated lysine residues on H3 histone 
tails in a protein context dependent manner (Taverna, Li et al. 2007). 
Another important and interesting characteristic of these complexes is their involvement in 
non-replicative incorporation and stabilization of histone variants H3.3 (Chd1 or ATRX) 
(see page 18 for more information about histone variants), H2A.Z (Swr1 (Mizuguchi, Shen 
et al. 2004)) (see page 20 and Chapter II) and CenH3/CENP6A (Chd1 and RSF). For this 
process, it is difficult to distinguish if the histone variant represents only the product of the 
remodeler-driven incorporation reaction or whether already incorporated H3.3, H2A.Z or 
CenH3 recruits additional remodeling complexes to enhance the reaction. In any case, 
histone variants have been identified as signals that change the activity of chromatin 
remodelers. The histone H2A.Z, which is often found in nucleosomes at transcriptional 
control regions, increases the activity of the human ISWI remodeling complex in vitro
(Goldman, Garlick et al. 2010). 
D. Histone modifications. 
Within the fundamental chromatin unit, the nucleosome, N-terminus and, in some cases, 
the core and the C-termini of histones are subject to a multitude of covalent modifications. 
In this manner, the histone-modifying enzymes can alter the chromatin structure and/or 
influence the binding of effector molecules that affect patterns of gene expression. 
Combinations of modifications generate the so-called “histone code”. On a given gene 
promoter can be found several histone marks (activating or/and repressive), which as a 
result of the balance between these modifications (sometimes more than one on the same 
 
histone) and their reading by protein complexes, will influence gene activation or 
repression (Strahl and Allis 2000). Principal histone modifications are lysine acetylation, 
lysine and arginine methylation, serine and threonine phosphorylation, ADP-ribosylation, 
ubiquitination, sumoylation, propionylaiton, butyrylation, crotonylation and other yet 
unknown or poorly appreciated chemical modifications. 
A plethora of specific enzymes catalyzes these modifications. In fact, each histone 
modification is created by a specific enzyme: histone methyl transferases (HMT) catalyze 
histone methylation, histone acetyl transferases (HAT) are responsible for histone 
acetylation, etc. Most modifications are reversible and specific enzymes are required for 
demethylating (HDM), deacetylating (HDAC) histones (see below for more explanations). 
1. Histone methylation. 
Methylation of histones can occur on lysine and arginine residues. Lysines can be mono, 
di- , or tri-methylated, whereas arginines can be mono- or di-methylated, thus greatly 
extending the complexity of histone modification-dependent gene regulation. Some 
evidence suggests that arginine methylation on H3 and H4 histones is more dynamic than 
lysine methylation and marks domains of active or inactive  gene expression  (Stallcup 
2001; Bannister, Schneider et al. 2002). In fact, arginine methylation and its involvement 
in transcriptional regulation seems to be complex. It depends on the enzyme “employed” 
by the cell; in particular, arginines methylated by PRMT1 (Protein Arginine Methyl-
Trasferase) and CARM1 (Coactivator-associated Arginine Methyl-Trasferase) are found 
on transcriptionally active genes. In contrast, di-methylation of arginines due to the action 
of PRMT5 protein is involved in repression (Wysocka, Allis et al. 2006). 
Lysine methylation seems to be a quite stable mark, with what appears to be a more 
complicated readout (Zhang and Reinberg 2001). Moreover, some lysine methylations are 
involved specifically in gene activation whereas others are in gene silencing. In the case 
of lysine 4 and lysine 9 and 27 on H3 histone, lysine 4 methylation is a gene activation 
mark whereas lysine 9 and 27 methylation correlates with gene repression (Bannister, 
Schneider et al. 2002; Fischle, Wang et al. 2003). These marks are “written” by histone 
methyltransferases (HMTs) and “read” by chromodomain-containing proteins, such as 
heterochromatin protein 1 (HP1) and Polycomb (Pc). These proteins specifically recognize 
methyl marks, depending on their location on the histones (Fischle, Wang et al. 2003) 
(Figure 5). Several studies demonstrate the dynamic character of lysine methylation and 
tear down the old “dogma” which proposed that this mark is irreversible (Dillon and 
Festenstein 2002). Several evidences show that active demethylation exists even for 
 
lysine 4 and/or 9 of H3 histone (Ma, Baumann et al. 2001; Ghosh and Harter 2003; 
Nicolas, Roumillac et al. 2003; Janicki, Tsukamoto et al. 2004). 
Two main explanations for demethylation: the first supposes nucleosome disassembly 
and the substitution of methylated histones by a newly synthesized, unmodified histone 
(Ahmad and Henikoff 2002). The second is due to the discovery of a new class of 
enzymes. The first protein described is the human enzyme PAD4 (peptidylarginine 
deiminase 4), which converts the methyl group in citrulline (Cuthbert, Daujat et al. 2004; 
Denman 2005). In 2004, the enzyme LSD1 (lysine-specific histone demethylase) was 
described. It is able to demethylate the mono- and di-methylated lysine 4 of H3 in vivo
(Shi, Lan et al. 2004). Metzger showed in 2005 that the LSD1 protein is able to 
demethylate lysine 9 of H3, too (Metzger, Wissmann et al. 2005). More recently another 
histone lysine demethylase, JHDM1 (Jumonji domain-containing histone demethylation) 
was discovered (Tsukada, Fang et al. 2006). This protein needs Fe2+ and alpha-
ketoglutarate as cofactor to demethylate lysine 36 of the histone H3 specifically, either 
mono- or di-methylated (Figure 4). 
Two other enzymes are important for the demethylation process: Histone Demethylase 
Jumonji D3 (JMJD3) and Jumonji D2 (JMJD2). These enzymes have a role in breast 
cancer in particular. JMJD2B is highly expressed in human breast cancer. 17-beta-
estradiol (E2) induces JMJD2B expression in an ER (Estrogen Receptor ) -dependent 
manner. This enzyme interacts with ER and components of the SWI/SNF-B chromatin-
remodeling complex. JMJD2B is recruited to ER target sites to demethylate H3K9me3, 
allowing the transcription of ER-regulated genes (MYB, MYC and CCDN1) leading to cell 
proliferation and tumor development. As a consequence, knockdown of JMJD2B severely 
impairs estrogen-induced cell proliferation and the tumor formation capacity of breast 
cancer cells (Kawazu, Saso et al. 2011). 
JMJD3 is specifically required to demethylate H3K27me3 (Xiang, Zhu et al. 2007) on the 
anti-apoptotic ER target gene BCL2. In hormone responsive breast cancer cell such as 
MCF-7, JMJD3 and ER work in concert following estradiol (E2) stimulation. In fact, these 
two proteins colocalize on the Estrogen Responsive Elements present on the BCL2 gene 
promoter to remove the H3K27me3 repressive mark. By removing this mark from the 
poised (yet silent) enhancer region, they permit appropriate gene activation and anti-
apoptotic effects following E2 stimulation. Interestingly, the depletion of JMJD3 in ER-
positive cells (MFC-7) dramatically increases apoptosis in E2-treated cells. In contrast, 
ER-negative cells (MDA-MB231) are insensible to JMJD3 depletion, suggesting that 
JMJD3 effects are specific to E2-responsive cells. In conclusion, JMJD3 seems to play an 
important role in apoptosis control in ER-dependent breast cancer cells (Svotelis, Bianco 
et al. 2011). 
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2. Histone phosphorylation. 
Histone phosphorylation involves threonine and serine residues. It is a dynamic 
modification; in fact, its regulation depends on the “balance” between kinase and 
phosphatase activity. H1 phosphorylation, for example, leads to the condensation and 
segregation of chromosomes during mitosis and meiosis (Gurley, Walters et al. 1978). 
The phosphorylation of serine 10 of H3 histone is involved in chromosome condensation 
and has a role in mitosis. Recent work revealed a new role of this modification in 
transcription activation. This modification inhibits the interaction between the HP1 protein 
and the methyl-lysine 9 of H3 histone (Eissenberg and Elgin 2005). 
Histone phosphorylation seems to be involved in apoptosis as well (Lee, Nakatsuma et al. 
1999). In particular, the phosphorylation of serine 32 on the H2B histone seems to be a 
good marker of apoptotic cells (Ajiro 2000). Moreover, phosphorylation of the histone 
variant H2A.X (-H2A.X) is the canonical mark for DNA double strand breaks (Rogakou, 
Pilch et al. 1998; Ismail and Hendzel 2008) (see below). 
3. Histone acetylation. 
Histone acetylation is canonically associated to transcriptional activation (Allfrey, Faulkner 
et al. 1964; Hebbes, Thorne et al. 1988). In fact, this modification helps histone 
disassembly by decreasing the electrostatic interactions occurring between DNA 
(negatively charged) and the histones (positively charged) (Travers and Thompson 2004). 
In this manner, histone acetylation “opens” chromatin and allows transcriptional factors to 
access the DNA template (Kuo, Zhou et al. 1998; Strahl and Allis 2000). Conversely, 
histone deacetylation mainly contributes to a “closed” chromatin state and transcriptional 
repression.  
Two classes of enzymes, Histone Acetyl Transferases (HAT) and Histone Deacetylases 
(HDAC), assure the balance between acetylation and deacetylation. There are three 
families of HAT : the GNAT (Gcn5 related N-Acetyltransferases, (Georgakopoulos T 
1992)) family, the MYST family (Tbf2/Sas3 Sas2 Tip60, (Utley and Cote 2003)) and the 
p300/CBP proteins (Bannister and Kouzarides 1996). The majority of HAT is active in 
multiproteic complexes (Yang 2004) and the associated factors at these complexes seem 
control the substrate specificity and increase the catalytic activity (Grant, Duggan et al. 
1997). The histone acetylation is recognized by bromo-domain proteins (Dhalluin, Carlson 
et al. 1999; Loyola and Almouzni 2004) (Figure 5). 
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The first member of HDAC family discovered was HDAC1 (Taunton, Hassig et al. 1996). 
Up to now, eighteen enzymes have been discovered, in human, and classified in four 
groups (I to IV). The first group has a strong homology with the yeast protein Rpd3 
(Reduced Potassium Dependency), these enzymes are called class I (HDAC 1,2,3 and 8). 
Class II (HDAC 4, 5, 6, 7, 9 and 10) proteins display some homologies with the yeast 
protein Hda1 (Histone Deacetylase1). HDAC11 is the only member of the class IV. These 
three groups have a zinc-dependent enzymatic activity whereas the HDACs of class III, 
called “sirtuins”, homologs of Sir2 (Silent Information Regulator 2) of Saccharomyces 
cerevisiae, form a separate family and their deacetylase activity is NAD+ dependent 
(Figure 5). 
It is important to note that the HDACs are characterized from their activity on histones, but 
they have other substrates: they regulate the acetylation of other proteins, which have an 
important role in cells like p53, Bcl-6, E2Fs factors, tubulin, HSP90 (Heat Shock Protein 
90), -catenin and some others (Dokmanovic, Perez et al. 2007). Maybe “lysine 
deacetylases” would be the best name for these enzymes but it is rarely used and HDAC 
remains the most commonly used name (Yang and Seto 2008). 
Figure 5. Schematic representation of histone acetylation and methylation pathways complexity: 
chromatin marks and epi-enzyme deregulation in cancer. Chromatin enzymes able to deposit or erase 
an epigenetic mark are indicated as writers (teal blue) and erasers (purple), respectively. Epi-drugs 
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able to inhibit the activity of chromatin enzymes are indicated as blockers (brown).  (Conte and Altucci 
2012). 
4. Other histone modifications. 
Acetylation, methylation and phosphorylation are the most studied histone modifications, 
but other modifications exist that play important roles in cellular processes. The mono-
ADP-ribosylation for example, involves arginine and glutamate residues of H1 and H2B 
histones (Burzio, Riquelme et al. 1979; Golderer and Grobner 1991). From a general point 
of view, the ADP-ribosylation seems to be involved in DNA damage repair (Kreimeyer, 
Wielckens et al. 1984). 
Mono-ubiquitination is the covalent addition of an ubiquitin peptide on a lysine residue 
(Jason, Moore et al. 2002). Generally, the addition of a poly-ubiquitine leads to protein 
degradation; but histone mono-ubiquitination seems to correlate with transcription 
activation (Thorne, Sautiere et al. 1987). In fact, it has been shown that the H2B mono-
ubiquitination can promote the H3 lysine4 methylation in yeast, contributing to 
transcriptional regulation (Dover, Schneider et al. 2002; Sun and Allis 2002). 
Sumoylation, the addition of a SUMO peptide -normally involved in protein degradation- 
has been described and studied on the H4 histone. This modification seems to be 
involved in gene silencing. It recruits histone deacetylase (HDAC1) and the 
heterochromatin protein1 (HP1) to sumoylated H4 (Shiio and Eisenman 2003). 
Biotinylation of lysine residues through the addition of a biotine peptide leads to a 
competition with other modifications on the same residue (Camporeale, Shubert et al. 
2004) and seems to be involved in cellular proliferation (Stanley, Griffin et al. 2001; 
Narang, Dumas et al. 2004).  
Butyrylation and propionylation are structurally similar to acetylation. These histone 
modification, were found for the first time in vivo on the histone H4 and share with 
acetylation the same enzymes, the acetyltransferases CBP and p300 (Chen, Sprung et al. 
2007). These enzymes can use propionyl-CoA and butyryl-CoA as precursors. Moreover, 
in the case of propionylation, the NAD+ dependent deacetylase Sir2 is involved in the 
removal of the propionyl group. Like acetyl-CoA, propionyl- and buryryl-CoA are 
intermediates in biosynthesis and energy production. It has been proposed that 
propionylation is used as an alternative to the acetylation, depending on the metabolic 
pattern of the cell. Studying the propionylation of the lysine 23 of the H3 histone, Liu et al; 
suggest that the propionylation might be a stage-specific marker in hematopoiesis and 
leukemogenesis (Liu, Lin et al. 2009).   
Recently, using different approaches based on mass spectrometry, 67 histone post-
translational modification sites were identified. Among these, 28 sites are characterized by 
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a new histone modification: lysine crotonylation (Kcr). Crotonylation differs structurally 
from methylation and acetylation. It may thus require specific enzymes for recognition, 
addition and removal. Despite the fact that the co-enzyme involved (Crotonyl-CoA) is 
generated from acetyl-CoA, the enzymes responsible of histone acetylation are not 
involved in crotonylation. In fact, overexpression of canonical histone acetyl-transferases 
and the exposure to histone deacetylases do not change the amount of Kcr. This histone 
modification is conserved during evolution and has a characteristic genomic pattern. Kcr is 
enriched at enhancers and the TSS of active genes. Moreover, in mouse male germ cells, 
the histone Kcr marks the postmeiotically expressed X-linked genes. Indicating that Kcr 
may be involved in male postmeiotic gene expression pattern. Similar to histone 
hyperacetylation, Kcr seems to be associated with histone removal that follows germ cell 
maturation. So, Kcr may affect chromatin structure and therefore facilitate histone 
replacement. In this manner, this newly characterized histone modification could be an 
important histone mark in the establishment of a region-specific male epigenome 
organization (Tan, Luo et al. 2011; Montellier, Rousseaux et al. 2012). 
5. Histone modification networks. 
Histone modifications are not independent of each other. The first evidence concerns the 
modifications on H3 lysine 9. This lysine can be methylated or acetylated; these two 
modifications are totally exclusive because they happen on the same lysine NH2 group. 
Another example: in yeast, the phosphorylation of the serine 10 promotes H3-K14 
acetylation by Gnc5 (Cheung, Briggs et al. 2000) and, at the same time, inhibits the 
methylation of H3-K9 by Suv39H1 (Ahringer 2000). In this manner, serine 10 
phosphorylation has a positive effect on transcription since blocking H3-K9 methylation 
(repressive mark) and promoting H3-K4 acetylation increases transcription activation. In 
contrast, H3-K9 methylation inhibits H3-S10 phosphorylation by Aurora kinase in vitro
(Ahringer 2000). In addition, the same methylation (H3-K9) inhibits, in vitro, H3-K4 
methylation (activation mark) by Set7 (Decristofaro, Betz et al. 2001). Therefore, the 
transcriptional repressive state is due to lysine 9 deacetylation followed by H3-K9 
methylation, which keeps the domain in an inactive state blocking H3-S10 phosphorylation 
and H3-K4 methylation.  
A similar situation involves the H4 histone and its modifications. H4-R3 methylation 
promotes H4-K8 and K12 acetylation (in vitro by p300); but it is a negative feedback, 
because this acetylation inhibits H4-R3 methylation by PRMT1, suggesting that H4-R3 
methylation might come before acetylation for transcriptional activation (Decristofaro, Betz 
et al. 2001). The network is more complex, in fact it can involve different tails of different 
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histones. For example, ubiquitination of lysine 123 of H2B histone, which promotes and is 
essential for H3-K4 methylation in S. cerevisiae (Briggs, Xiao et al. 2002; Dover, 
Schneider et al. 2002). In the same manner, but in vitro, H3-K4 methylation by Set7 
promotes H4 acetylation by p300, and is inhibited by H3-K9 methylation (Decristofaro, 
Betz et al. 2001). Moreover, H2B ubiquitination is essential for H3 methylation. In 
particular the ubiquitination of H2B catalyzed by the ubiquitin-conjugating enzyme Rad6, 
is required for K4 and K79 methylations of H3 histone. The precise mechanism remains 
poorly understood, but several studies support the idea that H2Bub may act as a bridge to 
recruit Set1-COMPASS (methylation complex, required for silencing of genes located near 
telomeres or within rDNA) and Dot1, involved in K4 and K79 methylations, respectively. 
This process results in gene silencing (Dover, Schneider et al. 2002; Chandrasekharan, 
Huang et al. 2010). 
Therefore, post-translational modifications of histones have a fundamental role in the 
transcription process. The cell defines gene fate (transcribed or not) through stable marks, 
such as methylation or acetylation, inherited during meiosis, or through other marks 
induced by signaling, such as phosphorylation. Moreover, histone modifications allow 
chromatin remodeling and therefore affect recruitment and processing of transcriptional 
machinery. 
E. Histone variants. 
Canonical histone genes are intronless and occur in clusters, facilitating coordinated gene 
regulation (Albig and Doenecke 1997). Their mRNAs lack a polyA tail, instead having a 
dyad sequence that forms a 3’ stem loop structure. Their expression is replication-
dependent. The number of canonical genes that code for each histone family member can 
exceed ten genes (Marzluff, Gongidi et al. 2002).
In contrast to canonical histone genes, expression of most known histone variants is 
replication-independent. Genes encoding histone variants typically lay outside of clusters, 
can contain introns, and occur in low copy numbers. Like standard genes, mRNAs 
produced from histone variant genes possess a polyA tail (Doenecke, Albig et al. 1997). 
These variants have distinct genomic localizations and post-translational modifications 
(PTM), thus increasing the complexity of chromatin architecture. Several studies about 
histone variants indicate that they play a role in many biological processes such as 
transcription, DNA damage response, and cell cycle. For all these reasons they are 
proposed to form an extra layer of the “histone code” (Hake and Allis 2006; Arnaudo, 
Molden et al. 2011). 
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All canonical histones have a family of variants except histone H4. These variants have 
different roles in cell processes (Figure 6). 
Figure 6. Canonical core histones and their variants. The major core histones contain a conserved 
histone-fold domain (HFD). In addition, they contain N- and C-terminal tails that harbor sites for 
various post-translational modifications. For simplicity, only well-established sites for lysine 
methylation (red flags) and serine phosphorylation (green circles) are shown (other types of 
modifications, such as ubiquitylation, are not shown). In the histone H3.3 variant, the residues that 
differ from the major histone H3 (also known as H3.1) are highlighted in yellow. H1 variants are not 
shown, see text. (Sarma and Reinberg 2005) 
1. Histone H3 family. 
Histone H3 (known as H3.1) has three major variants as well as a testis specific variant 
5H3t and a variant that localizes to centromeres (CENP-A) which plays a role in 
chromosome segregation during mitosis (Howman, Fowler et al. 2000). The other three 
variants of H3 are surprisingly similar. In fact H3.1 only differs from H3.2 by a change in 
Cysteine 96 to Serine, and H3.3 differs from H3.1 by only 5 residues. However, their 
expression levels, localization in chromatin and modification states vary significantly. H3.3 
is expressed in a replication independent manner, while canonical variants (H3.1 and 
H3.2) are only expressed during S phase (Stein and Stein 1984). Moreover, different 
chaperones recognize and assemble H3.1 and H3.3 into nucleosome in a replication 
dependent and independent manner respectively (Tagami, Ray-Gallet et al. 2004). H3.3 is 
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localized to heterochromatin and enriched for histone modifications that are associated 
with gene activation (Ahmad and Henikoff 2002; McKittrick, Gafken et al. 2004) (Figure 6). 
H3.1 and H3.2 do not show specific localization in genome and are considered identical; 
however, one study suggests that H3.2 is modified with marks associated with gene 
repression while H3.1 shows both activating and repressive marks (Ahmad and Henikoff 
2002; Hake, Garcia et al. 2006). 
The presence of these different H3 variants and their involvement in specific processes, 
led some authors to propose an intriguing hypothesis. Hake and Allis proposed the “H3 
barcode hypothesis”. Mammalian H3 variants, although similar in amino-acid sequence, 
are able, through different and specific post-translational “signatures”, to create distinct 
chromosomal domains and territories, which influence epigenetic states during cellular 
differentiation and development (Hake and Allis 2006). 
2. Histone H2A family. 
H2A family is one of the most sequence divergent families, with 20 unique sequences in 
humans. Canonical human H2A is encoded by 16 genes within gene clusters and has 12 
unique sequences. Sequence diversity comes from divergent C-terminal tails, but the 
biological relevance of this diversity remains unknown. H2A family variants include H2A.X, 
H2A.Bbd, macroH2A and H2A.Z; these variants differ in sequence and have different 
functions. (Figure 6). 
H2A.X is most similar in sequence to its canonical version but has divergent C-terminal 
tail. H2A.X mRNA can have either a polyA tail or the stem and loop dyad structure, 
indicating that it can undergo both replication dependent and independent transcription 
(Mannironi, Bonner et al. 1989). This variant can be acetylated, ubiquitinated and 
phosphorylated. The phosphorylation occurs in response to DNA damage at Serine 129; 
H2A.X phosphorylated localizes to DNA double strand breaks, helping to recruit proteins 
for DNA repair (Rogakou, Pilch et al. 1998; Ikura, Tashiro et al. 2007). Acetylation and 
ubiquitination also play a role in this process; in particular, acetylation at lysine 5 is a 
prerequisite for ubiquitination and subsequent release of H2A.X from DNA damage sites 
(Ikura, Tashiro et al. 2007). 
The second variant is H2A.Bbd, his name derives from the fact that this variant is 
excluded from inactive X (Barr body deficient). H2A.Bbd is associated with acetylated H4, 
and therefore implicated in transcriptional activation (Chadwick and Willard 2001). The 
sequence of this variant is short and rich in arginine in comparison to canonical H2A. 
Nucleosomes containing H2A.Bbd contain 128bp of DNA as opposed to the traditional 
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146, indicating that the incorporation of this variant impacts chromatin structure (Doyen, 
Montel et al. 2006). 
MacroH2A is the largest H2A variant containing a 30kDa macro domain at its C-terminus 
which can recognize ribosylated protein residues (Karras, Kustatscher et al. 2005). 
Human macroH2A is encoded by two genes macroH2A2 and macroH2A1. MacroH2A1 
has two splicing variants: macroH2A1.1 and macroH2A1.2. macroH2A1.1 but not 1.2 is 
able to bind metabolites of NAD+ and may have unique, yet to be discovered,  functions. 
Interestingly, the macroH2A1 splicing isoforms are differentially expressed in primary 
tumors that either give rise to metastases or do not. In fact, it has been shown that the 
splicing factors Ddx7 and Ddx5 are overexpressed in invasive tumor cells and participate 
in tumor-cell migration and invasion. These splicing factors control alternative-splicing 
networks, including macroH2A1 histone genes. macroH2A1 splicing isoforms differentially 
regulate the transcription of a set of genes involved in redox metabolism. In this manner, 
the splicing choice of an epigenetic factor, as macroH2A1, plays a critical role in tumor 
progression (Dardenne, Pierredon et al. 2012). macroH2A is generally enriched in silent 
areas both on autosomes and on inactive X. However, recent ChIP-on-Chip experiments 
have shown that macroH2A1 can be found at a subset of active genes. Moreover, 
macroH2A can be ubiquitinated, acetylated and phosphorylated. Ubiquitination at K115 is 
implicated in X-inactivation, while phosphorylation of S137 is enriched during mitosis 
(Chu, Nusinow et al. 2006; Bernstein, Muratore-Schroeder et al. 2008). 
Finally, the histone H2A.Z variant is highly conserved during evolution and is essential for 
development in higher eukaryotes (Draker and Cheung 2009). H2A.Z localizes to the 
promoters of genes and, in mammals, its localization to the transcription starting site 
correlates with gene activation (Barski, Cuddapah et al. 2007). In yeast, H2A.Z is found at 
transcriptionally active areas near the telomeres and silent mating loci to prevent 
spreading of heterochromatin. These findings suggest that H2A.Z is important for 
maintaining active chromatin in regions near silent chromatin (Meneghini, Wu et al. 2003). 
Acetylation of H2A.Z is linked to gene activation. However, there is evidence that H2A.Z 
can also act in gene repression (Millar, Xu et al. 2006; Draker and Cheung 2009; Mehta, 
Braberg et al. 2010) – see below for more details. 
3. Histone H2B family. 
Human H2B has 17 isoforms, which are encoded by 25 genes. Most H2B sequences vary 
by just a few amino acids and are encoded by genes located in the main cluster. There 
are two proteins that differ significantly from other H2B, which are the testis-specific H2B 
(H2B1A and H2BFWT) (Zalensky, Siino et al. 2002; Churikov, Siino et al. 2004). H2B 
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variants are poorly studied, maybe because of their sequence similarity, so their biological 
function is not well understood. Moreover, these variants are not extensively modified as 
H3 or H4, and aside from a few lysine acetylation sites, other modified forms are sparsely 
abundant. 
4. Histones H1. 
Histone H1 is commonly referred to as the linker histone. A single copy of this histone has 
been proposed to bind near the entry/exit site of DNA on the nucleosome, thus stabilizing 
chromatin and DNA structure (Bustin, Catez et al. 2005; Woodcock, Skoultchi et al. 2006). 
Most H1 proteins contain a globular domain, a short N-terminal tail and a longer lysine rich 
C-terminal tail. Sequence divergence between histone H1 isoforms is high, and occurs 
mainly in the N- and C- terminal regions of the protein. There are 11 isoforms in 
mammals. These isoforms are generally classified based on the timing of expression or 
tissue specificity (Izzo, Kamieniarz et al. 2008). The replication-dependent isoforms 
include histone H1.1 – H1.5 and H1.t, while replication-independent variants are H1.X, 
H1.t2, HILS1, H1oo and H1.0. Histone H1.0 – H1.5 are expressed in somatic cells, with 
H1.1 restricted to certain tissue types (Daujat, Zeissler et al. 2005; Godde and Ura 2008). 
Histone H1.t, H1.t2 and HILS1 are expressed in testis specific tissues and H1oo is oocyte 
specific (Godde and Ura 2008). Histone H1.X has mainly been reported in tissue culture 
cells (Wisniewski, Zougman et al. 2007). Moreover, a large number of post-translational 
modifications have been shown for the H1 family, including lysine methylation, 
phosphorylation, acetylation, ubiquitination, formylation, and ADP ribosylation (Poirier and 
Savard 1980; Garcia, Busby et al. 2004; Wisniewski, Zougman et al. 2007; Talasz, Sarg 
et al. 2009).  
Several studies have supported the fact that H1 variants are redundant, lacking specific 
functions in chromatin organization and gene expression control (Fan, Sirotkin et al. 
2001). However, it seems that it is not true concerning H1.4 and H1.2. In fact, H1.4 is 
involved in a heterochromatization process. This variant is deacetylated at lysine 26 and 
methylated, facilitating recruitment of Polycomb complexes and HP1, whereas 
simultaneous phosphorylation of serine 27 blocks HP1 binding (Vaquero, Scher et al. 
2004; Daujat, Zeissler et al. 2005). H1.2 is involved in apoptosis induced by double-strand 
breaks (Konishi, Shimizu et al. 2003). A H1.2 containing complex involved in repression of 
p53-mediated transcription has also been isolated (Kim, Choi et al. 2008). These variants 
seem to have a role in breast cancer. In fact, the depletion of H1.4 in the human breast 
cancer cell line T47D leads to cellular death. Moreover, in the same cell type, the 
depletion of H1.2 leads to a stop in G1 of the cell cycle, a defect in chromatin structure 
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and changes in expression of specific genes involved in the cell cycle (Sancho, Diani et al. 
2008). 
The high number of isoforms and their modification patterns may thus result in a linker-
code similar to the histone code (Godde and Ura 2008). 
II. Histone H2A.Z 
As we have seen, gene regulation is based on a complex crosstalk between different 
actors: DNA modifications, chromatin composition, histone post-translational 
modifications, histone variant incorporation and chromatin remodeling complexes interplay 
to an accurate and fine gene regulation. This regulation has an impact on all the biological 
processes. Our particular interest is the involvement of the histone variant H2A.Z in gene 
regulation.  
H2A.Z is a highly conserved histone variant of H2A. It is essential for viability in different 
organisms such as Tetrahymena thermophila (Liu, Li et al. 1996), Drosophila 
melanogaster (Clarkson, Wells et al. 1999), Xenopus laevis (Ridgway, Brown et al. 2004), 
and mice (Faast, Thonglairoam et al. 2001). In contrast, loss of H2A.Z is tolerated in 
Saccharomyces cerevisiae, suggesting that this variant may have different roles in 
different organisms. H2A.Z variants share about 90% similarity among the various higher 
eukaryotes. H2A and H2A.Z differ in amino acids sequence but share about 60% of 
identity (Jackson, Falciano et al. 1996). These changes are sufficient to create a unique 
chromatin conformation in H2A.Z enriched regions. H2A.Z differs from H2A by a C-
terminus containing an alternative docking domain and an extended specific acidic patch. 
This acidic patch and C-terminus contain some residues that are important for H2A.Z 
deposition into chromatin (Jensen, Santisteban et al. 2011; Wang, Aristizabal et al. 2011). 
This replacement creates a different interface in the nucleosome that can recruit specific 
factors/modulators (Figure 7). 
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Figure 7. Schematic representation of histone H2A.Z role in gene activation. (A) Incorporation of H2A.Z 
in chromatin by the replacement of H2A–H2B dimers with H2A.Z–H2B dimers. ATP-dependent 
exchange by Swr1-related complexes is assisted by H2A.Z–H2B chaperones. H2A.Z-containing 
nucleosomes are less stable than canonical nucleosomes. (B) Promoter of yeast inactive gene has a 
nucleosome-free region (NFR) surrounded by two well positioned nucleosomes. (C) Specific 
incorporation of H2A.Z at nucleosomes −1 and +1 poises genes for transcriptional activation. (D) 
Binding of activators leads to H2A.Z acetylation, eviction of H2A.Z nucleosomes and transcription 
initiation. (Billon and Cote 2012) 
A. H2A.Z localization in the genome. 
Nevertheless, the relevance of H2A.Z in biological processes is due to its localization 
within the genome. In Tetrahymena, the equivalent of H2A.Z, hv1, is found exclusively in 
the transcriptionally active macronucleus, but is absent in the transcriptionally inert 
micronucleus, suggesting that this variant has a function in transcription (Allis, Glover et 
al. 1980). In Drosophila's H2A.Z variant, H2AvD, has a nonrandom distribution on 
polytene chromosomes, and antibodies against H2AvD stain both euchromatin and 
heterochromatin regions of the genome (Leach, Mazzeo et al. 2000). Moreover, in flies, 
H2AvD variant is unique, in that it is a functional fusion between H2A.Z and H2A.X in 
other organisms. So, the distinctive distribution of H2AvD may have been adopted to 
accommodate the dual functions of H2A.Z and H2A.X in this organism. 
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Immunofluorescence examination of differentiated mouse fibroblasts showed that H2A.Z 
is distributed across the entire interphase nucleus, but is excluded from transcriptionally 
silent and HP1-enriched pericentric heterochromatin (Sarcinella, Zuzarte et al. 2007). 
Staining of mouse metaphase chromosomes also showed that H2A.Z is enriched on 
chromosome arms and depleted from the constitutive centromeric heterochromatin. 
Based on these observations, distribution between H2A.Z and H3K9me3 (mark of 
constitutive pericentric heterochromatin) in mouse embryonic fibroblasts was proposed to 
be mutually exclusive (Bulynko, Hsing et al. 2006). In contrast, in trophoblast cells of the 
developing mouse embryo, H2A.Z is concentrated at pericentric heterochromatin and 
colocalizes with HP1 (Rangasamy et al., 2003). At present, it is unclear why H2A.Z 
genomic distribution changes with developmental stages, but it is possible that H2A.Z’s 
function switches at different stages of development or differentiation. 
Using 2D and 3D immunofluorescence analysis to examine the inactive X chromosome in 
female mouse cells, H2A.Z was found to localize to only one side of the centromere of 
each sister chromatid (Rangasamy et al., 2003). Additional studies support the idea that a 
specific fraction of H2A.Z may have centromere-related functions. Firstly, H2A.Z binds to 
CENP-A (the H3 variant specific to centromere) in a nucleosomal purification fraction 
(Foltz, Jansen et al. 2006). Second, RNAi-mediated depletion of H2A.Z in mouse L929 
and monkey Cos-7 cells resulted in chromosome segregation defects characterized by 
formation of chromatin bridges between separating nuclei (Rangasamy, Greaves et al. 
2004). Finally, in yeast, colony-sectoring studies showed that H2A.Z-deletion strain 
(htz1) has increased rates of chromosome loss, suggesting that a chromosome 
segregation function of H2A.Z is conserved between yeast and human cells (Krogan, 
Baetz et al. 2004). 
B. H2A.Z deposition. 
It is now believed that SWR1-related ATP-dependent chromatin remodelers that 
specifically exchange canonical H2A-H2B for H2A.Z-H2B dimers within nucleosomes 
(Morrison and Shen 2009) perform the majority of H2A.Z incorporation into chromatin. 
To replace canonical dimers by variants dimers, SWR1-related complexes evict them from 
the nucleosome and replace them by an H2A.Z-containing nucleosome. It has been 
proposed that this process is catalyzed by two families of large ATP-dependent 
complexes, both highly conserved during evolution. 
Using the energy from ATP hydrolysis, these complexes are able to slide, disrupt, evict 
nucleosomes or exchange histone-dimers (Clapier and Cairns 2009). A subclass of the 
SWI2/SNF2 superfamily of enzymes is responsible for H2A.Z incorporation in chromatin 
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(Morrison and Shen 2009). In yeast, the complex responsible for H2A.Z deposition is 
SWR1; it removes H2A-H2B dimers to replace it by H2A.Z-H2B dimers. For to perform 
this action, the SWI2/SNF2 ATPase/helicase domain of the SWR1 subunit is necessary 
(Figure 8). Recent studies in higher eukaryotes identified p400 and SRCAP (SWI2/SNF2-
related CBP activator protein) complexes as homologous to the SWR1 complex (Figure 8) 
(Kusch, Florens et al. 2004; Ruhl, Jin et al. 2006; Wong, Cox et al. 2007). The purification 
of these complexes showed functional conservation, as they were able to catalyze 
exchange activity similar to the yeast SWR1 complex. These different complexes may be 
involved in different types of H2A.Z exchange depending on cellular stimuli and chromatin 
context. 
Another important chromatin-remodeling complex, involved in H2A.Z deposition/eviction is 
INO80. It belongs to the same SWI2/SNF2 subfamily as Swr1 and plays a role in 
transcription, DNA repair and replication (Morrison and Shen 2009; Watanabe and 
Peterson 2010). Under stress conditions, the INO80 complex seems to be recruited to the 
coding regions for elongation of transcription as well as replication forks (Papamichos-
Chronakis and Peterson 2008; Klopf, Paskova et al. 2009). H2A.Z eviction in yeast 
suggests a role for this complex in the relocalization of H2A.Z under stress conditions. It 
remains to be determinated if the described mammalian INO80 complex has similar roles 
in higher eukaryotes (Conaway and Conaway 2009). In addition, it has recently been 
shown that eviction of H2A.Z by INO80, from an in vitro exchange, is ATP-dependent 
(Papamichos-Chronakis, Watanabe et al. 2011). 
Some other complexes are involved in H2A.Z deposition: TIP48/TIP49 containing 
SWR1/SRCAP (Cai, Jin et al. 2005) and/or TIP60/P400 (Ikura, Ogryzko et al. 2000), 
(Kusch, Florens et al. 2004). It has been shown that p400 is responsible for H2A.Z 
incorporation into the TFF1/pS2 gene when the estrogen receptor binds the promoter 
(Gevry, Hardy et al. 2009). Moreover, was reported that the AAA+ family (ATPases 
Associated with various cellular Activities) members TIP48/TIP49 participate in the 
exchange H2A – H2A.Z (Choi, Heo et al. 2009). The replacement is facilitated by TIP60-
mediated H2A acetylation. TIP48/TIP49 proteins (also known as TIP49b/TIP49a, 
Rvb2/Rvb1 or even reptin/pontin) are important for assembly and activity of the histone 
acetyltransferase TIP60 complex (Jha, Shibata et al. 2008)(Dalvai et al., 2013 PLOS 
Genetics, in press). 
In higher eukaryotes, the p400 protein is associated with Tip60, a MYST-family 
acetyltransferase, creating a physical merge of the yeast SWR1 remodeler and NuA4 
acetyltransferase complexes (Figure 8). Drosophila's Tip60 is able to acetylate and 
exchange H2A.Z and has a p400/domino subunit homologous to SWR1 (Eissenberg and 
Elgin 2005). In human cells, p400 is implicated in the p53/p21 senescence pathway by 
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inhibiting p21 and stimulating p53 toward apoptosis (Fuchs, Gerber et al. 2001; Chan, 
Narita et al. 2005; Samuelson, Narita et al. 2005). This complex is involved in H2A.Z and 
responsible for incorporation of H2A.Z at specific promoters in vivo (Gevry, Chan et al. 
2007; Gevry, Hardy et al. 2009; Cuadrado, Corrado et al. 2010). 
Figure 8. SWR1-related complexes in mammalian cells. (Billon and Cote 2012) 
C. H2A.Z on gene promoters. 
Several studies using chromatin immunoprecipitation (ChIP) in S. cerevisiae have shown 
that H2A.Z maps preferentially to the 5’ ends of genes within euchromatic regions 
(Guillemette, Bataille et al. 2005; Li, Pattenden et al. 2005; Zhang, Roberts et al. 2005), 
(Dalvai, Bellucci et al. 2012). In fact, the common feature of yeast RNA polymerase II 
promoters is the presence of an approximately 150bp-long nucleosome-free region 
located about 200 bp upstream of the translation initiation codon (Yuan, Liu et al. 2005). 
ChIP-microarray analysis shows that H2A.Z is specifically found in the nucleosomes that 
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flank these nucleosome-free regions (Raisner, Hartley et al. 2005). Moreover, some of 
these yeast studies show that H2A.Z is associated with inducible genes under repressed 
or basal-expression conditions (Guillemette, Bataille et al. 2005; Millar, Xu et al. 2006). 
Interestingly, depleting H2A.Z in yeast did not repress genes but activation of transcription 
was reduced. Therefore, H2A.Z localization at the 5’ of genes may act to set up a 
chromatin architecture compatible with gene regulation at promoters. 
Similar studies in mammalian cells show that H2A.Z preferentially localizes to gene 
promoters (Barski, Cuddapah et al. 2007; John, Sabo et al. 2008; Dalvai, Bellucci et al. 
2012). However, there are some distinctive characteristics of H2A.Z distribution in 
mammalian cells. First, H2A.Z deposition spreads over several nucleosomes upstream 
and downstream of the transcription starting site (Schones, Cui et al. 2008). Second, in 
human T cells, H2A.Z enrichment is correlated with gene activity, since H2A.Z is often 
associated with actively expressed genes (Barski, Cuddapah et al. 2007). Additional 
studies show that H2A.Z can be found at promoters of inducible genes. In fact, genome 
wide analysis of chromatin at binding sites of a nuclear hormone receptor, the 
glucocorticoid receptor (GR), revealed an enrichment of H2A.Z at constitutive and 
hormone-induced GR-binding sites (John, Sabo et al. 2008). Similarly, a recent study 
shows that H2A.Z can recruit Brd2 to Androgen-Receptor-regulated genes. Brd2 seems to 
be a coactivator of transcription of the BET family of proteins, containing tandem 
bromodomains to bind acetyl-lysines. The primary site of interaction between Brd2 and 
H2A.Z is acetylated H4, a mark of gene activation (Draker, Ng et al. 2012). In the same 
manner, different studies in our laboratory show a characteristic localization and behavior 
of H2A.Z on the promoters of inducible genes. H2A.Z localizes to the starting site (in the 
case of Cyclin D1 gene also at the 3’ end of the gene) and, after gene induction, its 
enrichment decreases but the rate of H2A.Z acetylation increases, which finally activates 
gene expression (Dalvai, Bellucci et al. 2012). We will have the possibility to discuss these 
H2A.Z characteristics later. Similarly, H2A.Z is enriched at the promoter of the p53-
regulated p21 gene in U2OS osteosarcoma cells and target p53 binding sites (Gevry, 
Chan et al. 2007). In this case, H2A.Z depletion activates p21. On the other hand, we 
demonstrated that for the same p21 gene in another cellular context (ER-negative, p53-
negative breast cancer cells), the depletion of H2A.Z was not sufficient to activate p21. 
We needed to increase H2A.Z acetylation for p21 expression. Hence, H2A.Z acetylation 
seems to be more important than the presence of the non-acetylated form of H2A.Z for 
gene activation (Bellucci et al., 2012). 
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D. H2A.Z and regulation of gene expression. 
The localization of H2A.Z at gene promoters close to the TSS suggests that this histone 
variant has a role in regulating gene expression. For example, in yeast, GAL1/GAL10 
genes are activated upon switching from glucose to galactose-containing growth media, 
and PHO5 gene is induced upon growth under low phosphate conditions. Some studies 
have shown that H2A.Z is required for the induction of these genes. In fact, when H2A.Z is 
depleted their activation is greatly impaired (Santisteban, Kalashnikova et al. 2000; Adam, 
Robert et al. 2001). In the same manner, H2A.Z is enriched at the promoters of heat 
shock activated genes. Only an attenuated activation of these genes occurs after H2A.Z 
depletion (Zhang, Roberts et al. 2005). 
Deletion of H2A.Z in S. cerevisiae results in downregulation of 214 genes, the majority of 
which are clustered at regions adjacent to telomeres (Meneghini, Wu et al. 2003). The 
authors suppose that downregulation is a consequence of heterochromatin spreading into 
adjacent euchromatin. Sir2/3 (the heterochromatin-associated proteins) are found in the 
telomere-proximal euchromatin regions in the mutant strain htz1. Interestingly, deletion 
of Sir2 in the htz1 background restored expression of many downregulated genes. This 
study defines a role for H2A.Z in regulating expression of the genes located near 
heterochromatin-euchromatin boundaries, and suggests that H2A.Z antagonizes the 
physical spreading of heterochromatin. A similar function is conserved in higher 
eukaryotes. H2A.Z is distributed throughout euchromatin regions of the mouse cell 
nucleus, and is excluded from the pericentric heterochromatin (Sarcinella, Zuzarte et al. 
2007). ChIP analysis in chicken and human T cells show that H2A.Z is enriched at 
insulator regions (Bruce, Myers et al. 2005; Barski, Cuddapah et al. 2007). If insulators 
are specialized structures that define heterochromatin-euchromatin boundaries, the 
presence of H2A.Z at these structures supports a role in mediating a boundary function for 
H2A.Z. 
Finally, many studies suggest a repressive role of H2A.Z on inducible genes. It is the case 
of p21, upon DNA damage, in U2OS and in a p53-dependent manner (Gevry, Chan et al. 
2007). In fact, depletion of H2A.Z results in the derepression on the p21 gene. This is not 
always the same case: changing cellular context and p53 status changes the role of 
H2A.Z. Our studies on inducible genes show that depleting H2A.Z activates gene 
expression, and this activation is accompanied by an increase in H2A.Z acetylation 
(Dalvai, Bellucci et al. 2012). The same phenomenon was observed on the p21 gene in 
ER, p53-negative cells (MDA-MB231). Here, however, depletion of H2A.Z was not 
sufficient to activate p21. To activate p21, in fact, it was necessary to increase H2A.Z 
acetylation, using for example a treatment with HDACi (Bellucci, Dalvai et al. 2013). 
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Thus, it becomes clear that post-translational modifications of H2A.Z, as of all the other 
histones and their variants, are key for regulating gene expression. 
E. H2A.Z acetylation. 
The N-terminal tail of H2A.Z is acetylated in different species (Bruce, Myers et al. 2005; 
Mehta, Braberg et al. 2010; Dalvai, Bellucci et al. 2012). Human H2A.Z is acetylated at 
residues K4, K7, K11 and K13 while yeast H2A.Z is at K3, K8, K10 and K14 residues 
(Raisner, Hartley et al. 2005; Samuelson, Narita et al. 2005; Halley, Kaplan et al. 2010). In 
yeast, the predominant acetylation site is the K14 and several groups have reported that 
Esa1 (the histone acetyltransferase found within the NuA4 HAT complex) and Gcn5 (the 
HAT part of the SAGA complex) are responsible for H2A.Z acetylation in vivo (Keogh, 
Mennella et al. 2006; Millar, Xu et al. 2006). H2A.Z K14 acetyl is found on the promoters 
of actively transcribed genes, whereas the non-acetylated form is associated with 
inducible but repressed genes (Millar, Xu et al. 2006). Similar studies in chicken cells have 
shown that the acetylated form is concentrated at the 5’ end of active genes but absent 
from inactive gene (Bruce, Myers et al. 2005). In addition, activation of genes in 
mammalian cells is accompanied by loss of H2A.Z at the 5’ end of genes: this is the case 
for c-myc gene upon activation by interleukin-2 (Farris, Rubio et al. 2005), p53-regulated 
p21 upon DNA damage (Gevry, Chan et al. 2007) and GR-regulated genes upon hormone 
activation (John, Sabo et al. 2008). Valdés-Mora et al. however, suggested in a genome-
wide analysis that in prostate cancer cells, acetylation of H2A.Z at the promoter of genes 
correlated with their activity and with tumor development (Valdes-Mora, Song et al. 2012). 
We further developed this notion by demonstrating that acetylation of H2A.Z is a key 
player for gene activation in breast cancer cells. While the total amount of H2A.Z usually 
decreases after induction, the ratio of acetylated H2A.Z/total H2A.Z increases and leads 
to gene activation (Dalvai, Bellucci et al. 2012; Bellucci, Dalvai et al. 2013). (Figure 9) 
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Figure 9. H2A.Z deposition by the SWR1 complex and the connection with histone acetylation. (1) 
Canonical H2A, H4 and variant H2A.Z histones are acetylated by yeast NuA4 acetyltransferase. (2) 
Acetylation of H2A and H4 N-terminal tails by NuA4 stimulates the SWR1 complex through interaction 
with its bromodomain subunit Bdf1. This leads to enhanced ATP-dependent dimer exchange activity 
which replaces H2A–H2B dimers with H2A.Z–H2B dimers. (3) NuA4 might acetylate H2A.Z N-terminal 
tails to promote local chromatin remodeling and gene activation. (Billon and Cote 2012) 
III. HDAC inhibitors. 
We have seen in the preceding chapters that histone acetylation directs regulation of gene 
expression. The balance between histone acetylation (performed by histone 
acetyltransferases (HAT)) and histone deacetylation (performed by histone deacetylases 
(HDAC)) is important for this process. The ability to move this balance in favor of hyper- or 
hypo-acetylation of histones allows modulation of gene expression. 
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HDAC enzymes, in fact, play an important role in cell proliferation and are involved in 
several pathologies, in particular in cancer. 
Purification and characterization of HDAC enzymes lead to the development of specific 
inhibitors for the different classes of HDAC (HDACi). HDAC inhibition is now considered 
for experimentally modifying gene expression and, as a consequence, also for therapeutic 
treatments.  It is possible to propose therapeutic trials adapted to different cancer types, 
depending on the HDAC involved. 
Histone deacetylase enzymes can be inhibited by different means. First, using RNAi to 
inhibit the mRNA translation; second, by using molecules, such as MC1568 
(Scognamiglio, Nebbioso et al. 2008) or the DIM (3,3’-diindolylmethane) (Li, Li et al. 
2010), which allow protein degradation. Moreover, using for example calyculine A, protein 
complexes formation which are important for HDAC function can be blocked. This 
compound inhibits all cellular phosphorylation phenomena and the action of some HDAC. 
However, several compounds that inhibit the catalytic activity are available. They 
specifically block or compete with access to the active site of the enzymes. Among these, 
there are Trichostatin A (TSA) and Sodium Butyrate (from natural sources), and SAHA, 
Tubacin and others (which are synthetic) (Figure 10). 
One of the most powerful HDAC inhibitors is TSA. This compound is produced by 
Streptomyces during fermentation. TSA is, naturally, an antifungal agent, but in 1990, 
Yoshida showed that it is able to inhibit HDACs (Yoshida, Hoshikawa et al. 1990). TSA is 
able to inhibit the HDAC enzymes of class I, II and IV. 
In general, there are six classes of HDACi: the carboxylates, the benzoamides, the epoxy 
acetones, the cyclic peptides, the hybrid molecules and the hydroxamic acids and their 
derivatives (Figure 10). Most known HDACi are pan-inhibitors of one or more classes of 
HDAC enzymes.  
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Figure 10. Structural classes of HDAC inhibitors. Six basic classes of HDAC inhibitors are shown: a) 
small-molecular-weight carboxylates, including sodium butyrate, valproic acid, and sodium 
phenylbutyrate; b) hydroxamic acids, including CBHA, TSA, SAHA, and LAQ824; c) benzamides, 
including MS-275 and CI-994; d) epoxyketones, including AOE and trapoxin B; e) cyclic peptides, 
including depsipeptide and lapicidi; and f) hybrid molecules, such as CHAP31 and CHAP50 
(Drummond, Marx et al. 2005). 
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A. Inhibitors for HDAC class I/II. 
The inhibitors of the HDAC class I and II can regulate gene expression directly via histone 
hyper acetylation or indirectly through the acetylation of transcription factors controlled by 
this modification type. Generally, the HDACi regulated genes are involved in proliferation 
and cellular cycle progression (oncogenes or oncosuppressors), cell survival, DNA 
replication or repair, or protein degradation by the ubiquitin/proteasome system 
(Drummond et al., 2005). Natural molecules like Sodium Butyrate (NaBu), the 
phenylbutyrate (PB), the phenylacetate (PA) and valproic acid (VPA) are carboxylates. 
These compounds have a lower efficiency than hydroxamic acids (Gottlicher, Minucci et 
al. 2001). VPA is used as an anti-epileptic treatment. The NaBu can be obtained from 
fermentation of an anaerobic bacteria present in the human intestinal lumen. It is known to 
be a non-competitive inhibitor of HDAC but it is less specific and powerful than TSA (Kruh 
1982). 
MS275 and N-acetyldinaline are benzamides and act like the hydroxamates on the active 
site of the HDAC (see below). MS275 has a strong inhibitory activity (Saito, Yamashita et 
al. 1999) and has entered clinical trial phase under the brand name Etunostat. The 
cyclopeptides are characterized by their structure and their strong inhibitory action of 
HDAC. They have a bacterial or fungal origin. Trapoxine, for example, at nanomolar 
concentration induces histones hyperacetylated accumulation in mammalian cells and 
inhibits in an irreversible manner the purified HDAC deacetylation (Kijima, Yoshida et al. 
1993). The CHAPs inhibitors (Cyclic hydroxamic acid-containing peptides) are TSA and 
Trapoxine hybrids and have a reversible action on HDAC (Furumai, Komatsu et al. 2001). 
Since the 1990s, TSA remains the HDAC inhibitor of reference. The inhibitory activity of 
TSA in the catalytic pocket of HDAC has been a model for the synthesis of other 
inhibitors. For example, SAHA, also called Vorinostat, is a HPC (Hybrid polar compounds) 
synthetic compound, which is a hydroxamic acid inhibitor of second generation (Richon, 
Emiliani et al. 1998). 
B. Inhibitors for class III HDACs 
Different type of compounds, synthetic or natural, can inhibit Sirtuin deacetylase activity. 
Nocotinamide, for example, a product of the deacetylation reaction, is a non-competitive 
inhibitor for HDACs of class III. There is also the splitomycine, found by screening 
(Bedalov, Gatbonton et al. 2001). But, the most commonly used is sirtinol (Sir 2 inhibitor 
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naphtol) (Grozinger, Chao et al. 2001). To study sirtuins, activator compounds can be 
used to stimulate their activity. One of them, Reveratrol, is also a SERM (Selective 
Estrogen Receptor Modulator). Such compound is of interest since it emphasizes the link 
between estrogen receptor and HDAC activities (Bhat, Lantvit et al. 2001). 
Increasingly often, the HDAC inhibition is used in fundamental or clinical research to 
modulate gene regulation. In particular, our group is interested in estrogen-dependent 
gene regulation in breast cancer cell lines. Therefore, we decided to use the characteristic 
effects of HDAC inhibitors to investigate changes in gene expression and regulation (see 
Results). Here, the aim is to introduce and explain the basis of estrogen-dependent gene 
regulation: the mechanisms, the actors, the “exceptions” and the aberrations.  
IV. Estrogen-dependent gene regulation. 
Four pathways controlling estrogen-activated transcription have been described (Hall, 
Couse et al. 2001) (Figure 11) 
• The classic pathway (genomic pathway): ER binds estradiol, dimerizes and 
associates with EREs (estrogen Responsive Elements) within regulatory 
sequences of estrogen-regulated genes. 
• The growth factor dependent pathway: growth factors activate kinase function to 
phosphorylate a variety of transcription factors, including AP1 and ER. Activation 
of ER-target genes can occur in the absence of estradiol, but still requires ER. 
• The ERE-independent pathway. In this pathway, the ER interacts with other 
transcription factors and does not need to bind ERE sequences on DNA. 
• The non-genomic pathway. ER plays no direct role in gene expression. 
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Figure 11. The different mechanisms of estradiol and estrogen receptor signaling. The biological 
effects of estradiol (E2) are mediated through four ER pathways. 1, classical ligand-dependent, E2-ER 
complexes bind to EREs in target promoter leading to an up- or down-regulation of gene transcription. 
2, ligand-independent. Growth factors (GF) activate intracellular kinase pathways, leading to 
phosphorylation (P) and activation of ER at ERE-containing promoters in a ligand-independent 
manner. 3, ERE-independent, E2-ER complexes alter transcription of genes containing alternative 
response elements such as AP-1 through association with other DNA-bound transcription factors 
(Fos/Jun), which tether the activated ER to DNA, resulting in an up-regulation of gene expression. 4, 
Cell-surface (nongenomic) signaling, E2 activates a putative membrane-associated binding site, 
possibly a form of ER linked to intracellular signal transduction pathways that generate rapid tissue 
responses. (Hall, Couse et al. 2001) 
When ER is inactive, it is present in cell as a monomeric form aporeceptor. This monomer 
shuttles between the cytosol and the nucleus, and is associated with a multiprotein 
complex: dimers of heat shock protein hsp90 (Catelli, Binart et al. 1985), a monomer of 
hsp70 (Ratajczak, Carrello et al. 1993), the p59 protein (Renoir, Radanyi et al. 1990) and 
many other proteins (Segnitz and Gehring 1995). Hsp90, hsp70 and the other proteins, 
bind the receptor to keep it in a “standby” conformation, ready to associate with ligands 
(Bohen 1995). 
Estradiol binds to the ER in the cytosol; activated ER dissociates from the chaperon 
protein complex. The hormone binds the E domain of ER (Figure 11). The ligand-binding 
domain (LBD) changes conformation. This conformational change allows the passage at a 
phosphorylate and transcriptionally active form of ER. This phosphorylation is performed 
after E2 binding and increases the affinity of the ER/E2 complex (Denton, Koszewski et 
al. 1992). 
E2 binding induces ER dimerization, essential for the normal functions of ER. Mutations 
that block the dimerization inactivate ER (Lees, Fawell et al. 1990). In all the cases, the 
agonists as well as the antagonists of ER, stabilize the dimer (Tamrazi, Carlson et al. 
2002). ER dimers, in the nucleus, bind DNA on the ERE sequences which are minimal 
palindromic sequence of 13bp: 5’-GGTCAnnnTGACC-3’ (Klein-Hitpass, Ryffel et al. 
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1988). In fact, the majority of EREs are imperfect palindromes; this is the case of the ERE 
on pS2/TFF1 promoter (Berry, Nunez et al. 1989), of the half ERE on the cathepsin D 
promoter and it’s the same (half ERE) for the progesterone receptor (PR) promoter 
(Augereau, Miralles et al. 1994). ER in complex with an agonist or antagonist has the 
same affinity for the ERE sequences (Cheskis, Karathanasis et al. 1997). Once 
associated with EREs, ER recruits many cofactors, which can be transcription activators 
or repressors depending on the target gene (Klinge, Jernigan et al. 2001) (Table 1-2). The 
majority of the phosphorylation sites of ER localize in the AF-1 domain on the protein 
(Figure 12). The Cdk2/cyclineA complex phosphorylates the serines 104 and 106 
(Rogatsky, Trowbridge et al. 1999). Serine 118 can be phosphorylated in two manners: in 
an estrogen-dependent manner, via the cdk7 subunit of TFIIH complex (Chen, Riedl et al. 
2000) or in an estrogen-independent manner via MAP kinases activity (Kato, Endoh et al. 
1995; Bunone, Briand et al. 1996). RSK1, a kinase of the MAPKs pathway, 
phosphorylates the serine 167 (Joel, Smith et al. 1998). The same serine can be 
phosphorylated also by AKT (Campbell, Bhat-Nakshatri et al. 2001). PKA phosphorylates 
the serine 236, which localizes in the DNA binding domain (Chen, Pace et al. 1999). 
Finally, the Src tyrosine-kinases family can phosphorylate ER in the E region on the 
tyrosine 537 (Migliaccio, Wetsel et al. 1993; Arnold, Vorojeikina et al. 1995).  
Figure 12. Schematic diagram of the human estrogen receptor, ER. The estrogen receptor consists of 
six functional domains, including the DNA-binding domain (DBD), the ligand-binding domain (LBD), 
the ligand-independent activation function AF-1, and the ligand-dependent activation function AF-2. 
(Adapted from (Shao and Brown 2004)). 
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Table 1-2. Adapted from (Hall and McDonnell 2005). 
In the majority of the cases, the ER phosphorylation has a positive effect on the 
transcriptional activity. The phosphorylated AF-1 domain is a docking platform for the 
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recruitment of chromatin modification and remodeling complexes. In addition, the AF-2 
domain can also be phosphorylated (Figure 12). The Src kinases are able to 
phosphorylate ER on the tyrosine 537. This phosphorylation can control, maybe through 
a conformational change, the ER/E2 binding, the ER dimerization (Migliaccio, Wetsel et 
al. 1993; Arnold, Vorojeikina et al. 1995) and/or cofactor recruitment. The PKA (Protein 
kinase A) can negatively regulate ER in absence of hormone. In fact, this enzyme 
phosphorylates ER on serine 236 and prevents its dimerization (Chen, Pace et al. 1999). 
ER is a target for other post-translational modifications. Certain lysine residues can be 
acetylated by p300 (Wang, Fu et al. 2001). In addition, ER acetylation is ligand- and 
p160-dependent. Lysines 266 and 268 are targeted by p300. The acetylation of these 
residues increases the ER binding to the DNA and its ligand-dependent transcriptional 
activity (Kim, Woo et al. 2006). ER can be sumoylated by SUMO-1; this modification has 
an impact on the transcriptional activity of ER (Sentis, Le Romancer et al. 2005). Finally 
ER can be ubiquitinated, the ubiquitination plays a role in ER degradation via the 
proteasome (Nawaz, Lonard et al. 1999) and in ER activity regulation (Reid, Hubner et 
al. 2003).  
Finally, ER can bind DNA in an ERE independent manner. When bound by ligands, the 
ER can behave as a cofactor for other transcriptional factors: fos/jun (AP-1), Sp1, NF-kB 
or ATF-2/c-jun (Nilsson, Makela et al. 2001; Baron, Escande et al. 2007). ER forms 
different complexes that are able to recognize different promoter elements (responding to 
AP-1, to SP1, to NF-kB) and modulate the transcription by “docking”. In fact, ER after E2 
binding can interact with fos/jun transcription factors to modulate their transcriptional 
activity when they bind DNA via the AP-1 sites (Gaub, Bellard et al. 1990). Moreover, the 
complex ER/E2 can bind physically with Sp-1 protein modulating its transcriptional 
activity (Porter, Saville et al. 1997; Saville, Wormke et al. 2000). The effects of this 
interaction on the transcription are cell type dependent (Saville, Wormke et al. 2000; Safe 
2001). In addition, several studies have shown that the ER/E2 complex inhibits the NF-
kB activity (Stein and Yang 1995; Harnish, Scicchitano et al. 2000). A study shows that in 
U2OS and MFC-7 cell lines, the ER/E2 complex interacts with NF-kB and prevents its 
binding at the response elements present on the IL6 gene promoter (Stein and Yang 
1995). In conclusion, ER/E2 binds ATF-2/c-jun increasing the transcriptional activity on 
the CRE (cAMPC response element) sites. This induction, described for the CCND1 
(Cyclin D1) expression regulation, is hormone-dependent and needs the functions of AF-1 
and AF-2 domains on ER (Sabbah, Courilleau et al. 1999). 
In 1994, Lieberherr and Gross have shown the increase of the intracellular concentration 
of calcium, inositol triphosphate (IP3) and diacylglycerol (DAG), after estradiol induction. 
In addition, they showed that using pertussis toxin (which blocks the receptor binding G 
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proteins), it is possible to prevent these effects. These observations suggest the existence 
of a cell membrane receptor, involved in estrogen response, coupled to phospholipases 
and proteins (Lieberherr and Grosse 1994). G-proteins coupled receptors represent a 
large receptor family with seven transmembrane domains. They recognize stimuli in 
heterodimeric form (G) to dissociate the complex in G G subunits (Gatherer 2000). 
The best candidate to translate estrogen activation in this manner is the G-proteins 
coupled receptor G30 (GPR30). Thomas and collaborators have shown a strong affinity of 
E2 for GPR30 in ER-negative but GPR30-positive cells (Filardo and Thomas 2005). 
Moreover, they have shown that GPR30 activation induces calcic mobilization and MAP 
Kinases pathway activation (Revankar, Cimino et al. 2005). In addition, this membrane 
receptor seems to be involved in anti-estrogens resistance effects. 
V. Breast cancer. 
Cancer is a major health problem, which is actually the first cause of death in men (33%) 
and the second cause of death in women (23%). In the past 20 years, the mortality rate 
was diminished by 22% with an acceleration in decrease during the last 10 years for men. 
For women, mortality also decreased but not with the same trend as for men in the same 
period. 
Breast cancer in particular, is a pathology with a slow evolution. The main risk is 
development of metastasis, which represents the first cause of death for this disease. 
There are different types of breast cancer, among which adenocarcinomas are the most 
common (95%). The breast cancer evolves from channels (canal cancers) or from lobes 
(lobular cancers) of mammary glands. They are called in situ if the cancer cells are 
confined to the canals or lobes, and infiltrating if the cancer cells are present in 
neighboring tissues. In this latter case, the malignant cells spread into the ganglions in the 
armpits, but also in the rest of organism. 
Upon diagnosis, a breast cancer is classified for its morphology, size, invasive capacity, 
and for the presence of hormone receptors or for hyper-expression of HER2 protein 
(Human epidermal growth factor receptor). Recently, this classification has been 
improved, thanks to genomic analysis that permits distinction into luminal, basal or HER2+ 
type cancers. The basal cancers (or cell lines) are the most aggressive ones. 
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A. Breast cancer treatments. 
The treatment depends on the patient. Depending on the tumor characteristics, five 
different treatments are possible and frequently combined: surgery, radiotherapy, 
chemotherapy, hormone therapy and targeted treatments.  
Our group is interested in the gene regulation program induced upon hormone treatments. 
Important differences characterize tumors that express the Estrogen Receptor and tumors 
that do not express this receptor. The first one can be treated by hormone-therapy, while 
the second type is insensitive to all hormonal treatments. Hormone therapy works by 
blocking the activity of the estrogens, which are the steroid hormones involved in the 
development of breast cancer. There are different strategies: the suppression of the 
estrogens production via oophorectomy; the inhibition of the steroidal precursor 
conversion in estrogen using aromatase inhibitors (AI) or, finally, the direct inhibition of the 
estrogen receptors (ER) activity. This last approach uses anti-estrogen compounds as 
competitive inhibitors of estrogens such as SERMs (Selective estrogen receptor 
modulator): Tamoxifen or Raloxifen for example. Alternatively, pure anti-estrogen 
compounds such as ICI182780 (Fulvestrant) which bind to ER and induce its degradation 
and are therefore called SERD (Selective estrogen receptor disruptor) (Howell 2000) can 
be administered. 
These treatments are helpful for the cancer type called "hormone-dependent". Clinically, 
there are some biological markers used to predict the cancer hormone-therapy response 
(Osborne and Schiff 2005; Nguyen, Taghian et al. 2008). The key biomarkers are 
expression levels of ER, PR (progesterone receptor) or HER2 in cancer biopsies. 
B. Biomarkers. 
The majority of breast cancers (60 – 70%) are hormone-dependent. The analysis of ER
expression level consents to classify clinically the cancer in two categories: breast 
cancers called ER+ (Estrogen receptor positive, hormone-dependent) and the cancers 
called ER- (Estrogen receptor negative, hormone-independent). Actually, the presence of 
ER is associated with a better vital prognosis.  
The progesterone receptor has two isoforms (PRA and PRB), which are under the control 
of E2 and reflect the good functioning of ER. In fact, a study has shown that 53% of 
patients ER+ respond to hormonal therapy. This proportion increases to 69% if the tumor 
is ER+ PR+, and decreases to 32% if the cancer is ER+ PR- (Horwitz 1988). 
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HER2 expression is also used for the choice of the therapy (Skliris, Leygue et al. 2008). In 
fact, HER2 hyper-expression allows erbB2 (Erythroblastic leukemia viraloncogene 
homolog 2) expression, which plays a major role in the development of the tumors called 
HER2+ (Slamon, Clark et al. 1987). Recently, Arteaga et al. have shown that 30% of 
breast cancers overexpress HER2 and that it is a negative indicator for survival (Arteaga, 
O'Neill et al. 2008). Based on these markers we can distinguish four therapeutic 
categories: ER+/HER2-, ER+/HER2+, ER-/HER2+, ER-/HER2-. 
Hormonal therapies are based on the use of SERMs and SERDs. SERMs are divided into 
two families: the triphenyllethylenic derived, the most used being Tamoxifen and the 
benzothiophene derivative, Raloxifen (Jordan, Gapstur et al. 2001). Tamoxifen has been 
one of the first and most effective therapy for the treatment and prevention of breast 
cancer (Jordan, Osipo et al. 2003). This molecule can behave like estrogens or anti-
estrogens depending on the tissue (Jordan, Gapstur et al. 2001). In some cell lines where 
this molecule acts like an antagonist, it induces the recruitment of several transcriptional 
corepressors by ER. In endometrial cells, where it acts like an agonist, tamoxifen induces 
the recruitment of transcriptional coactivators (Shang and Brown 2002).  
The secondary effects of SERMs have induced the development of another class of 
modulators: SERDs (Miller, Bartlett et al. 2007). The compound ICI182780 is the SERD's 
most employed in therapy (Osborne, Wakeling et al. 2004). Unlike SERMs, which stabilize 
ER and induce an increase in protein accumulation, SERDs induce rapid degradation of 
the ER via the proteasome (Callige, Kieffer et al. 2005). In fact, SERDs bind the ER
and direct it on the ERE present on the promoters of ER regulated genes allowing the 
recruitment of the corepressor N-CoR (Nuclear receptor corepressor) (Webb, Valentine et 
al. 2003). SERDs can block breast cancer cell proliferation of MCF-7 (ER + cell line) 
(Pink and Jordan 1996). The ICI182780 is an interesting treatment used for the 
Tamoxifen-resistant breast cancers (Fan, Wang et al. 2007). 
In contrast with SERMs and SERDs, Aromatase Inhibitors (AI) do not interact directly with 
the ER, but prevent estrogens synthesis by inhibiting the aromatase enzyme (CYP19A1), 
which converts androgens into estrogens in tumors (Bulun, Lin et al. 2009).  In fact, AI 
inhibits the aromatase activity and diminishes estrogens concentration until almost 
undetectable levels (Ali and Coombes 2002).  
All these compounds and treatments target the normal estrogenic regulation. To better 
understand how the treatments or/and therapy work, we need investigate the mechanisms 
that underlie canonical estrogen-regulation. 
Tumors and cells that are non-responsive to estrogen and hormone-treatments are, as 
said, more aggressive and difficult to treat. One of the major characteristics of these cells 
 
is the loss of the canonical cell cycle regulation. ER-negative MDA-MB231 cells, for 
example, have a non-functional p53 protein. This loss leads to the deregulation of the 
normal p53 pathway, which is involved in several processes, as well as DNA damage 
response, apoptosis, cell survival, etc. (Gartel and Radhakrishnan 2005). One of the most 
important effector of p53 signaling is p21 (Waldman, Kinzler et al. 1995). The loss of a 
functional p53, is frequently also associated with loss of p21 expression. As a 
consequence, cell cycle control is lost and cells become hyperproliferative and more 
aggressive. 
VI. P21 
p21CIP1/waf1 is a cyclin-dependent kinase inhibitor (cdki) belonging to the Cip/kip family. 
This transcription factor negatively modulates cell cycle progression by mainly inhibiting 
the activity of cyclin/Cdk2 complexes during G1 phase, and cyclin/Cdk1 during G2 phase. 
Overexpression of p21 results in G1 or S phase arrest (Ogryzko, Wong et al. 1997). 
Similarly, cells lacking p21 cannot properly block cell cycle in response to p53 activation 
following DNA damage (Waldman, Kinzler et al. 1995). 
Various mechanisms exist to regulate the levels of p21 in a cell. There is a transcriptional 
regulation throughout the cell cycle, following DNA damage, and during differentiation and 
senescence (Gartel and Radhakrishnan 2005). c-Myc is a proto-oncogene which 
represses p21 transcription. The exact mechanism of repression is not clear and still 
controversial but c-Myc may employ a multitude of pathways to repress p21 (Caldon, Daly 
et al. 2006). Likewise, epigenetic silencing or modifications of mRNA stability are known to 
modify p21 activity. In addition, the stability of p21 is regulated by proteasomal 
degradation. An ubiquitin ligase, Skp2, triggers p21 degradation by ubiquitination of the N-
terminal part of the protein (Bloom and Pagano 2004). P21 can also be inactivated by 
PKB/Akt phosphorylation that leads to a cytoplasmic localization (Liang and Slingerland 
2003).  
This protein mediates growth arrest after a transcriptional activation by p53 when cells are 
exposed to DNA damaging agents such as Doxorubicin or -irradiation. In addition, p21 
can bind the proliferating cell nuclear antigen (PCNA) and thereby block DNA synthesis 
(Brugarolas, Moberg et al. 1999) (Waga, Hannon et al. 1994). Apart from p53, a variety of 
other factors including Sp1/Sp3, Smads, Ap2, signal transducers and activators of 
transcription (STAT), BRCA1, E2F-1/E2F-3, and CAAT/enhancer binding protein  and 
are known to activate p21 transcription (Gartel and Tyner 1999). 
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A. The p21 promoter and HDACi activation of p21. 
p21 expression can be modulated via promoter composition changes. In fact, the proximal 
p21 promoter contains six Sp1 binding sites (Gartel, Goufman et al. 2000). Both Sp1 and 
Sp3 factors were found to regulate promoters of several cell cycle regulating genes, 
whereby Sp1 is a potent trans-activator and Sp3  rather a repressor (Birnbaum, van 
Wijnen et al. 1995). Co-factors such as p300/CBP and the p300/CBP-associated factors 
(PCAF) that possess intrinsic HAT activity cooperate with Sp1/Sp3 to induce expression 
of the p21 promoter in response to different stimuli (Owen, Richer et al. 1998; Billon, 
Carlisi et al. 1999; Kardassis, Papakosta et al. 1999). P300/CBP can be stimulated by 
p21-induced inhibition of their repressor domains in the amino-terminal end of the protein 
(Snowden, Anderson et al. 2000). 
Many reports indicate that HDACi induce p21 expression mainly by activating the Sp1/Sp3 
pathway independently of p53 (Nakano, Mizuno et al. 1997; Gartel and Tyner 1999). 
Recent studies clearly show that multiple factors, such as ATM (Ju and Muller 2003) and 
c-Myc (Li and Wu 2004) are involved in HDACi-induced p21 expression in several human 
cancer cell lines. A direct role for p53 in HDAC-associated p21 expression has also been 
reported (Lagger, Doetzlhofer et al. 2003). 
HDACi induce p53-independent expression of p21 via Sp1-binding sites in the p21 
promoter. In fact, it seems that HDAC1 competes with p53 to bind a specific region on the 
p21 promoter. After HDACi treatment, HDAC1 Is released from the Sp1-binding site at the 
p21 promoter leading to loss of repression and an induction of transcription (Figure 13). 
Furthermore, p300 is recruited to the p21 promoter (Zhao, Subramanian et al. 2006). 
Although Trichostatin A effectively induces p21 expression, cell cycle arrest and apoptosis 
in human gastric and oral carcinoma cell lines (Suzuki, Yokozaki et al. 2000), it has a 
lower ability to induce p53 acetylation but promotes the recruitment of co-activators to the 
p21 promoter and enhances histone acetylation around it (Barlev, Liu et al. 2001). The 
HDACi butyrate induces p21 and apoptosis in colorectal cancer cells (Mahyar-Roemer 
and Roemer 2001), and the absence of p21 increases butyrate-induced apoptosis in 
HCT116 colon cancer cells. Varinostat (SAHA) induces an up to nine-fold increase in p21 
mRNA and p21 protein in T24 bladder carcinoma cells (Richon, Sandhoff et al. 2000) 
mainly due to enhancement of acetylation of the histones H3 and H4 around the promoter 
region (Gui, Ngo et al. 2004). Moreover Lin et al. showed that HDAC1 and HDAC2 are 
recruited to the Sp1/Sp3 sites to repress p21 expression. Lovastatin expels HDAC1/2 
from the p21 promoter and recruits CBP, resulting in histone-H3 acetylation (Lin, Lin et al. 
2008). 
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The dissociation of HDAC and binding of p300/CBP to the gene promoter other than p21 
were only found in transforming growth factor- type II receptor induced by TSA (Huang, 
Zhao et al. 2005). The HDACi-induced p21 expression may depend on cellular context, 
p53 expression pattern, p21 promoter composition and other factors. In fact, we show that 
in ER- p53- negative breast cancer cells HDACi-induced p21 expression seems to depend 
on H2A.Z acetylation. In this cellular context the depletion of this histone variant prevented 
p21 activation by TSA treatments (see Results and Discussion) (Bellucci, Dalvai et al. 
2013). 
Figure 13. Schematic model of p21cip1/waf1 regulation. (A) Repression of the p21cip1/waf1 promoter 
by different factors acting at the transcriptional and the post-transcriptional (blue filled) level. Whereas 
some can bind at the p21cip1/waf1 promoter directly (Sp1, p53, p300, HDAC1, E2F), others interfere 
with these regulators (c-Myc, DNMT3a, DNMT1, PCNA). (B) Putative p21cip1/waf1 promoter status after 
HDACi treatment. Acetylated histones around the p21cip1/waf1 promoter facilitate the access of 
transcription factors and secondly, HDAC1 is released from the Sp1 site (where it competes with p53 
for binding at the p21cip1/waf1 promoter) leading to a loss of repression and induction of 
p21cip1/waf1 expression. Acetylated p53 has a higher binding efficacy and is recruited to the 
p21cip1/waf1 promoter together with co-activators such as p300 or P/CAF. (Ocker and Schneider-
Stock 2007) 
 

VII. Thesis project. 
As we have seen, epigenetic mechanisms play a major role in regulating gene expression.  
Recent advances in experimental and computational technologies (genome wide, ChIP-
seq, ChIP on Chip etc etc) rendered gathering genome-wide information on the presence 
and possible role of chromatin components possible, without, however, understanding the 
mechanisms that act at the level of a single gene, a precise protein and its modification in 
specific cell types. 
Using breast cancer cells as a model system, I was interested in the involvement of the 
histone variant H2A.Z in the transcriptional gene regulation. We decided to study the 
expression control of a non-ER target gene, p21. In the laboratory, we had two principal 
breast cancer cell types. MCF-7, which are ER positive, respond to antiestrogen 
treatment, in which ER-regulated genes are activated by addition of estradiol. MCF7 
cells express a wild type p53 protein. In contrast, the MDA-MB-231 cell line is ER-
negative and p53 is mutated. Their growth is insensitive to estradiol or antiestrogen 
treatments. In fact, some genes are constitutively silenced and some others escape to the 
canonical ER-dependent activation. Although epigenetic modifications are associated 
with their transcriptional states, the mechanisms by which these genes escape hormonal 
regulation durably are largely unknown.  
I focused on regulation of p21 gene expression in MDA-MB231 cells. P21 is 
transcriptionally repressed in MDA-MB231 and the findings on how p21 would be 
activated were controversial. A recent study had linked H2A.Z recruitment to p21 gene 
expression (Gevry, Chan et al. 2007). This study was performed in osteosarcoma cells, 
which are p53-positive. In this study, H2A.Z was shown to bind the p53-binding sites at 
the p21 promoter. For p21 activation, during DNA damage response, H2A.Z dissociates 
from the p53 binding sites to allow p53 to bind and to activate p21 transcription. At the 
same time, p21 expression is known to be stimulated by inhibitors of histone deacetylases 
(HDACi). Normally, this activation can be p53-independent or dependent, according to the 
cell system used (Nakano, Mizuno et al. 1997; Gartel and Tyner 1999; Lagger, 
Doetzlhofer et al. 2003). But the mechanism behind p21 activation, via HDACi, remains 
poorly understood. 
My challenge was to understand the implication of H2A.Z in p21 activation in MDA-
MB231 cells (ER-negative, p53 -/-). Would HDACi modulate this activation? 
My studies show that p21 gene activation in MDA-MB231 cells is p53-independent and 
controlled by the H2A.Z histone variant and its acetylation (Bellucci, Dalvai et al. 2013). 
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We found that H2A.Z was strongly associated with the transcription start site of p21. A 
TSA treatment stimulated p21 expression and increased acetylation of H2A.Z present at 
the p21 promoter. Depleting the cellular pool of H2A.Z compromised p21 activation and 
response to HDACi. Acetylation of H2A.Z rather than its association of regulatory element 
per se was important for p21 expression. 
It had been also shown that H2A.Z plays a role in Estrogen Receptor-dependent gene 
activation (Gevry, Hardy et al. 2009). In this study, using MCF-7 (ER-positive cell line) 
and the TFF1 gene, they show that H2A.Z is recruited with ER in a cyclic pattern for 
gene activation.  
In our laboratory, we had preliminary data showing that H2A.Z behavior on gene 
promoters and enhancers could not be generalized although a subset of genes was 
regulated in a similar fashion, distinct from what had been proposed for TFF1. In 
particular, following gene activation until estradiol treatment, H2A.Z was lost from several 
ER-target genes, including CCND1, PGR and ESR1 in MCF7 and MDA-MB231 cells. In 
addition, the posttranslational status of H2A.Z, in particular its acetylation appeared to 
correlate with regulation of gene expression. We decided to use an ER inducible gene in 
MCF-7, which in MDA-MB231 was constitutively expressed at very low levels. We 
demonstrated that H2A.Z acetylation was critical for Cyclin D1 regulation in estrogen 
receptor positive and negative breast cancer cells. We identified the enzymes involved in 
H2A.Z acetylation (Tip60) and in chromatin remodeling (Tip48), to propose a model for 
priming chromatin to prepare for transcription activation of this gene (Dalvai, Bellucci et al. 
2012) Dalvai et al., PLOS Genetics, in press.) 
Here, I would like to emphasize that breast cancer cell lines are used as a model for 
studying molecular mechanisms. Our research is mechanistical in nature and aims at 
understanding the mechanism of H2A.Z involvement in gene regulation. Our findings will 
have some repercussions on the comprehension of breast cancer physiology, but it is not 
our principal aim. The immediate aim was to clarify the role of H2A.Z and its acetylation in 
gene expression; to give, in this manner, our contribution to better understanding how 
chromatin structure and composition can affect the biology of a cell. It is notable that 
depleting a single histone variant can reverse aberrant gene expression independently of 
expression of canonical transcription factors, here the ER. Thus, our findings open new 
avenues for acting upon deregulated gene expression with the aim to better know how 
cancer cells function, or rather, disfunction, or evolve.  
 
VIII. Results. 
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Abstract
Differential positioning of the histone variant H2A.Z in a p53 dependent manner was shown to regulate p21 transcription.
Whether H2A.Z is involved in p21 activity in the absence of p53 is not known. The p21 gene is repressed in estrogen
receptor (ER) negative cell lines that are p532/2 and hormone independent for their growth. Here we demonstrate that
class I and II pan Histone deacetylase inhibitors (HDACi) induce p21 transcription and reduce cell proliferation of MDA-
MB231, an ERa-negative mammary tumor cell line, in a H2A.Z dependent manner. H2A.Z is associated with the transcription
start site (TSS) of the repressed p21 gene. Depleting H2A.Z did not lead to transcription of p21 but annihilated the
stimulating effect of HDACi on this gene. Acetylation of H2A.Z but not of H3K9 at the p21 promoter correlated with p21
activation. We further show that HDACi treatment reduced the presence of the p400 chromatin remodeler at the p21 TSS.
We propose a model in which association of p400 negatively affects p21 transcription by interfering with acetylation of
H2A.Z.
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Introduction
Estrogen receptor negative breast cancer types are generally
more aggressive and prone to metastasize. The absence of
Estrogen receptor-alpha (ERa) correlates with hormone-indepen-
dent growth of these mammary tumor cells and causes un-
controlled proliferation and insensitivity to anti-hormonal treat-
ments. In ERa-negative cell lines, a subset of genes is
epigenetically silenced [1,2], while the majority of genes involved
in cell cycle control and proliferation are constitutively expressed
[1,3,4]. Aberrant gene expression is frequently the result of
chromatin modifications and composition, including histone post-
translational modifications and/or incorporation of histone
variants [5–9]. In particular, deregulation of enzyme complexes
responsible for histone acetylation and deacetylation can be
associated with breast cancer progression and an increase in tumor
malignancy [5]. Thus, compounds that change chromatin
modifications are a promising anti-cancer approach. Histone
deacetylase (HDAC) inhibitors, such as Trichostatin A (TSA),
Suberoylanilide hydroxamic acid (SAHA), Panobinostat (LBH598)
and sodium butyrate (NaB) can inhibit cancer cell growth in vitro
and in vivo [10–12] as a result of selective induction of
endogenous genes that play significant roles in G1-S progression
[5]. One of the major regulators of cell cycle progression is the
cyclin-dependent kinase inhibitor p21 CIP1/WAF1, a gene of the
CIP/KIP family, which inhibits CDK activity. p21 can be
stimulated by p53 and its activity results in cell cycle arrest and/
or apoptosis. Much of research on HDAC inhibitors has focused
on the upregulation of p21. Activation of p21 involves acetylation
of promoter chromatin, but the mechanism remains poorly
understood [13,14].
The histone variant H2A.Z has been shown to bind to the
promoter of p21 at the p53 binding sites in p53+/+ cells (U2oS)
[15]. In response to stress, H2A.Z is evicted to allow p53 to bind
which leads to p21 expression [15]. The p400 complex takes part
in this pathway and was proposed to be responsible for H2A.Z
deposition into the p21 promoter. Depleting p400 by siRNA
increases p21 expression in a p53 dependent manner and induces
premature senescence [16]. The mechanism of this activation is
unclear.
In the ERa-negative breast cancer cell line MDA-MB231 p53 is
mutated and non-functional. Here we show that activation of p21
in response to HDACi treatment of these ERa-negative cells
requires H2A.Z acetylation and exchange at its transcription start
site.
Materials and Methods
Cell Lines, Transfection and Western Blotting
MDA-MB231, Hs-578T and HeLa cells were purchased from
ATCC (used up to 15 passages). All cell lines were maintained in
Dulbecco’s modified Eagle’s medium (DMEM) with Glutamax
containing 50 mg/ml gentamicin, 1 mM sodium pyruvate and
10% heat-inactivated fetal calf serum (FCS) (Invitrogen). MDA-
MB231 cells were treated with 50 or 100 ng/ml TSA (Sigma-
Aldrich) and with LBH589 561028 or 561029 M for the
indicated times. 46106 MDA-MB231 cells where mock-trans-
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fected (pcDNA3.1) or transfected with 2mg of pcDNA3.1/Tip60
(gifts from Dr. Didier Trouche) with AmaxaH Cell line
Nucleofactor Kit V program X-013 according to the manufac-
turer’s protocol. MDA-MB231 cells were mock-transfected or
transfected with H2A.Z siRNA ON-TARGET plus SMARTpool
or scrambled (scr) siRNA (Dharmacon Thermo Scientific) with
Interferine (Ozyme) according to the manufacturer’s protocol.
Tip60 siRNA [17] was purchased from Eurogentec, and
transfected with Interferine (Ozyme) according to the manufac-
turer’s protocol. For western blotting total cell extracts were
isolated and proteins levels of p21 and GAPDH was analyzed by
immunoblotting on gel SDS-page 15% with anti-p21 (SantaCruz
Biotechnology, sc-397), anti-Tubulin (SantaCruz Biotechnology,
sc-5286) and with anti-GAPDH (Millipore, mab374).
RNA Analysis
Total RNA was extracted using an RNeasy mini-kit (Qiagen)
and eluted with 35 ml of RNAase-free water. First strand cDNA
was generated using 1 or 2 mg of total RNA in a reaction
containing random oligonucleotides as primers with the Thermo-
Script RT-PCR system (Invitrogen). Real-time PCR was per-
formed on a MastercyclerH ep realplex (Eppendorf) using the
platinum SYBR Green q-PCR SuperMix (Invitrogen) according to
the manufacturer’s instructions. Amplification conditions: 1 min at
50uC, 3 min at 95uC followed by 40 cycles (20 s at 95uC, 20 s at
60uC, 20 s at 72uC). q-PCR for RPLP0 mRNA was used as an
internal control. The primers used in q-PCR: CDKN1A (p21, Cip1):
59-GGAAGACCATGTGGACCTGT-39 and 59-GGAT-
TAGGGCTTCCTCTTGG-39, H2AFZ: 59-
CCTTTTCTCTGCCTTGCTTG-39 and 59-CGGTGAGG-
TACTCCAGGATG-39, RPLP0: 59-TGGCAGCATCTA-
CAACCCTGAA-39 and 59- CACTGGCAACATTGCGGACA-
39, TIP60: 59-CAGGACAGCTCTGATGGAATAC-39 and 59-
AGAGGACAGGCAATGTGGTGAG-39, p400: 59-TGGCAGA-
GACTTGCTAAGGA-39 and 59-AGCGTCAACATCAGCT-
CACT-39 [18].
ChIP Assays
ChIP analyses were performed as described previously [19]
from MDA-MB231 cells. Samples were sonicated to generate
DNA fragments between 500 and 700 bp. Chromatin fragments
were immunoprecipitated using antibodies against H2A.Z
(ab4174, ABCAM), Acetyl H2A.Z (ab18262, ABCAM), RNA
pol II (N20X, Santa Cruz), H3 (ab1791, ABCAM), Acetyl H3K9
(06–942, Millipore), TIP60 [20], p400 (ab70301, ABCAM), p300
(SC-584, SantaCruz Biotechnology) or an irrelevant HA antibody
(H6908, Sigma) as control. The precipitated DNA was amplified
by real-time PCR, with primer sets designed to amplify the
promoter and the coding region of the p21 gene. The primers used
in q-PCR are listed here: Primers 1: 59-TCAATGCCACCACCT-
TAACA-39 and 59-AGAGAGGCATCCTCCAGACA-39, Primers
2: 59-CTGTGGCTCTGATTGGCTTT-39 and 59-CTCCTAC-
CATCCCCTTCCTC-39, Primers 3: 59-GAAATGCCTGAAAG-
CAGAGG-39 and 59-GTCTGCACCTTCGCTCCTAT-39, Pri-
mers 4 (TSS): 59-ACTGGGGGAGGAGGGAAGT-39 and 59-
AGCTGAGCCTGGCCGAGT-39, Primers 5: 59-CCAG-
GAAGGGCGAGGAAA-39 and 59-GGGACCGATCCTAGAC-
GAACTT-39, Primers 6: 59-AGCCGGAGTGGAAGCAGA-39
and 59-AGTGATGAGTCAGTTTCCTGCAAG-39, Primers 7:
59-GCACCATCCTGGACTCAAGTAGT-39 and 59-
CGGTTACTTGGGAGGCTGAA-39.
Proliferation and Cell Death Assays
MTT assay was performed using CellTiter 96H AQueous One
Solution Cell Proliferation Assay (Promega) according to the
manufacturer’s instructions. For Trypan blue assay, 26105 cells
seeded in 35 mm dishes. Cells were harvested and counted by
trypan blue staining at indicated times following the different
treatments.
Results
Histone Deacetylase Inhibitors Block Proliferation and
Activate p21 Expression
Proliferation of estrogen receptor alpha-negative (ERa-) breast
cancer cell lines is estrogen-independent. A priority in breast
cancer treatment is the development of agents able to contain or
reduce growth of these cell types, which are more aggressive and
insensitive to antiestrogens used to control estrogen responsive
tumors. ERa- cells, MDA-MB231, were grown in standard
medium and treated with the histone deacetylase inhibitors
(HDACi) Trichostatin A (TSA) or panobinostat (LBH589). Cell
growth was arrested by 50 or 100 ng/ml TSA (Fig. 1a) and 50 nM
LBH589 (Fig. S1) during the first 48 h of treatment. At later time
points, cell density decreased suggesting that prolonged exposure
to HDACi induced cell death. Growth arrest and apoptosis are
under the control of metabolic sensors, in particular the p21 gene
and its regulatory pathway. As previously described for pan
HDACi [21–23] p21 transcription was greatly activated in cells
exposed to TSA for 24 h in which we detected .3-fold increase in
p21 mRNA levels (Fig. 1b) and a massive augmentation in p21
protein expression compared to untreated cells (Fig. 1c, S1d).
Acetylated Histone H2A.Z Associates with the
Transcription Start Site of p21
Transcription regulation of the p21 gene is mediated by
dynamic binding of the histone variant H2A.Z to p53 binding
sites within the p21 promoter region in p53 positive cells, such as
ERa-positive MCF-7 (data not shown) or U2OS cells [15]. The
ERa- MDA-MB231 cell line bears a mutated, non-functional
p53 gene. We thus asked whether H2A.Z was also associated
with the p21 promoter in these cells as was shown to be the case
in the p53- osteosarcoma, SaOS cell line [15]. Using chromatin
immunoprecipitation (ChIP), we determined that H2A.Z was
present at the transcription start site (TSS) of the p21 gene. The
amplified fragment (#4, Fig. 2) is adjacent to a set of six putative
Sp1 binding sites that were shown to mediate p21 transcription
in a reporter assay [13]. The amount of H2A.Z detected at
upstream sequences, including the p53 recognition elements
(fragment #2), was significantly less abundant than at the TSS
(Fig. 2b). According to the hypothesis that H2A.Z containing
nucleosomes direct p53 binding [15], it was not surprising that
H2A.Z was absent from these sites. As previously described in
yeast [24], [25], decondensed chromatin is found at promoters of
inactive but inducible genes. Based on this observation, we
reduced the cellular pool of available H2A.Z by small interfering
RNAs directed against H2A.Z and assessed p21 mRNA
expression (Fig. 2c). p21 transcription remained insignificant
(Fig. 2c). ChIP experiments further confirmed that despite
a reduction in H2A.Z association with the TSS, polymerase II
(pol II) was not recruited to this inactive gene (Fig 2d). Thus, p21
transcriptional regulation does not only depend on the amount of
H2A.Z associated with its TSS. Interestingly, treatment with
50 ng/ml TSA reduced H2A.Z binding to the activated p21
(Fig. 2e, 1b). Release of H2A.Z was accompanied by recruitment
of pol II and, strikingly, by an increase in the presence of
p21 Activation by HDACi and H2A.Z Acetylation
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acetylated H2A.Z at the p21 TSS (Fig. 2f). This increase in
acetylation was not seen for histone H3K9 (Fig. 2g). Moreover,
the amount of acetylated H2A.Z and acetylated H3K9 present at
the TSS did not vary in siH2A.Z transfected cells in which p21
remained repressed (Fig. 2h–2i). We propose that acetylation of
H2A.Z rather than its presence correlates with p21 transcription
activation in ERa- breast cancers. We postulated that the anti-
proliferative effect of HDACi via p21 expression depends on
acetylation of H2A.Z. We thus asked whether this effect would
be abolished in siH2A.Z treated cells.
H2A.Z Controls HDACi Induced Growth Arrest via p21
Expression
MDA-MB231 cells were grown in standard medium, treated or
not with siH2A.Z for 24 hours before adding TSA or LBH.
Surviving cells (MTT test, Fig. 3a) and dead cells (trypan blue,
Fig. 3b) were counted before treatment as well as 24 h and 48 h
following HDACi addition. Reduced cell growth in TSA treated
cells was partly rescued in cells previously transfected with
siH2A.Z (Fig. 3a). In particular, significant counts of dead cells
were determined as soon as 24 h post treatment (Fig. 3b). While
siH2A.Z transfected cells also showed a 2-fold increase in cell
death compared to untreated cells, these cells were much less
sensitive to TSA (Fig. 3b). Cell death at 48 h was almost similar in
untreated cells compared to siH2A.Z transfected and TSA
exposed cultures. Furthermore, p21 mRNA levels did not vary
in siH2A.Z transfected cells upon HDACi treatment compared to
control cells treated only with TSA or LBH (Fig. 3c, S1c). H2A.Z
is also required for p21 activation upon TSA treatment in ER-
negative, p532/2 Hs-598T cells (Fig. S2c). In contrast, knock-
down of H2A.Z had no effect on p21 activation in HeLa cells (Fig.
S2a). Thus, H2A.Z specifically regulates p21 in ERa-negative
breast cancers following HDAC inhibitor treatment. We further
found that acetylation of H2A.Z bound to the p21 TSS was greatly
reduced in siH2A.Z treated cells exposed to TSA (Fig. 3d). Pol II
recruitment and elongation was abolished in TSA treated MDA-
MB231 cells, from which H2A.Z was depleted (Fig. 3e). Thus,
H2A.Z appears essential to mediate the anti-proliferative effect of
HDACi by regulating p21 expression. Notably, acetylation of
H2A.Z was necessary for this regulation. We next wanted to gain
insight into the mechanisms of H2A.Z acetylation at the p21
promoter in ERa- cells.
A Role for p400 but not Tip60 in p21 Transcription
Regulation
We first tested the impact of depleting or overexpressing Tip60,
a histone acetyltransferase frequently found in complex with p400
and known to participate in H2A.Z mediated transcription
regulation [15,26]. Modulation of Tip60 mRNA levels did not
alter p21 expression levels, which remained almost undetectable
(Fig. 4a). Accordingly, association of H2A.Z, acetylated H2A.Z
and pol II did not vary at the p21 TSS in Tip60 depleted cells
(Fig. 4b). We next investigated which cofactor could be responsible
for TSA induced activation of p21. Tip60 did not seem to be
associated with the p21 TSS in MDA-MB231 cells treated or not
with TSA (Fig. 4c). In contrast, we detected significant amounts of
the p400 remodeler at the p21 TSS. Association of p400 decreased
in TSA treated cells in which p21 was activated (Fig. 4c). Reducing
the available pool of p400 alone was able to activate p21
expression (Fig. 4d) suggesting that the presence of p400 at the
p21 TSS represses this gene. Reduction of p400 allowed
recruitment of the p300 acetyltransferase (Fig. 4e). Concomitantly,
acetylation levels of H2A.Z markedly increased, due to eviction of
a fraction of H2A.Z and an increase in acetylated H2A.Z at the
p21 TSS (Fig. 4e). We propose that TSA controls cell growth by
modulating p21 expression. p21 activation requires release of p400
and H2A.Z, and an increase in acetylation of H2A.Z.
Discussion
Lack of regulation of the p21 gene whose expression is needed
for cells to respond to insults by arresting proliferation is frequently
observed in cancer. This loss is exacerbated by the absence of the
functional tumor suppressor p53 protein in more aggressive tumor
types. Histone acetyltransferase inhibitors have been shown to
activate p21 independently of p53. TSA (500 ng/ml) reduced
growth of MG63 osteosarcoma, p532/2 cells and activated
various p21 promoter constructs driving a luciferase reporter gene
[27]. We demonstrate that the endogenous p21 gene is also
activated by TSA or LBH589 in ERa- mammary tumor cells
whose growth rate is insensitive to hormones and antihormones. In
this study we provide a comprehensive analysis of the activation of
the p21 gene in ERa- MDA-MB231 cells which provides
a mechanistic link between histone acetylation, H2A.Z variant
incorporation and p21 mediated growth arrest.
Unlike in p53 positive cells, U2OS osteosarcoma or MCF-7
cells, where the histone variant H2A.Z is associated with the p53
binding sites of the inactive p21 gene, H2A.Z was present at the
Figure 1. HDAC inhibitors reduce proliferation and activate p21 transcription in ERa- negative/p53 mutated mammary tumor cells.
a) MTT assay to quantify proliferation rates in the presence of Trichostatin A of MDA-MB231 cells. Two different concentrations (50 ng/ml and 100 ng/
ml) were used. b-c) q-PCR and western blot analysis of p21 mRNA expression and protein levels. Experiments were performed three times.
doi:10.1371/journal.pone.0054102.g001
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TSS in ERa- cells. H2A.Z binding to the TSS was frequently been
observed in yeast [25] and human cells [28] where is thought to
create a chromatin structure that is responsive to stimuli and co-
factor binding. Its presence in promoter chromatin was also shown
Figure 2. Acetylation of H2A.Z at the p21 promoter is necessary for its transcription. a) Schematic representation of the p21 promoter
region showing PCR amplified fragments (1–4). b) Binding of H2A.Z to the p21 promoter in MDA-MB231 cells. c) mRNA expression of H2AFZ (left) and
p21 (right) in MDA-MB231 cells transfected with a smartpool siH2A.Z for 72h. d) H2A.Z and polymerase II (pol II) binding to the p21 TSS (fragment#4)
in cells transfected with siH2A.Z or scramble siRNAs. e) H2A.Z binding to the p21 TSS (fragment#4) in cells treated with TSA (50 ng/ml) for 48 h. f–g)
acetylated H2A.Z, polymerase II (pol II) (f) and acetylated H3K9 (g) binding to the p21 TSS (fragment #4) in cells treated with TSA. h-i) acetylated
H2A.Z (h) and H3K9 (i) amount at p21 TSS in cells transfected with siH2A.Z or scramble siRNA.
doi:10.1371/journal.pone.0054102.g002
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to be important for activation of ERa target genes such as TFF1,
PGR or CCND1 [29], [30]. Association of H2A.Z with promoter
sequences could thus be related to an alternative pathway of gene
activation in the absence of cognate transcription factors, including
p53 or ERa. However, loss of H2A.Z binding was not sufficient to
stimulate p21 expression in MDA-MB231 cells. This observation
correlates with previous studies showing that a 50% reduction
H2A.Z association was not sufficient to induce changes in gene
regulation [31].
In 2007 Gevry et al. showed that p400 and H2A.Z associate
with the repressed p21 gene in U2OS cells [15]. In response to
DNA damage, p400 and H2A.Z were evicted to allow TIP60
recruitment and subsequent p21 activation [15]. More recently
Park et al., however, demonstrated that p400 inhibits TIP60
activity by direct binding to TIP60 via its SANT domain [26].
In ER-negative, p53 mutant breast cancer cell lines, TSA
treatment activates p21. Under these conditions, binding of p400
and H2A.Z to the p21 promoter was reduced, but the concomitant
increase in H2A.Z acetylation was independent of TIP60.
Figure 3. H2A.Z is required for the antiproliferative effect of HDACi. a) Cell growth assay b) Trypan blue assay c) qPCR analysis of p21 mRNA
expression. d) ChIP analysis of Acetyl-H2A.Z. e) ChIP analysis of RNA pol II. MDA-MB231cells were treated or not with TSA (50 ng/ml) for 24 h/48 h
and/or transfected with a smartpool siH2A.Z (72 h) as indicated.
doi:10.1371/journal.pone.0054102.g003
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Furthermore, depleting p400 also stimulated p21 expression
independently of TIP60 suggesting that p400 exerts a repressive
effect. In contrast, depleting H2A.Z was not sufficient to mediate
p21 repression under normal conditions but it played a central role
in p21 activation upon TSA treatment. We propose that
acetylation of H2A.Z rather than H2A.Z per se is important to
drive proper p21 gene expression. A ratio in favor of acetylated
H2A.Z was associated with p21 activation upon TSA treatment.
This observation corroborates findings by Valdes-Mora and
colleagues who recently correlated aberrant gene expression in
prostate cancer cells with H2A.Z acetylation at specific promoters
[32]. It is tempting to speculate that p400 favors p21 activation by
catalysing H2A.Z eviction and allowing the recruitment of HATs
such as p300.
The histone-acetyltransferase CBP/p300 has been shown to act
on the p21 promoter at several Sp1 sites and independently of p53
as part of a multiprotein complex which also contains PR and Sp1
[33] in T47 mammary tumor cells. Here, in triple negative MDA-
MB231 cells (ER-, PR-, HER-), p300 was also present at the p21
promoter at levels proportional to transcriptional activity. Hence,
the cofactors required for p21 activation are distinct in p53
negative compared to positive cells [34]. These alternative
pathways in cells in which regulation of p21 does not obey to
the classical pathways, open new avenues for growth control
therapies.
Hua et al. [35] identified the histone variant H2A.Z as
a potential epigenetic marker since its hormone-dependent
expression correlates with increased probability of metastasis and
decreased patient survival in a large scale study. For it to serve as
a prognostic factor in breast cancer, the mechanisms unraveled by
our study are relevant in ER- p532/2 cells that are otherwise
difficult to act upon.
Supporting Information
Figure S1 p21 is activated in response to pan HDAC
class I and II inhibitors. a) MTT assay to quantify
proliferation rates in the presence of LBH589 of MDA-MB231
cells cultured in rich medium. Two different concentrations
(5*1029 M and 5*1028 M) were used. b) q-PCR analysis of p21
mRNA expression levels. c) p21 mRNA expression level in MDA-
MB231 treated or not with LBH589 (5*1029 M) for 48 h and/or
transfected with a smartpool siH2A.Z (72 h) as indicated. d)
Western blot analysis of p21 protein levels after 24 h of TSA
treatment at the indicated doses.
(PDF)
Figure S2 H2A.Z specifically regulates p21 in ERa-
negative breast cancers following HDAC inhibitor
treatment. a, b, c, d) q-PCR analysis of p21 and H2A.Z mRNA
expression in Hela (a, b) and in Hs-578T (c, d) cells. Cells were
treated with siH2A.Z or scramble siRNA and treated for 24 h with
two different concentrations of TSA.
(PDF)
Figure 4. p400 but not Tip60 functions in p21 expression in the absence of p53. a) Tip60 and p21 mRNA expression. b) H2A.Z, Acetyl-H2A.Z
and RNA pol II binding to the p21 TSS in cell transfected with siTip60 or scramble siRNA. c) ChIP analysis of Tip60 and p400 recruitment to the p21 TSS
(fragment #4) in cells treated with TSA. d) p21 mRNA expression in MDA-MB231 transfected with siRNA against p400 and treated or not with TSA. e)
H2A.Z, Acetyl-H2A.Z and p300 enrichment at p21 TSS (fragment #4) in MDA-MB231 transfected with si p400.
doi:10.1371/journal.pone.0054102.g004
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ORIGINAL ARTICLE
H2A.Z-dependent crosstalk between enhancer and promoter
regulates Cyclin D1 expression
M Dalvai1,2, L Bellucci1,2, L Fleury1,2, A-C Lavigne1,2, F Moutahir1,2 and K Bystricky1,2
H2A.Z association with specific genomic loci is thought to contribute to a chromatin structure that promotes transcription
activation. Acetylation of H2A.Z at promoters of oncogenes has been linked to tumorigenesis. The mechanism is unknown. Here, we
show that in triple negative breast cancer cells, H2A.Z bound to the promoter of the constitutively, weakly expressed cyclin D1
oncogene (CCND1), a key regulator of cellular proliferation. Depleting the pool of H2A.Z stimulated transcription of CCND1 in the
absence of its cognate transcription factor, the estrogen receptor (ER). During activation of CCND1, H2A.Z was released from the
transcription start site (TSS) and downstream enhancer (enh2) sequences. Concurrently, acetylation of H2A.Z, H3 and H4 at the TSS
was increased but only H2A.Z was acetylated at enh2. Acetylation of H2A.Z required the Tip60 acetyltransferase to be associated
with the activated CCND1 on both TSS and enh2 sites. Depletion of Tip60 prevented CCND1 activation. Chromosome conformation
capture experiments (3C) revealed specific contacts between the TSS and enh2 chromatin regions. These results suggest that
release of a histone H2A.Z-mediated repression loop activates CCND1 for transcription. Our findings open new avenues for
controlling and understanding aberrant gene expression associated with tumorigenesis.
Oncogene advance online publication, 29 October 2012; doi:10.1038/onc.2012.442
Keywords: H2A.Z; chromatin; acetylation; enhancer; intragenic loop; cyclin D1
INTRODUCTION
Estrogens are intimately linked to hormone-dependent breast
cancer progression by promoting G1–S transition through
regulation of key cell cycle regulatory factors including induction
of cyclin D1, MYC, HER2 and c-SRC and repression of cyclin G2,
caspase 9 and p21.1,2 17b-estradiol (E2) functions are mediated by
specific estrogen receptors (ERs), which are transcription factors
belonging to the nuclear receptor family.3 Two ERs, ERa and ERb,
each expressed as several isoforms, have been characterized.4–6
A majority of breast tumors (about 80%) express both receptors
and are hormone-dependent for growth. These tumors are less
invasive and generally not metastatic.7 In contrast, ERa-negative
breast tumors (ERaÿ ) are hormone-independent for proliferation,
more invasive and prone to metastasize.8 In ERaÿ cell lines, both
ESR1 and ESR2 encoding ERa and ERb respectively, are silenced
together with many ER-target genes including pS2/TFF1 and the
progesterone receptor gene (PGR). On the other hand, another
group of ER target genes including cathepsin D (CTSD), VEGF
or cyclin D1 (CCND1) escape transcriptional regulation.9,10
Cyclin D1, encoded by the CCND1 gene, is a D-type cyclin
whose growth factor-induced expression and accumulation are
tightly controlled.11–13 Cyclin D1 regulates G1–S progression and
gene expression via chromatin modifications and a plethora of
cellular functions (for a review see14). Its relative abundance has
major effects on cell growth and metabolism via cell cycle regu-
lated dosage of its expression.15 CCND1 transcription is regulated
by an estrogen-regulated cell-type-specific enhancer and is cell
cycle regulated in ER-positive breast cancer cells (ERaþ , MCF-7
cells).15,16 Downregulation of Cyclin D1 has nevertheless been
shown to increase migratory capacity and is associated with poor
prognosis.17,18 CCND1 expression is low, and hormone- and cell
cycle-independent in ERaÿ MDA-MB231 cells9,19 (unpublished
observations). The CCND1 ORF spans 14 kb and is flanked by
50 and 30 enhancers identified by Eeckhoute et al.16 as DNAse I
hypersensitive site, to which transcription factors are recruited in
estrogen responsive ERaþ cells.16,19–21 The 30 enhancer (enh2)
defined as a major site of CCND1 regulation in these cells, was
thought to be dysfunctional in ERaÿ MDA-MB231 cells. It is
plausible that the lack of enh2 function relates to poor CCND1
transcription. To date the mechanisms responsible for the loss
of hormonal regulation of gene expression, and subsequently
of proliferation and differentiation processes, are not fully
understood. In addition to aberrant DNA methylation, an
unidentified epigenetic mark imposes formation of a chromatin
state that forms a barrier to ERa binding in hormone-independent
cell lines.22 Epigenetic or chromatin marks are thought to mediate
a functional dialog with DNA-binding factors to coordinate the
activity of cis-regulatory elements in space and time. Chromatin
properties can be regulated by DNA methylation and histone
post-translational modifications, but also by replacement of
histones with variants.23–29 Incorporation of histone H2A.Z into
the chromatin of inactive gene promoters and its removal
according to physiological signals participates in regulating gene
expression.30–33 H2A.Z is principally found at the promoters of
poised genes and released during gene activation in both yeast
and human cells.31,34–36 In euchromatin, a sharp peak of H2A.Z is
seen at the 50 end of numerous genes and at enhancers.37 A
recent genome-wide analysis38 showed that acetylated H2A.Z is
generally found near the transcription start site (TSS) of active
genes in prostate cancer cells.
Here, we investigate the role of the histone variant H2A.Z in the
transcriptional regulation of the ER-target gene in ERaÿ breast
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cancer cells. Our results demonstrate that stimulation of CCND1
transcription requires release of H2A.Z from both the TSS and
downstream enhancer (enh2) sequences of CCND1. Acetylation of
H2A.Z and Tip60 acetyltransferase regulate TSS-enhancer crosstalk
via chromatin looping.
RESULTS
Depletion of H2A.Z activates CCND1 transcription
We first investigated whether H2A.Z was present at ER-target gene
loci in ERÿ cells. Chromatin immunoprecipitation (ChIP) experi-
ments revealed that H2A.Z bound to sequences flanking the
CCND1 ORF, to the TSS and the downstream enhancer defined by
Eeckhoute et al.16 but not to distant upstream sites in two distinct
cell lines, MDA-MB231 (Figure 1a) and MDA-MB436 (Supplemen-
tary Figure S1A). H2A.Z was also present at the promoters of the
silent ER-target genes, PGR, TFF1 or ESR1 (Supplementary Figure
S1B). ChIP-on-chip experiments confirmed that H2A.Z associated
exclusively with flanking regions of all tested genes and, in
particular, the enh2 sites of CCND1 (J Eeckhoute, data not shown).
The presence of H2A.Z at these regulatory elements in ERaÿ
MDA-MB231 cells, prompted us to assess its potential role in
transcriptional repression of these genes. To this end, we
selectively depleted H2A.Z by small interference RNA (siRNA)
(Figure 1b, Supplementary Figures S1C, D). Seventy-two hours
following siRNA transfection, CCND1 mRNA levels increased four-
fold compared with mock-transfected cells (Figure 1b), whereas
PGR, TFF1 and ESR1 remained silent (Figure 1b). Under these
conditions, a potential role of the ER in stimulating CCND1
expression could thus be excluded (Figure 1b). ChIP confirmed
that H2A.Z siRNA treatment lead to markedly reduced binding of
H2A.Z to the CCND1 TSS (Figure 1c left panel). Concomitant to
increased mRNA levels, polymerase II (pol II) recruitment to the
CCND1 TSS slightly increased. In contrast, decreased H2A.Z
binding to the PGR promoter did not allow polymerase II
recruitment to this silent gene (Supplementary Figure S1E). Thus,
H2A.Z eviction is sufficient to stimulate CCND1 transcription in
ERaÿ breast cancer cells. Yet, its depletion alone cannot restore
the expression of silenced genes as PGR, TFF1 or ESR1.
We next asked whether activation of CCND1 following release of
H2A.Z from the TSS also altered the chromatin structure of the
downstream enhancer enh2, previously shown to be inactive in
these cells.16 In H2A.Z siRNA transfected cells, H2A.Z binding to
enh2 was significantly diminished (Figure 1c, right panel). In
addition, CCND1 activation in siH2A.Z-transfected MDA-MB231
cells was accompanied by a strong recruitment of pol II to enh2
(Figure 1c, right panel), as described previously for E2 stimulated
MCF-7 cells.16 We conclude that enh2 has an active role in
ER-independent CCND1 activation. H2A.Z seemed to interfere with
stimulation of transcription when bound to TSS and enhancer
sequences of CCND1. We investigates how modulating
incorporation of this histone variant regulates gene activity.
H2A.Z acetylation correlates with activation of CCND1
transcription
Recently, Valdes-Mora et al.38 demonstrated in a genome-wide
study that H2A.Z acetylation marks chromatin at the TSS of active
genes, which are frequently deregulated in prostate cancer cells.
Thus, we examined whether acetylation of H2A.Z was involved in
CCND1 function in breast cancer cells. A variety of inhibitors allow
modulation of histone post-translational modifications with the
aim to alter gene expression patterns. Exposure of mammary
tumor cell lines to trichostatin A (TSA), a pan HDACi of class 2
HDACs, reduces their growth rate39 and induces changes in gene
expression patterns.40–44 We tested whether TSA would stimulate
CCND1 expression. MDA-MB231 cells were cultivated in normal
media and exposed to 50 ng/ml TSA for 24 h before mRNA
quantification. CCND1 mRNA increased four-fold in treated
compared with untreated cells (Figure 2a). We also noticed that
TSA treatment negatively affected H2AFZ mRNA levels, which
were reducedB2-fold (Figure 2a). The ESR1 gene remained silent
as previously shown22 excluding the possibility that stimulation of
CCND1 was due to binding of ERa in these TSA treated ERaÿ cells.
These results prompted us to further investigate the mechanism
by which transcription of CCND1 was stimulated.
As expected, concomitant to increased transcription in the
presence of TSA, acetylation of histone H3 at the CCND1 TSS
increased (Figure 2b). In these cells, H3 was also acetylated at
enh2 suggesting that this enhancer participates in CCND1
activation (Figure 2b). We show that H2A.Z was associated with
the CCND1 TSS and that a fraction of this histone variant was
evicted from the TSS in response to TSA treatment of MDA-MB231
cells (Figure 2c). Interestingly, upon eviction from the TSS, H2A.Z
was also lost from enh2 (Figure 2d). Under the same conditions,
we monitored binding of acetylated H2A.Z (Ac-H2A.Z) to the
CCND1 TSS and enh2 using an antibody that specifically
recognizes H2A.Z acetylated at K4, K7 and K14 (see Materials
and methods). The amount of Ac-H2A.Z present at the CCND1 TSS
or enh2 did not vary following TSA treatment. However, the ratio
of Ac-H2A.Z was greatly augmented relative to the total, sharply
reduced amount of H2A.Z detected at these sequences (Figures 2c
and d right panel).
Based on the fact that TSA negatively affected H2AFZ mRNA
levels (Figure 2a) we wondered whether stimulation of CCND1 was
the result of increased histone acetylation or of a reduction of
H2A.Z abundance. We then analyzed if depletion of the cellular
pool of H2A.Z also altered Ac-H2A.Z binding at the stimulated
CCND1 locus. We found nearly three-fold greater amounts of
acetylated H2A.Z at the TSS (Figure 3a, left panel) and six-fold
greater amounts (Figure 3b, left panel) at the enh2 in
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Figure 1. Depletion of H2A.Z correlates with CCND1 transcriptional
activation. (a) The recruitment of H2A.Z to the CCND1 gene at
ÿ 2000, TSS and enh2 was analyzed by ChIP. (b) Expression levels of
H2AFZ, CCND1, ESR1, PGR and TFF1 in ERaÿ MDA-MB231 cells
transfected with SMARTpool H2A.Z siRNA (þ ) or scramble siRNA
(ÿ ) were analyzed by q-PCR. mRNA expression levels were
normalized against expression levels of the RPLP0 ribosomal gene.
(c) The recruitment of H2A.Z and RNA pol II was analyzed by ChIP at
the CCND1 promoter (left panel) or enh2 enhancer (right panel).
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siH2A.Z-transfected cells (þ ) compared with scrambled siRNA
(ÿ ) treated MDA-MB231 cells. As the total amount of H2A.Z was
reduced three-fold at these sites upon H2A.Z depletion, the
relative ratio of Ac-H2A.Z to total H2A.Z increased significantly
(Figures 3a and b, right panels).
In conclusion, these results reveal that the presence of hypo-
acetylated H2A.Z at the proximal promoter around the TSS and at
the 30 enhancer negatively controls CCND1 expression in triple
negative mammary tumor cells. Reducing the pool of free H2A.Z
led to an increase in the amount of Ac-H2A.Z present at both
regulatory sequences at the expense of unmodified H2A.Z. We
therefore attempted to identify the factors involved in acetylation
of H2A.Z and chromatin modifications associated with CCND1
transcriptional activation.
Recruitment of Tip60 and H2A.Z acetylation regulates enhancer
chromatin structure
Histone acetylation has long been associated with active
transcription45,46 and thus the increase in acetylation of H2A.Z
bound to the CCND1 locus may be part of general acetylation of
chromatin in MDA-MB231 cells. Indeed, acetylation of H3K9 and
H4 increased upon depletion of H2A.Z by siRNA at the proximal
promoter (Figures 4a and b, upper panel). Global acetylation was
accompanied by the recruitment of elongating pol II phosphory-
lated at serine 5 (P-Ser 5; Figure 4d, upper panel). In contrast,
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acetylation of H3K9 was low at the downstream enhancer
enh2 and did not vary with transcription activation (Figure 4a,
lower panel). Acetylation of H4 also remained unchanged
(Figure 4b, lower panel). In addition, H3 binding to the CCND1
30 enhancer but not to the TSS varied following H2A.Z eviction
in these ERaÿ cells (Figure 4c). In contrast to previous
observations in prostate cancer cells,38 nucleosome density did
not vary at the promoter of the activated CCND1 gene. However,
decreased nucleosome density at enh2 points to chromatin
decondensation usually associated with DNAse I hypersensitive
sites, which reinforces the notion that the enh2 site is a key
element for CCND1 gene activation.16 P-ser 5 binding did not
vary at the 30 end of the gene as expected47 (Figure 4d, lower
panel). Hence, acetylation of chromatin is linked to transcription
initiation and elongation near the 50 end of CCND1 while
acetylation of H2A.Z characterized the active state at both the
TSS and the 30 enh2.
Several studies in yeast have shown that the NuA4 (an ortholog
of the human Tip60/p400 complex) and the SAGA histone
acetyltransferase complexes acetylate multiple lysine residues of
H2A.Z.48–50 Tip60 could then be one of the HATs capable of
acetylating H2A.Z in mammalian cells. Indeed, we found that
Tip60 was recruited to both the TSS and enh2 of the activated
CCND1 gene in MDA-MB231 cells transfected with siH2A.Z
(Figure 5a). Upon overexpression of Tip60 in MDA-MB231 cells
(Supplementary Figure S2A) CCND1 expression increased nearly
two-fold (Figure 5b), whereas transcription levels of ESR1 and
H2AFZ remained unchanged (Supplementary Figure S2B). The
selective knockdown of Tip60 did not affect the basal, uninduced
expression level of CCND1 (Figure 5c, Supplementary Figure S2C),
but prevented gene activation upon H2A.Z depletion (Figure 5c,
Supplementary Figure S2D). In the absence of Tip60, the amount
of H2A.Z and pol II bound to the TSS and enh2 of CCND1 did not
vary (Figure 5d) but the presence of acetylated H2A.Z was
markedly reduced. We conclude from these ChIP experiments that
Tip60 has a central role in CCND1 activation independently of E2
and is the likely candidate for acetylating H2A.Z at both TSS and
enh2 sites.
Acetylation of H2A.Z regulates promoter/enhancer crosstalk via
loop formation
To investigate whether the CCND1 TSS interacts with enh2, we
used a chromatin conformation capture (3C) assay,51,52 which
detects physical proximity between distal DNA sites by ligation of
cross-linked restricted DNA fragments (Figure 6a). Ligation
products between enh2 and promoter sequences, and between
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enh2 and a control fragment inside the CCND1 ORF were
amplified and normalized to the amplified enh2 PCR product
used in ChIP experiments (see Materials and methods; Figure 6b).
We measured significant interaction frequencies between enh2
and promoter sequences in MDA-MB231 transfected with
scramble siRNA (control) while in cells transfected with siH2A.Z,
this interaction was reduced more than five-fold (Figure 6b). In
contrast, depletion of Tip60 alone or in combination with siH2A.Z
did not affect contact frequencies between these sites (Figure 6b).
No amplification was observed between enh2 and the internal
control fragment. We did not detect amplification of any of these
fragments in undigested samples. Hence, an intragenic loop
mediated by specific promoter–enhancer interactions is present
when CCND1 expression is low (Figure 5c). Upon transcription
activation, gene lopping is markedly reduced. In conclusion, we
propose a model (Figure 7) in which looping of the CCND1 50 and
30 ends is mediated by histone H2A.Z and exerts repressive effects.
Acetylation of H2A.Z by Tip60 reduces interactions between TSS
and enh2 sites, creating a chromatin environment favorable for
transcriptional activation.
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Figure 7. Model of the role of H2A.Z and Tip60 in the control of loop formation between enhancer and promoter sequences implicated in the
transcriptional regulation of CCND1.
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DISCUSSION
We demonstrate that binding and acetylation of the histone
variant H2A.Z regulates CCND1 expression via specific enhancer/
promoter interaction in ERaÿ breast cancer cell lines. In particular,
H2A.Z was present at the CCND1 locus when the gene displayed
little transcriptional activity. Recently, Valdes-Mora et al.38 reported
in a genome-wide study of normal and prostate cancer cells, that
acetylation of H2AZ at the TSS correlated with activation of
oncogenes and that reduced H2A.Z acetylation marked silenced
tumor suppressor genes.38 Here we extend these findings to
breast cancer cells. In addition, we propose a mechanism by which
H2A.Z acetylation modulates transcription associated with
deregulated gene activity in cancer cells.
Reducing the pool of H2A.Z resulted in release of H2A.Z from
promoter and enhancer sequences and increased CCND1 expres-
sion. This is consistent with the previously proposed model that
nucleosomes containing H2A.Z are more labile. Eviction of H2A.Z
thus promotes chromatin accessibility.53 It is tempting to
speculate that modulation of the 3D intragenic organization
may be key for creating a window of opportunity for secondary
factors to regulate transcription. Hence, not the action of specific
transcription factors and downstream events resulting from their
association once favorable conditions are encountered,54 but
structure would guide activity. Concomitantly to chromatin
reorganization, acetylation of the remaining H2A.Z, but not of
other histones, was a characteristic feature of chromatin in the
30 enhancer region, suggesting that this modification specifically
regulates 3D organization of genetic loci.
Enhancers are thought to allow transcription activators to bind
inactive genomic loci in order to facilitate the onset of
transcription. This usually involves chromatin modifying com-
plexes55 such as CBP/p300 in mammalian cells.56,57 Here we show
that Tip60, a histone acetyltransferase that has been shown to
acetylate histones H3, H4, H2A,58,59 and H2AX60 in vivo, is recruited
to a 30 enhancer of the CCND1 gene upon activation. Tip60 is an
essential cofactor for numerous transcription factors and
important for cell proliferation. Binding to promoter and
enhancer sequences of the stimulated CCND1 gene coincided
with an increased ratio of acetylated H2A.Z. Thus, for the first time,
we provide evidence for a role of Tip60 in transcriptional
activation of the CCND1 oncogene in ERaÿ breast cancer cells
potentially by acetylation of the histone variant H2A.Z.
Replacement of H2A by H2A.Z alters nucleosome conformation
creating docking sites for distinct cofactors and chromatin
remodelers.61,62 Tip60 could therefore be recruited to H2A.Z
containing loci as has been demonstrated for the NuA4 complex
in yeast.48 We hypothesize that Tip60 is capable of regulating
CCND1 gene expression by acetylating H2A.Z at the downstream
enh2, which then disturbs repressive promoter enh2 crosstalk.
Here, ERa was not required for Tip60 recruitment to these CCND1
regulatory elements unlike the mechanism recently described in
ERþ cells.62 Our data thus illustrate that the expression levels of
tissue or cell-specific genes are largely modulated by the ability of
transacting factors to associate with regulatory elements.
Long-range interactions between distant enhancers and pro-
moter regions via chromatin looping has been shown to allow
activation of single genes or gene clusters.63–66 This looping
generally occurs in the 50 part of genes and over tens or hundreds
of kb. The role of such loops is thought to isolate chromatin from
surrounding repressive environment via insulator elements.67
Long-range intragenic interactions implicate transcription
activators, histone variants, including H2A.Z and macro H2A.1,
and chromatin remodelers bound to promoter and enhancer
regions, but direct experimental evidence for intragenic looping
is still lacking.19,30,68,69 As shown by results of large-scale chromo-
some conformation (4C) and ChiA-PET experiments, such
interactions are well correlated with the existence of chromatin
domains of distinct properties around highly regulated genes,70–72
via interchromosomal but also intrachromosomal loops, but their
functional significance remains to be established. However, dy-
namic chromosome folding within distinct domains accompanies
transcription activation73,74 (Kocanova et al., unpublished data). It
is thus plausible that local decondensation of chromatin is, at least
in part, the result of releasing looping.
Finally, H2A.Z associates with a subset of ER-target genes that are
differentially regulated in different breast cancer cell lines. Hormone
treatment can lead to recruitment of H2A.Z to the TSS of the TFF1
gene30 or its eviction at the PGR or CCND1 promoters (unpublished
observations) in MCF-7 cells. These data suggest that there is no
general mechanism linking H2A.Z binding to transcription regulation.
Indeed, H2A.Z was also associated with silenced or repressed genes in
ERÿ breast cancer cells. Similarly to prostate cancer cells, it is the
acetylation of H2A.Z that has a key role in transcription regulation of
genes in breast cancer cells. The ratio of acetylated relative to bulk
H2A.Z bound to TSS and 30 enhancer sequences controls gene
function. Modification of this ratio allowed reversing uncontrolled
gene expression in the more aggressive ERÿ breast cancer cells for
which targeted treatments are critically lacking. Interfering with the
ratio of bound acetylated H2A.Z to promoter and enhancer
sequences in ERÿ cells mimics the effect of the estradiol bound ER.
This mechanism may increase our understanding of tumorigenesis
and offer new perspectives for re-activating control gene pathways.
MATERIALS AND METHODS
Cell lines, transfection and western blotting.
MDA-MB231 and MDA-MB436 cells were purchased from ATCC (Rockville,
MD, USA, used up to 15 passages). MDA-MB231 cells were maintained in
Dulbecco’s modified Eagle’s medium (DMEM) and MDA-MB 436 in DMEM/
F12 medium, both with Glutamax containing 50mg/ml gentamicin, 1mM
sodium pyruvate and 10% heat-inactivated fetal calf serum (Invitrogen,
Carlsbad, CA, USA). MDA-MB231 cells were treated with 50 ng/ml TSA
(Sigma-Aldrich, Inc., St Louis, MO, USA) for the indicated times. In all,
4 106 MDA-MB231 cells where mock-transfected (pcDNA3.1) or trans-
fected with 2 mg of pcDNA3.1/Tip60 (gifts from Dr Didier Trouche) with
Amaxa Cell line Nucleofactor Kit V program X-013 according to the
manufacturer’s protocol. Breast cancer cells were mock-transfected or
transfected with H2A.Z siRNA ON-TARGET plus SMARTpool or scrambled
(scr) siRNA (Dharmacon Thermo Scientific, Waltham, MA, USA) with
Interferine (Ozyme, Bedford, MA, USA) according to the manufac-
turer’s protocol. H2A.Z depletion was also performed with another siRNA
(H2AZ-1), kindly provided by Dr Didier Trouche (Supplementary Figure
S1D).75 Tip60 siRNA76 was purchased from Eurogentec, and transfected
with Interferine (Ozyme) according to the manufacturer’s protocol. A total
of 3 105 MDA-MB231 cells were seeded in six-well plates. Seventy-two
hours following siRNA transfection, total cell extracts were isolated and
protein level of H2A.Z and Tip60 was analyzed by immunoblotting on gel
SDS–PAGE 15% with anti-H2A.Z (Abcam, Cambridge, UK, ab4174), anti-
Tip6076 and with anti-GAPDH (Millipore, Bedford, MA, USA, mab374) or
anti-Tubulin (Sigma, DM1A) antibodies as loading control.
RNA analysis.
Total RNA was extracted using an RNeasy mini-kit (Qiagen, Valencia, CA,
USA) and eluted with 35ml of RNAase-free water. First strand cDNA was
generated using 2 mg of total RNA in a reaction containing random
oligonucleotides as primers with the ThermoScript RT–PCR system
(Invitrogen). Real-time PCR was performed on a Mastercycler ep realplex4
(Eppendorf) using the platinum SYBR Green q-PCR SuperMix (Invitrogen)
according to the manufacturer’s instructions. Amplification conditions:
1min at 50 1C, 3 min at 95 1C followed by 40 cycles (20 s at 95 1C, 20 s at
60 1C, 20s at 72 1C). q-PCR for RPLP0 mRNA was used as an internal control.
The primers used in q-PCR: ESR1: 50-CATGGTCATAACAGCCTCCTG-30 and
50-TAGAATGGGCAGGAGAAA GG-30 , H2AFZ: 50-CCTTTTCTCTGCCTTGCTTG-30
and 50-CGGTGAGGTACTCCAGGATG-30 , CCND1: 50-GCGTCCATGCGGAAGA
TC-30 and 50-ATGGCCAGCGGGAAGAC-30 , RPLP0: 50-TGGCAGCATCTACAACC
CTGAA-30 and 50-CACTGGCAACATTGCGGACA-30 , PGR: 50-CTTAATCAACTAG
GCGAGAG-30 and 50-AAGCTCATCCAAGAATACTG-30 , TFF1: 50-CAGATCCCTG
CAGAAGTGTCT-30 and 50-CCCCTGGTGCTTCTATCCTAAT-30 .
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ChIP assays
ChIP analyses were performed as described previously77 from MDA-MB231
cells. Samples were sonicated to generate DNA fragments o500 bp.
Chromatin fragments were immunoprecipitated using antibodies against
H2A.Z (ab4174, Abcam), Acetyl H2A.Z (ab18262, Abcam), RNA pol II (N20X,
Santa Cruz biotechnology, Santa Cruz, CA, USA), Acetyl H3K9 (06-942,
Upstate, Bedford, MA, USA), RNA pol II serine 5 phosphorylated (MPY-127R,
H14, Covance, Vienna, VA, USA; IF), pan Acetyl H4 (39 243, active motif), H3
(ab1791, Abcam), Tip60 78 or an irrelevant HA antibody (H6908, Sigma) as
control. The precipitated DNA was amplified by real-time PCR, with primer
sets designed to amplify the promoter region of the PGR, ESR1, TFF1 and
CCND1 genes, as well the enh2 enhancer and ÿ 2000 region of CCND1. The
primers used in q-PCR are listed here: CCND1 (TSS): 50-CGGGCTTT
GATCTTTGCTTA-30 and 50-ACTCTGCTGCTCGCTGCTAC-30 , distal CCND1
enhancer (enh2): 50-CAGTTTGTCTTCCCGGGTTA-30 and 50-CATCCAGAGCAA
ACAGCAG-30 , ÿ 2000 region: 50-GCTCTTTACGCTCGCTAACC-30 and 50-GCAA
GACAGAGGAAACTGGAA-30 , PGR: 50-TCGGGGTAAGCCTTGTTGTA-30 and 50-GC
CTCGGGTTGTAGATTTCA-30 , ESR1: 50-CATGGTCATAACAGCCTCCTC-30 and
50-TAGAATGGGCAGGAGAAAGG-30 , TFF1: 50-ATGGGAGTCTCCTCCAACCT-30
and 50-TTCCGGCCATCTCTCACTAT-30 .
All ChIP data are shown as percent input. For the ratio of acetylated
H2A.Z, the amount of Ac-H2A.Z in percent of input was divided by the
percent input of H2A.Z in order to have a percentage of global Ac-H2A.Z
on a promoter.
3C assays
Chromatin conformation capture assays were performed essentially as
described,52 with only minor modifications. MDA-MB231 cells were
transfected with a scrambled control siRNA (ÿ ), with H2A.Z SMARTpool
siRNA (þ ) (Dharmacon Thermo Scientific), Tip60 siRNA (þ ) or both siRNAs
and cultured in phenol red-free DMEM containing 10% FBS-T for 72h before
cross-linking. The culture medium was removed, and cells were fixed with
1.5% formaldehyde for 10min at room temperature. Cells were then washed
twice with cold phosphate-buffered saline solution, and resuspended in ice-
cold lysis buffer (10mm Tris–HCl, pH 8.0, 10mm NaCl, 0.2% nonidet P-40, and
protease inhibitor mixture). Nuclei were resuspended in 1ml of buffer B 1.2X
buffer (MBI Fermentas, Thermo Fisher Scientific, Rockford, IL, USA)
supplemented with SDS 0.3%. Triton X-100 1.8% was added to sequester
the SDS and incubated for 1h at 37 1C. The cross-linked DNA was digested
overnight with 400 units of restriction enzyme Csp6I (MBI Fermentas). The
restriction enzyme was inactivated by incubation at 65 1C for 20min The
reactions were diluted with ligase buffer (50mm Tris–HCl, pH 7.5, 10mm
MgCl2, 10mm dithiothreitol, 1mm ATP and 25mg/ml bovine serum albumin),
supplemented with Triton X-100 (1% final concentration). The DNA was ligated
using T4 DNA ligase (New England Biolabs, Ipswich, MA, USA) overnight at
16 1C and an additional 100 units for 2h at 37 1C. RNase was added for 30min
at 37 1C, and samples were incubated with SDS overnight at 70 1C to reverse
the crosslink. The following day, samples were incubated for 2h at 45 1C with
proteinase K, and the DNA was purified by phenol–chloroform extractions and
ethanol precipitation. Interaction between chromatin domains was assessed
by PCR amplification carried out using similar conditions as for real-time PCR
amplification but with four nested primer pairs for each predicted ligation
event (four possibilities) as performed by Deschenes et al.79 with minor
modifications. The second PCR reaction was performed and analyzed by
q-PCR. Primers were designed on the digested BAC fragments, directly around
the putative site of ligation for the four possibilities. BAC clones RP11-300ID
(BACPAC Resources Center at Childrens Hospital Oakland Research Institute,
Oakland, CA, USA) containing the CCND1 gene and downstream 160-kb region
were used. Forty microgram of BAC was digested by Csp6I overnight and
ligated. This product was purified by phenol–chloroform and precipited in
order to generate 3C control templates. PCR primer efficiency was measured
by amplifying 0.01–50ng of digested BAC product and also tested on a fixed
amount (50ng) of digested genomic DNA. All primers have an annealing
temperature between 65 to 70 1C and a product size around 150–300bp. All
primer combinations showed PCR efficiency between 90 and 100%. chromatin
conformation capture assay results are presented as the average from three
independent preparations of 3C DNA, followed by q-PCR analysis in triplicate.
q-PCR for enh2 (PCR primers designed inside the Csp6I restriction fragment
including enh2) was used as an internal control to verify ligation events. Non-
digested samples and ligation between a control fragment with enh2 are
represented. List of primer sequences see Supplementary Figure S3.
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2Abstract 
Histone variants, including histone H2A.Z, are incorporated into specific 
genomic sites and participate in transcription regulation. The role of H2A.Z at these 
sites remains poorly characterized. 
Our study investigates changes in the chromatin environment at the Cyclin D1
gene (CCND1) during transcriptional initiation in response to estradiol in estrogen 
receptor positive mammary tumour cells. We show that H2A.Z is present at the 
transcription start-site and downstream enhancer sequences of CCND1 when the 
gene is poorly transcribed. Stimulation of CCND1 expression required release of 
H2A.Z concomitantly from both these DNA elements. The AAA+ family members 
TIP48/reptin and the histone variant H2A.Z are required to remodel the chromatin 
environment at CCND1 as a prerequisite for binding of the estrogen receptor (ERα)
in the presence of hormone. TIP48 promotes acetylation and exchange of H2A.Z, 
which triggers a dissociation of the CCND1 3’enhancer from the promoter, thereby 
releasing a repressive intragenic loop. This release then enables the estrogen 
receptor to bind to the CCND1 promoter. Our findings provide new insight into the 
priming of chromatin required for transcription factor access to their target sequence. 
Dynamic release of gene loops could be a rapid means to remodel chromatin and to 
stimulate transcription in response to hormones.
3Author summary 
Our study investigates changes in the chromatin environment at the Cyclin D1
gene that are a prerequisite for transcriptional initiation in response to estradiol. 
Gene expression is under control of chromatin structure. Histone variants, including 
histone H2A.Z, are incorporated into specific genomic sites and participate in 
transcription regulation. We show that H2A.Z is present at the transcription start-site 
and downstream enhancer sequences of CCND1 when the gene is poorly 
transcribed. Stimulation of CCND1 expression required release of H2A.Z 
concomitantly from both these DNA elements. The TIP48/reptin protein which is part 
of several chromatin remodeling complexes also associated with the CCND1
regulatory elements. Here, TIP48 promotes exchange of H2A.Z, which triggers a 
dissociation of the CCND1 enhancer from the promoter, thereby releasing a 
repressive intragenic loop. This release then enables estrogen receptor to bind the 
CCND1 promoter. Acetylation of H2A.Z is required for these processes. Our findings 
provide new insight into the priming of chromatin required for transcription factor 
access to their target sequence. Hence, we propose a new model for early events in 
transcription activation that were not shown before. Specifically, release of looping 
could be a rapid means to activate transcription efficiently in response to stimuli, in 
particular estrogen. 
4Introduction 
Transcription activation relies on a careful choreography of local chromatin 
remodeling events that include posttranslational histone modifications and 
replacement of canonical histones by variants [1-4].  In ER-positive breast cancer 
cells gene activation can be advantageously studied by addition of hormone.  
Numerous chromatin modifying and remodeling complexes are dynamically 
exchanged during ER target gene activation in a gene specific manner [5,6]. 
Chromatin immunoprecipitation (ChIP) studies have provided extensive information 
on the recruitment of these complexes by the hormone bound estrogen receptor [7]. 
The first complex to occupy promoter sequences is the ATP-dependent SWI/SNF 
chromatin remodeling complex and its catalytic subunit Brg1. Its activity enables 
subsequent binding of a plethora of histone and protein modifying assemblies which 
lead to transcription initiation by polymerase II [5,6,8-10]. In contrast, it is less clear 
how local chromatin structure prepares for rapid and massive recruitment of the 
estrogen receptor itself in the presence of estrogen.  
Incorporation of histone variants constitutes a means to alter nucleosome 
properties and positioning at specific genomic loci.  The histone H2A variant H2A.Z is 
frequently found within nucleosomes at regulatory sequences [11-14]. In particular, 
H2A.Z occupancy characterizes inducible and constitutive DNAseI hypersensitive 
sites to which nuclear receptors bind [15]. This variant is believed to induce a 
chromatin conformation that poises genes for transcription in human cells [16].  In 
yeast, H2A.Z exchange is mediated by the SWR1 complex [17,18]. However, in 
mammalian cells, the mechanisms of H2A.Z deposition are still poorly characterized 
and may require several distinct protein complexes depending on the cellular context 
5(for a review see [19]). Among ATP-dependent chromatin remodeling complexes the 
TIP48/TIP49 containing SWR1/SRCAP [20] or TIP60/p400 [21,22] complexes have 
been shown to play a role in H2A.Z deposition [17,18,23]. p400 was also reported to 
be required for H2A.Z incorporation into the TFF1/pS2 gene concomitant to estrogen 
receptor binding [24]. In an in vitro study Choi et al. demonstrated that the AAA+ 
family (ATPases Associated with various cellular Activities) members TIP48/TIP49 
participate in the replacement of H2A by H2A.Z [25]. This H2A.Z exchange was 
facilitated by TIP60-mediated H2A acetylation. TIP48/TIP49 proteins (also known as 
TIP49b and TIP49a, Rvb2 and Rvb1, reptin and pontin) are important for assembly 
and activity of the histone TIP60 acetyltransferase complex [26].  
To gain a better understanding of the early steps required in estrogen receptor 
mediated transcription activation and the coordination between remodeling 
complexes and chromatin structure, we analyzed transcription of the cyclin D1 gene 
(CCND1) in ER-positive MCF-7 breast cancer cells. This oncogene is frequently 
overexpressed in human breast tumors [27]. Its down-regulation increases migratory 
capacity and is linked to unfavorable prognosis [28,29]. Cyclin D1 is a mitogenic 
sensor that modulates cell cycle progression. CCND1 transcription is stimulated by 
17-estradiol (E2), inhibited by antiestrogens and cell cycle regulated in ER-positive 
breast cancer cells [30,31].  
Here we show that TIP48 and H2A.Z associate with CCND1 promoter and 
enhancer sequences. TIP48 is required for chromatin reorganization which is initiated 
by release of H2A.Z and opening of a repressive promoter-enhancer gene loop 
enabling TIP60 and the E2 bound estrogen receptor to be loaded to stimulate 
CCND1 transcription.
6Results  
TIP48 and H2A.Z association with CCND1 regulatory sites is required for 
activation by estradiol. 
In ER-positive MCF-7 cells grown in steroid stripped media only basal 
transcription levels of the Cyclin D1 gene (CCND1) were measured. Addition of E2 
initiated CCND1 transcription activation lead to a 2.5-fold increase in mRNA levels in 
cells treated 6h with 100nM E2 (Fig. 1A). H2A.Z has been reported to act in concert 
with ER to regulate the TFF1 gene [24] prompting us to examine H2A.Z association 
with CCND1 regulatory elements. Analysis of ChIP-on-chip data revealed that H2A.Z 
was highly enriched at sequences 5’ and 3’ flanking the CCND1 gene, and largely 
absent from the open reading frame (Fig. 1B) [32]. By conventional ChIP, we found 
that the amount of H2A.Z present at the CCND1 promoter was reduced by 50% at 
the TSS (Fig. 1C). Eeckhoute et al. identified an enhancer (enh2) at the 3’end of the 
CCND1 gene which acts as the primary site for ER and cofactor binding during 
CCND1 transcriptional regulation [9]. We thus analyzed the chromatin organization of 
enh2. Similar to the promoter, H2A.Z present at enh2 was removed during 
transcription activation (Fig 1C). Reduced binding was not due to a decrease in 
H2AFZ expression in the presence of E2 (Fig. 1A). Chromatin modifications at the 
CCND1 promoter and enhancer appear to be coordinated. Removal of H2A.Z from 
promoter sequences upon transcription activation correlates with observations in 
yeast and several mammalian cells and points to a mechanism of regulation distinct 
from the one of the ER target gene TFF1 [33] [24,34]. Replacement of nucleosomal 
H2A with H2A.Z has been shown to be catalyzed by the TIP48/49 complex in vitro 
[25]. The TIP48/49 complex was thus a good candidate for regulating H2A.Z 
7dynamics at CCND1 regulatory sequences. TIP48 and TIP49 are ubiquitously 
expressed and are often part of the same complex. In most cell types, and in 
particular in epithelial cancer cells such as MCF-7 cells, silencing one of the partners 
by interference RNA lead to degradation of the other partner [35]. Better antibody 
specificity and efficiency prompted us to investigate TIP48. TIP48 was associated 
with the promoter and enh2 of CCND1 in non-induced ER-positive MCF-7 cells (Fig. 
1D). Binding of TIP48 to the CCND1 TSS and enh2 decreased rapidly following 
addition of 100 nM estradiol (E2). Expression of the gene coding for TIP48 was 
insensitive to E2 (Fig. S1A). To examine the relationship between TIP48 and H2A.Z, 
we selectively depleted TIP48 by siRNA (Fig. S1A). In siTIP48 transfected cells 
treated or not with E2, H2A.Z binding to CCND1 was reduced compared to control, 
non–specific siRNA transfected cells. Levels of H2A.Z binding in the absence of 
TIP48 were roughly equivalent to levels in E2 treated control cells (Fig. 2A). 
Moreover, nucleosome density assessed by immunoprecipitating histone H3 was 
unchanged near the TSS (Fig. 2B). Thus, eviction of H2A.Z upon initiation of E2 
stimulated transcription was not due to general chromatin decondensation around the 
CCND1 gene and its promoter region in particular. TIP48 appears to be necessary 
for recruiting H2A.Z to the CCND1 gene in MCF-7 mammary tumor cells. 
We thus asked whether binding of H2A.Z or its release were important for 
regulating CCND1 transcription. H2A.Z mRNA expression levels were reduced ~5-
fold in cells 48h post transfection with a smartpool siRNA directed against H2A.Z 
compared to control cells (Fig. S1B). Reduced levels of H2A.Z did not alter basal 
CCND1 expression levels, but impeded activation by E2 (Fig. 2C). Similarly, in the 
absence of TIP48, basal transcription levels were conserved, while activation of 
CCND1 by E2 was compromised (Fig. 2C). H2AFZ mRNA levels were not affected 
8by selective knockdown of TIP48 (Fig. S2A). Thus, Stimulation of CCND1 expression 
required release of H2A.Z concomitantly from both these DNA elements. 
TIP48 promotes ER binding during E2 activated transcription.
Absence of activation was likely due to failure of ER fixation to the CCND1
promoter. Under standard conditions, E2 stimulated ER binding to both the 
promoter and enh2 of CCND1 (Fig. 3A) [9]. Selective knock down of TIP48 hindered 
ER binding to these sites (Fig. 3A). Reduced binding could not be attributed to 
altered or decreased ESR1 expression patterns in cells transfected with control or 
TIP48 siRNAs (Fig. 3B). Therefore, TIP48 appears to be necessary to remodel 
CCND1 chromatin structure for productive ER binding in the presence of hormone.  
TIP48 promotes recruitment of TIP60 to CCND1
TIP48 and TIP60 have been found as part of the same complex [20,25]. TIP60 
also cooperates with ER and other chromatin-remodeling enzymes during estrogen-
induced transcription [36,37]. We tested whether TIP48 and TIP60 binding to the 
CCND1 promoter was coordinated. In the presence of E2, TIP60 was recruited to the 
CCND1 promoter (Fig. 4A). Upon depletion of TIP48, TIP60 no longer associated 
with the CCND1 TSS (Fig. 4A).  Cooperation between TIP48, ER and TIP60 binding 
was likely to be necessary for transcription activation. To unravel a functional link, we 
first over-expressed TIP60 in MCF-7 cells (Fig. S2B). TIP60 overexpression 
stimulated E2 activated CCND1 transcription nearly 5-fold compared to control 
untreated cells, without affecting neither basal, non-induced mRNA levels (Fig. 4B) 
nor the expression pattern of the H2AFZ gene (Fig. S2C). In siTIP48 transfected 
9cells, overexpression of TIP60 was no longer able to stimulate CCND1 transcription 
upon E2 stimulation (Fig. 4C), suggesting that TIP48 is required for TIP60 function.  
TIP60 is found in protein complexes able to acetylate histones, with a 
preference for lysine 5 of H2A [38]. Core histones are generally acetylated in the 
promoter region of transcribed genes. Acetylation of the histone variant H2A.Z was 
shown to characterize active genes in yeast and recently also in prostate cancer cells 
[13,39]. Using an antibody that specifically recognizes H2A.Z acetylated at 3 N-
terminal lysines, we determined that a large fraction of H2A.Z bound to the CCND1
promoter and the 3’ enh2, was highly acetylated (Fig. 5A). Acetylation levels of 
H2A.Z did not vary following E2 induced CCND1 gene activation in control samples 
(Fig. 5A). However, because H2A.Z was released during transcription activation, the 
ratio of acetylated H2A.Z/total H2A.Z increased nearly 2-fold at these sites (Fig. 5B). 
In siTIP48 transfected cells, we observed a decrease in acetylated H2A.Z present at 
the TSS and the enh2 (Fig 5A). The increased ratio of acetylated H2A.Z associated 
with the CCND1 gene following E2 was abolished in cells transfected with siTIP48 
(Fig. 5B). The reduced ratio of H2A.Z acetylation thus correlated with impeded 
transcription activation in siTIP48 transfected MCF-7 cells (Figs. 5B and Fig. 2C). 
In conclusion, failure of TIP60 to associate with CCND1 in the absence of 
TIP48 correlated with reduced binding of ER (Fig. 3), reduced levels of H2A.Z 
acetylation at the CCND1 gene (Fig. 5) and the inability to activate this gene by 
estrogen (Fig. 2C).  
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TIP48 modulates CCND1 chromatin structure by controlling gene looping
Long-range chromatin interactions between ERα recognition sequences and 
enhancers have been proposed to regulate ERα-target genes in breast cancer cells 
[40,41]. The main enhancer regulating CCND1 is located at the 3’ end of the gene, 
14kb distant from the promoter [9]. Gene looping via promoter-enhancer crosstalk is 
associated with repressed, low CCND1 expression in ERα-negative, MDA-MB231 
cells [42]. Thus we asked whether this loop also existed in MCF-7 cells and more 
importantly, whether looping was sensitive to hormone. 
We used a chromatin conformation capture (3C) assay. The 3C method 
detects physical proximity between distal DNA sites by ligation of cross-linked 
restricted DNA fragments [43,44]. Ligation products between enh2 and promoter, and 
between enh2 and a control fragment inside the CCND1 ORF were amplified and 
normalized to an amplified enh2 PCR product (see Materials and Methods) (Figure 
6A). We measured significant interaction frequencies between enh2 and promoter 
sequences in MCF-7 cells grown in hormone-stripped media (-E2). Interaction 
frequencies were reduced ~10-fold 45min after addition of E2 to the cell culture (Fig. 
6B). No significant amplification of ligation products between enh2 and the internal 
control fragment was detectable. Hence, an extragenic loop mediated by specific 
promoter enhancer interactions was present when CCND1 expression is low (Figs. 
6B and 2D). Upon transcription activation, gene looping is markedly reduced.  
It was tempting to speculate that TIP48 plays a role in regulating looping. We 
assessed the relative frequencies of interaction between enh2/promoter and 
enh2/internal control fragments in MCF-7 cells transfected or not by siTIP48.  
Depletion of TIP48 had no impact on enh2/promoter contacts in the absence of E2 
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(Fig. 6B). This observation correlated with identical basal expression levels of 
CCND1 in control and siTIP48 transfected cells (Fig. 2C).  
45min after addition of E2 to the cells, the frequency of enh2/promoter 
interaction was 5-fold greater in siTIP48 transfected cells compared to control cells 
(Fig. 6B). Conservation of significant repressive gene looping could thus account for 
impeded E2 bound ERα binding to the CCND1 promoter and compromised 
transcription activation. We propose a model (Fig. 7) in which TIP48 is required at 
early steps during transcription activation which is initiated by release of H2A.Z and 
subsequent dissociation of the enhancer from the promoter. E2 bound estrogen 
receptor can then recognize the promoter and stimulate transcription of CCND1. 
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Discussion 
We unraveled a role for TIP48 in initiating transcription activation of the 
CCND1 oncogene. Recruitment of the histone acetyltransferase TIP60 is dependent 
on TIP48 and H2A.Z binding to the promoter and 3’ enhancer of the CCND1 gene. 
We propose that low levels of CCND1 expression are regulated because the 
associated gene loop is transcription-dependent. This regulation is brought about by 
the activity of TIP48 containing complexes which locally act upon chromatin structure 
to release a disabling loop. Such a mechanism allows fine-tuning transcription 
regulation of genes pivotal for the cellular equilibrium in rapidly changing 
environments. 
Our work describes early events implicated in E2 induction of CCND1. These 
events include dynamic exchange of a series of cofactors, namely the TIP48 complex 
and histone variant H2A.Z, recruitment of TIP60 and acetylation of H2A.Z enabling 
the main transcription factor, the estrogen receptor, to associate with its target 
sequences. TIP60 can directly interact with ERα and its acetyltransferase activity is 
important during transcription initiation once ERα is bound to target gene promoters 
[36]. 
TIP60 is a versatile enzyme that functions with a variety of partners in a gene 
and cell specific manner [36,45]. Selective knock-down of TIP60 by siRNA 
compromises activation of some, but not all ERα target genes in MCF-7 cells, as well 
as nuclear receptor independent genes in several cell lines (unpublished 
observations). CCND1 was one of the genes found to be insensitive to siTIP60  [36]. 
This observation denotes that TIP60 can be replaced by other histone 
acetyltransferases in CCND1 transcription activation. Thus, dependency of early 
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chromatin remodeling steps on TIP48 and H2A.Z may be more generally applicable 
to allow cofactor recruitment for productive ERα binding in stimulated transcription. 
We found that H2A.Z was removed from CCND1 regulatory elements while 
this variant had previously been shown to be recruited to the promoter of the TFF1
gene upon E2 treatment of MCF-7 cells [24]. Differences in promoter structure are a 
plausible explanation for divergent remodeling mechanisms. It is also likely that post-
translational modifications of H2A.Z are important as shown in a recent genome wide 
study by Valdes-Mora et al. who found that H2A.Z acetylation at the TSS correlates 
with active transcription in prostate cancer cells [13]. Indeed, the level of acetylation 
of H2A.Z near the TSS of CCND1 was equivalent at non-activated and E2 stimulated 
cells. We propose that, in ER-positive breast cancer cells, the ratio of acetylated 
H2A.Z / H2A.Z rather than the total amount of H2A.Z bound to the CCND1 promoter 
correlates with transcriptional activity.  
Chromatin remodeling events are crucial for hormone stimulated activation of 
estrogen receptor target genes. However, so far, all data available describe the 
recruitment of remodeling complexes and cofactors once the estrogen receptor is 
bound. The Brg1 subunit of the SWI/SNF complex is one of the first proteins to 
associate with ERα and, although transcription is no longer activated in its absence, 
ERα remains bound in siBrg1 transfected cells [36]. Here we demonstrate that 
chromatin remodeling events prior to ERα binding are essential for initiating 
transcription. These events depend on TIP48 and H2A.Z specific nucleosome 
conformation. Chromatin structure impedes ERα loading via intragenic looping. 
Notably, interaction between promoter and enhancer sequences forms a repressive 
complex. Reduced distances between 5’ and 3’ ends of gene loci have been 
attributed to greater chromatin density. In this case, looping does not require 
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changes in chromatin compaction. Dynamic release of gene loops is consistent with 
rapid chromatin remodeling and transcription activation by hormone.  
Finally, addition of hormone triggers large scale chromatin remodeling. In 
breast cancer cells gene response to progestin is mediated by nucleosomes[46] and 
estradiol treatment leads to expansion of chromosome territories within minutes [47]. 
This latter phenomenon was also observed in ER negative cells (unpublished) 
suggesting that chromatin decondensation is independent of the receptor and may 
prepare its binding in ER positive cells. It is thus tempting to speculate that the 
signaling mechanism by which hormone addition primes chromatin triggers histone 
exchange and remodeling prior to ER binding.  
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Materials and Methods 
Cell lines, transfection and western blotting.  
MCF-7 cells were purchased from ATCC and were maintained in DMEM/F12 
without phenol red with Glutamax containing 50 mg/ml gentamicin, 1 mM sodium 
pyruvate and 10% heat-inactivated and steroid free fetal calf serum (FCS) 
(Invitrogen). MCF-7 cells were treated with 10-7 M estrogen E2 (Sigma) for the 
indicated times. 5x106 MCF-7 cells were transfected with 20 nM of H2A.Z siRNA ON-
TARGET plus SMARTpool, TIP48 siRNA ON-TARGET plus SMARTpool or 
scrambled (scr) siRNA (Dharmacon Thermo Scientific) using Interferine (Ozyme). 
Cells were mock-transfected (pcDNA3.1) or transfected with 1 µg of pcDNA3.1/TIP60
(gift from Dr. Didier Trouche) using the Amaxa® Cell line Nucleofactor Kit V program 
P-020 according to the manufacturer’s protocol. TIP60 siRNA [45] was purchased 
from Eurogentec, and transfected using Interferine (Ozyme). 5x105 MCF-7 cells were 
seeded in 6 well plates. 72 h following siRNA transfection, total cell extracts were 
isolated and protein levels of H2A.Z, TIP48 and TIP60 analyzed by immunoblotting 
on gel SDS-page 15% using antibodies against H2A.Z (ABCAM, ab4174), TIP48 (gift 
of Dr. Mikhaïl Grigoriev) TIP60 [45] or GAPDH (Millipore, mab374). 
RNA analysis.  
Total RNA was extracted using an RNeasy mini-kit (Qiagen) and eluted with 
35 µl of RNAase-free water. First strand cDNA was generated using 2 µg of total 
RNA in a reaction containing random oligonucleotides as primers with the 
ThermoScript RT-PCR system (Invitrogen). Real-time PCR was performed on a 
Mastercycler® ep realplex 4 (Eppendorf) using the platinum SYBR Green q-PCR 
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SuperMix (Invitrogen) according to the manufacturer’s instructions. Amplification 
conditions: 1 min at 50 °C, 3 min at 95 °C followed  by 40 cycles (20s at 95 °C, 20s at 
60 °C, 20s at 72 °C). mRNA expression were normaliz ed against expression levels of 
the RPLP0 ribosomal gene used as an internal control. qRT-PCR primers: H2AFZ: 
5’-CCTTTTCTCTGCCTTGCTTG-3’ and 5’-CGGTGAGGTACTCCAGGATG-3’, 
CCND1: 5’-GCGTCCATGCGGAAGATC-3’ and 5’-ATGGCCAGCGGGAAGAC-3’, 
RPLP0: 5’-TGGCAGCATCTACAACCCTGAA-3’ and 5’- CACTGGCAACATTG 
CGGACA-3’, TIP48: 5’-TGAAGAGCACTACGAAGACGC-3’ and 5’-
CCTTACTACCCAGCTC CTGA- 3’ 
ChIP assays 
ChIP analyses were performed as described previously [48]. Samples were 
sonicated to generate DNA fragments <500 bp. Chromatin fragments were 
immunoprecipitated using antibodies against H2A.Z (ab4174, ABCAM), Acetyl H2A.Z 
(ab18262, ABCAM), TIP48 (gift of Dr. Mikhaïl Grigoriev), ER (sc-543, Santa Cruz), 
H3 (ab1791, ABCAM), TIP60 [49] or an irrelevant HA antibody (H6908, Sigma). The 
precipitated DNA was amplified by real-time PCR, with primer sets designed to 
amplify the promoter (TSS) and enh2 enhancer regions of the CCND1 gene (Fig. 
1B). qRT-PCR primers: CCND1 (TSS): 5’-CGGGCTTTGATCTTTGCTTA-3’ and 5’-
ACTCTGCTGCTCGCTGCTAC-3’, distal CCND1 enhancer (enh2): 5’-
CAGTTTGTCTTCCCGGGTTA-3’ and 5’- CATCCAGAGCAAACAGCAG-3’. All ChIP 
data are shown as percent input.  
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3C Assays
3C assays were performed essentially as described [50,51], with minor 
modifications. MCF-7 cells were treated with E2 10-7 M for 45 mn or transfected with 
a scrambled control siRNA, with TIP48 SMARTpool siRNA (Dharmacon Thermo 
Scientific), and cultured in phenol red-free DMEM containing 10% FBS-T for 72h 
before cross-linking. The culture medium was removed, and cells were fixed with 
1.5% formaldehyde for 10 min at room temperature. Cells were then washed twice 
with cold phosphate-buffered saline solution, and resuspended in ice-cold lysis buffer 
(10 mm Tris-HCl, pH 8.0, 10 mm NaCl, 0.2% Nonidet P-40, and protease inhibitor 
mixture). Nuclei were resuspended in 1 ml of Buffer B 1.2X buffer (MBI Fermentas) 
supplemented with SDS 0,3%. Triton X-100 1,8% was added to sequester the SDS 
and incubated for 1 h at 37 °C. The cross-linked DN A was digested overnight with 
400 units of restriction enzyme Csp6I (MBI Fermentas). The restriction enzyme was 
inactivated by incubation at 65 °C for 20 min. The reactions were diluted with ligase 
buffer (50 mm Tris-HCl, pH 7.5, 10 mm MgCl2, 10 mm dithiothreitol, 1 mm ATP, and 
25 g/ml bovine serum albumin), supplemented with Triton X-100 (1% final 
concentration). The DNA was ligated using T4 DNA ligase (New England Biolabs, 
Ipswich, MA) overnight at 16°C and an additional 10 0 units for 2 h at 37°C. RNase 
was added for 30 min at 37°C, and samples were incu bated with SDS overnight at 
70°C to reverse the crosslink. The following day, s amples were incubated for 2 h at 
45°C with proteinase K, and the DNA was purified by  phenol-chloroform extractions 
and ethanol precipitation. Interaction between chromatin domains was assessed by 
real-time-PCR amplification for each predicted ligation event [50,52]. Primers have 
been designed on the digested BAC fragments, directly around the putative site of 
ligation for the four possibilities. BAC clones RP11-300ID (BACPAC Resources 
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Center at Childrens Hospital Oakland Research Institute, Oakland, CA) containing 
the CCND1 gene and downstream 160-kb region were used. 40 ug of BAC was 
digested by Csp6I overnight and ligated. This product was purified by phenol 
chloroform and precipitated in order to generate 3C control templates. PCR primer 
efficiency was measured by amplifying 0.01 to 50 ng of digested BAC product and 
also tested on a fixed amount (50 ng) of digested genomic DNA. All primers have an 
annealing temperature between 65 to 70° C and a pro duct size around 150-300 bp. 
All primer combinations showed PCR efficiency between 90 and 100%. 3C assay 
results are presented as the average from three independent preparations of 3C 
DNA, followed by qPCR analysis in triplicate. qPCR for enh2 (PCR primers design 
inside the Csp6I restriction fragment enh2) was used as an internal control to verify 
ligation events. Non-digested sample and ligation between a control fragment and 
enh2 were also performed (data not shown). Primers used for one of the four ligation 
event tested: Enh2/Prom: 5’-CTGGGAGAGATGGAGCTGAG-3’ and 5’-
GGTTTTGTTGGGGGTGTAGA-3’, Enh2/ctrl: 5’-AAGCTCTCCCACAACCCATT-3’ 
and 5’-GTCAGCCCCACTGTTGACTC-3’. Other primers available upon request. 
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Figure legends 
Figure 1: TIP48 and H2A.Z are required for CCND1 activation by estradiol. A)
MCF-7 cells were cultivated 3 days in steroid stripped (white) medium and then 
induced by E2 10-7 M for 6 h. CCND1, H2AFZ mRNA was quantified by real-time RT-
PCR. The mean and SD from three independent experiments are shown. (*) 
indicates a p value < 0.05 (Student t-test). B) MCF-7 H2A.Z ChIP on chip signal 
detected around the CCND1 gene on human chromosome 11 loaded from [32] on 
UCSC. C, D) H2A.Z (C) and TIP48 (D) occupancy at CCND1 TSS and enh2 before 
and after 30 min and 60 min of E2 10-7 M treatment analysed by ChIP. The values of 
ChIP efficiencies are given in % of input with s.e.m indicated (n=3). Positions of 
DNAseI hypersensitive sites and primers used for ChIP are indicated in C). 
Figure 2: TIP48 regulates estrogen-activated transcription via H2A.Z release. A, 
B) MCF-7 cells were cultivated 3 days in steroid free medium, transfected with, 
scramble (ctrl) or TIP48 siRNA for 72 h and induced by E2 10-7 M for 30 min. 
Association of H2A.Z (A) and histone H3 (B) with TSS and enh2 sites was analyzed 
by ChIP and shown as % input (n=2). C) MCF-7 cells were cultivated 3 days in 
steroid free medium and transfected at day 0 with a Scramble (Ctrl), a H2A.Z siRNA 
or a TIP48 siRNA for 72 h and then induced by E2 10-7 M for 6 h. CCND1 mRNA 
levels were determined by qRT-PCR. Control (Ctrl) without E2 treatment                
was set to 1. The mean and SD from three independent experiments are shown. (*) 
indicates a p value < 0.05. 
  
23
Figure 3: TIP48 is required for ER binding during E2 activated transcription. 
MCF-7 cells were cultivated 3 days in steroid free medium, transfected with scramble 
(ctrl) or TIP48 siRNA for 72 h and induced by E2 10-7 M for 30 min. A) ChIP analysis 
of ER occupancy at the CCND1 TSS and enh2 sites. Results are shown as % input 
(n = 2). B) qRT-PCR quantification of ESR1 mRNA expression relative to RPLO. The 
mean and SD from three independent experiments are shown. (**) indicates a p 
value < 0.01. 
Figure 4: TIP48 promotes TIP60 binding and CCND1 transcription activation.
MCF-7 cells were cultivated 3 days in steroid free medium and induced by E2 10-7 M 
for 6 h. A) Cells were transfected with scramble (-) or TIP48 siRNA for 72 h and 
induced by E2 10-7 M for 30 min. TIP60 binding to the CCND1 promoter was 
analyzed by ChIP and shown as percent of input (n=2). B) After 24 h in steroid free 
medium, MCF-7 cells were transfected with a mock vector or a vector expressing 
TIP60 for 48 h. CCND1 mRNA expression was analyzed by qRT-PCR. The mean 
and SD from three independent experiments are shown. (*) indicates a p value < 
0.05. C) MCF-7 cells were first transfected with scramble (-) or TIP48 siRNA as in 
(A). After 24 h, same cells were transfected with a mock vector or a vector 
expressing TIP60 for 48 h as in (B). CCND1 gene expression was analyzed by qRT-
PCR after 30 min of E2 10-7 M induction.
Figure 5: TIP48 promotes acetylation of H2A.Z.  MCF-7 cells were cultivated and 
transfected as in Fig 2. A) Association of Acetyl H2A.Z with CCND1 TSS and enh2 
sequences analyzed by ChIP and shown as % input (n=2). B) Ratio of acetylated 
versus total H2A.Z in %.  
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Figure 6: Release of CCND1 gene looping requires TIP48. A) Schematic 
representation of the CCND1 locus on h.s. chromosome 11 (adapted from the USCS 
genome browser http://genome.ucsc.edu/cgi-bin/hgGateway). DNAseI hypersensitive 
sites [9], Csp6I restriction sites and fragments assayed by 3C are represented. B) 
Quantitative PCR amplification of ligation events in a 3C assay in MCF-7 cells treated 
or not with E2 10-7 M for 45 min and transfected 72 h before with scramble (ctrl) or 
TIP48 siRNA. Crosslinked DNA was digested with the Csp6I restriction enzyme and 
ligated. qRT-PCR was performed with primers designed for the 4 possible ligation 
events (only one is shown).  
Figure 7:  Model for the role of TIP48, H2A.Z and TIP60 in initiation of transcription 
activation of CCND1 via promoter enhancer crosstalk.  
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Supplemental Figure legends 
Figure S1: Depletion of TIP48 and H2A.Z by siRNA. MCF-7 cells were cultivated 3 
days in steroid free medium and then induced by E2 10-7 M for 6 h. A) TIP48 mRNA 
expression levels analyzed by qRT-PCR and TIP48 protein analyzed by 
immunoblotting in siTIP48 transfected compared to control cells.  B) H2AFZ mRNA 
expression levels analyzed by qRT-PCR and H2A.Z protein analyzed by 
immunoblotting in siH2A.Z transfected compared to control cells.   
Figure S2: TIP60 overexpression and H2AFZ gene expression. MCF-7 cells were 
cultivated 3 days in steroid free medium and then induced by E2 10-7 M for 6 h. A) 
TIP60 gene expression analyzed by qRT-PCR. TIP60 protein expression analyzed 
by western-blotting. B) H2AFZ gene expression levels were analyzed by qR-PCR in 
siTIP48 transfected compared to control cells. C) H2AFZ mRNA expression levels 
analyzed by qRT-PCR in siTIP48 transfected compared to control cells. 
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IX. Supplementary data. 
During the last years, aspects of cellular biology became important to understand 
biological mechanisms and regulation. The spatial and temporal behavior of the genome 
is now recognized as intimately linked to control genome function. Further studies about 
the contribution of nuclear architecture and its impact on gene expression will be required 
to better understand physiological processes such as differentiation, development and 
diseases at the cellular level (Misteli 2005). 
It is now clear that chromatin organization in the vertebrate nucleus is non-random. 
Chromosomes adopt preferential position with regard to the center or edge of the nucleus 
and genes adopt preferential positions with regard to their own chromosome territory 
(Fraser and Bickmore 2007). In particular, the relative position of a gene with regard to its 
chromosome territory may be related to transcriptional gene regulation (Chambeyron and 
Bickmore 2004); (Kocanova, Kerr et al. 2010). 
Each chromosome’s neighbor in the nucleus varies between cell types, and it has 
consequences for the chromosome’s ability to interact in trans with other parts of genome, 
as revealed by the frequency of specific chromosome translocations (Bickmore and 
Teague 2002; Parada, McQueen et al. 2004). The positional organizations of 
chromosomes within the nucleus and of genes within chromosome territories impinge on 
other aspects of genome function and, in particular, on the regulation of gene expression 
(Xu, Tsai et al. 2006), (Bacher, Guggiari et al. 2006)). 
To study the organization of the genome in the nucleus, there are, essentially, two main 
techniques: fluorescent in situ hybridization (FISH) and chromosome conformation 
capture (3C). 
In 3C, chromatin fragments in close proximity in the nucleus are captured by fixation, 
restriction-enzyme digestion and intramolecular ligation. The interaction between two 
designated loci is tested by PCR with specific primers for the loci under investigation. 
In FISH, the relative nuclear position of genes, genomic region or even whole 
chromosomes are analyzed by the hybridization of fluorescent probes to nuclei fixed on 
glass slides. The hybridization signals are then visualized with fluorescent microscopy.  
With this technique in our laboratory, we performed several studies. In particular, we were 
interested in gene movements within nucleus and with regard to their chromosome 
territory, during gene activation. 
 
Using estrogen receptor target genes as a model, we can study and analyze in 3D the 
genes displacements and “interactions” (Kocanova, Kerr et al. 2010), clarifying the 
existence of a link between nuclear gene position and its transcriptional state. 

During my doctoral project, I tested the 3D nuclear organization preserving FISH 
technique on other genes,in particular, on non-estrogen receptor target genes. I analyzed 
p21 gene position relative to chromosome territories in ER-positive, p53-positive MCF-7 
cells, and asked whether its position changed after estradiol treatments. 
First, I performed 2D FISH on metaphase cells to know how many chromosomes 6 and 
p21 gene copies are present in MCF-7 cells (Figure 1). 

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So,I performed FISH experiments on interphase cells, using DNA from BAC clones as a 
fluorescent probe to visualize p21 gene and its chromosomal territory (chromosome 6). I 
treated or not the cells with estradiol (10nM) during 3h and I observed p21 gene behavior 
on fixed cells (Figure 2). 
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The first thing that we see is that the chromosomal territory occupancy is very precise and 
discrete in each nucleus. Each chromosome 6 territory includes a p21 copy, the p21 
localization is not fixed within territory and seems to be independent of transcriptional 
state. No relevant and statistical difference has been observed between treated and non-
treated cells. These types of experiments were thus inconclusive.  
The only relevant and interesting observation was the presence of some “doublets” 
(shown in figure 2B), indicating a decondensation of the locus, which may be in relation 
with an active transcription. 
The localization experiments on p21 were abandoned, but not the strategy. In the 
laboratory, investigation about gene movements and localization during activation and in 
different cellular contexts is actively pursued. Now, we search to visualize, using shorter 
fluorescent probes based on fosmids, chromatin behavior during gene activation. In 
particular, using the CCND1 gene as a model, we try to visualize the opening of the loop 
between its TSS and 3’ enhancer region (see results and discussion). 
Moreover, we try to perform the same observations but in living cells. In this manner, we 
will be able to follow all the steps of gene activation and the eventual displacements in 
nucleus. 
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A. Materials and Methods. 
For 2D FISH on metaphase cells. The cells were grown in DMEM (10% FCS, 1% 
Antibiotic, 1% glutamine), at 70-80% confluency, before addition of 2mM Thymidine for 
24h (S-phase block). Thymidine was then removed  by washing with 1xPBS; and cells 
cultured in fresh DMEM for 3-4h. After cell releasing, 100ng/ml Colcemid was added for 
12h (mitotic block). Cells were harvested in mitotic phase by shaking, after light 
trypsinization The rest of the cells were also harvested. They were centrifuged for 10 min 
at 1000 rpm. The supernatant was removed, and cell pellets resuspended. Gently add 75 
mM KCl (37°C) for hypotonic treatment. Incubate for  10 min in 37°C water bath. 
Centrifuge 10 min at 1000 rpm. Remove supernatant, leave about 1 ml, resuspend pellet. 
Add 2 ml fixative (ethanol/acetic acid 3 : 1; 150ml = 111ml EtOH + 37ml AcA), mix well 
and gently. Add fixative until 10 ml, mix meanwhile. Repeat the pellet is white. Remove 
fixative until about 1ml final volume. Resuspend pellet and apply suspension on clean 
slides stored at 4°C in 50% EtOH. 
For 3D FISH on interphase cells. Cells were grown for 3 days on coverslips in DMEM 
without phenol red, containing 5% charcoalstripped FCS, before addition of 10 nM or 100 
nM E2 for the indicated times. Coverslips were washed twice with PBS, fixed in 4% 
paraformaldehyde (pFA)/PBS for 10 min at room temperature and during the last minute 
200 ml of 0.5% Triton X-100/PBS were added into 500 ml of 4% PFA. After fixation, the 
cells were washed three-times for 3 min in 0.01% Triton X-100/PBS, incubated in 0.5% 
Triton X-100/PBS for 10 min at room temperature and then incubated with 0.1 mg/ml 
RNase in 2xSSC for 1 hour at 37°C. After 3 washes o f 10 min in PBS, cells were 
incubated in 0.1 M HCl for 5 min at room temperature, twice in 2xSSC for 3 min and then 
equilibrated overnight in 50% formamide/2xSSC (pH =7.2). 
DNA from BAC clones which include p21(RZPDB737B0916) and ESR1 (RP11-450E24) 
were labeled using nick translation (BioPrime DNA Labeling System, Invitrogen) by 
incorporation of fluorochrome-conjugated nucleotides ChromaTide AlexaFluor 488-5-
dUTP (Molecular Probes). Chromosome paints (chromosome 6) was obtained from 
Genetix Ltd., UK. We used 100 ng labeled DNA probe or 100 ng chromosome paint 
together with 7 mg Cot-1 DNA and 5 mg sonicated salmon sperm DNA per slide. 
 
X. Discussion and outlook. 
Biological complexity and variability is key to all evolutionary processes. Control of gene 
expression that underlies this complexity is tissue, cell or, even, gene dependent. If on the 
one side this constitutes the beauty of research, on the other side it represents a problem. 
Indeed, new findings cannot be generalized to all genes in a complex multicellular 
organism. It is thus necessary to select specific model genes and choose the appropriate 
cellular models to define molecular mechanisms regulating gene expression and to gain 
insight into functional pathways.  
We focus our interest, in particular, on epigenetic mechanisms. The cellular epigenetic 
pattern is like an “identity card” for the cell. Epigenetic mechanisms are involved in all 
“normal” cellular processes (cell cycle, cell division, transcription etc. etc.). At the same 
time, epigenetics can be involved in pathological situations, such as cancer, hyper-
proliferation, or drug resistances. Finally, epigenetics are involved, especially, in control 
and regulation of gene expression. In this case, the epigenetic programs represent a sort 
of “cellular memory”, a heritage that characterizes cell types, tissues, cancers etc.  
A case-by-case study of the biological mechanisms as well as epigenetic involvement in 
transcriptional gene regulation is important. In this manner, we respect the rudiments of 
biological investigation: understand the complexity and try to address it in our favor if it is 
possible. All our studies were performed keeping this idea in mind. In addition to our aim 
to define generally applicable mechanisms, we keep in mind that each gene (for example) 
is different and may, in a particular environment or condition, have different mechanisms 
of control.  
One of the most intriguing epigenetic mechanisms is to modulate chromatin structure by 
exchanging canonical histones with histones variants. Several studies show the 
involvement of specific histones variants in particular cellular processes. Among the 
plethora of the discovered and studied histone variants, we are interested in clarifying role 
of the histone variant H2A.Z in transcriptional gene regulation. We choose to use human 
breast cancer cell lines as a model. In fact, studying the activation of ER target genes, 
we are able to investigate both early and late processes of transcriptional activation. 
Moreover, we know that different breast cancer cell types have different epigenetic 
characteristics. In particular, there are some interesting differences between ER-positive 
and negative cells. ER-negative cells are more proliferative and aggressive due to 
“special” epigenetic patterns. Therefore, in these cell lines, epigenetic programs play a 
critical role for gene expression, activation and repression.  
 
We have shown that both the presence and the acetylation of H2A.Z are important for 
gene activation. Acetylation of H2A.Z seems to be truly critical for transcriptional gene 
regulation more than its presence. Treatment of ER-negative cells MDA-MB231 with TSA 
activates p21 expression. Interestingly H2A.Z depletion prevented TSA activation of p21. 
Looking at the H2A.Z acetylation on the p21 starting site, we show that it increases after 
TSA treatments leading to p21 activation. Depleting H2A.Z and its possibility to be 
acetylated, impairs p21 activation. Therefore, the critical element for p21 activation is 
H2A.Z acetylation more than its presence or not. 
Our findings are not the first that give due importance to H2A.Z acetylation and its 
involvement in gene expression. Several studies show that acetylated H2A.Z is present on 
gene promoters and represent a mark for gene activation, both in yeast and mammalian 
cells (Bruce, Myers et al. 2005; Millar, Xu et al. 2006). 
We still have to elucidate by which mechanisms H2A.Z interacting with the p21 promoter 
can be acetylated. In general, a good candidate for H2A.Z acetylation is the 
acetyltransferase Tip60 (Dalvai, Bellucci et al. 2012). However, this factor is not 
responsible for modification of H2A.Z on the p21 promoter. Likely, histone-modifying 
complexes are specific to various pathways and cells. In MDA-MB231, the activation 
HDACi dependent of p21 involving H2A.Z acetylation, did not require Tip60, but involved a 
strong recruitment of the HAT p300 to the p21 promoter accompanied p21 expression. 
P300 has been found to regulate p21 via promoter acetylation in other cellular contexts 
(Billon, Carlisi et al. 1999). 
Based on our results, we think that H2A.Z is involved in gene activation in different 
manners depending of observed gene, pathway, mechanism or cell type. We think, also, 
that the complexes (such as acetyltransferases) involved depend on cellular context. It 
was shown that Tip60 and p400 play an antagonistic role during p21 activation. Tyteca et 
al. showed that Tip60 participates in p21 activation through the stimulation of p53 DNA 
binding activity. In contrast, p400 represses p21 expression (Tyteca, Vandromme et al. 
2006). So, our cellular context being p53-negative, it is not surprising if p21 activation is 
Tip60 independent. At the same time, we find that p400 remains a negative factor for p21 
expression. It is highly enriched on the p21 promoter. p400 binding is reduced upon p21 
activation via HDACi treatments. We can thus speculate that modulation of the factors 
involved in gene regulation, also for the same gene, depends on cellular context and is 
the key during evolution and adaptation. 
Some proof for this may come from our other work. When we changed the gene, in the 
same cell type, the same complexes changed their role and behavior. We demonstrate 
that in MDA-MB231 H2A.Z, its acetylated form and Tip60 are critical for CCND1 gene 
expression (Dalvai, Bellucci et al. 2012). Moreover, we show that an H2A.Z-dependent 
 	
short-range loop exists between the transcription starting site and 3’ enhancer sequence. 
This loop correlates with downregulation of CCND1 expression. Unlike what was shown 
for p21, the depletion of H2A.Z leads to CCND1 expression accompanied by an increase 
of its acetylated form bound to the promoter. Acetylation of H2A.Z is, one more time, the 
fundamental mark for gene activation. Moreover, inducing CCND1 expression by TSA, we 
show that H2A.Z acetylation increases and Tip60 is the HAT involved in this process. In 
fact, depletion of Tip60 compromises the TSA-mediated CCND1 activation. It is the first 
time that we have evidence for a role of Tip60 in transcriptional activation of the CCND1 
oncogene in ER-negative breast cancer cells. Interestingly, H2A.Z is present both at the 
transcriptional starting site and the 3’ enhancer. Increase in H2A.Z acetylation is observed 
at both gene positions upon CCND1 activation by TSA.  
But the most interesting finding is the presence of a short-range loop that negatively 
controls CCND1 expression in MDA-MB231 cells. Long range interactions between 
distant enhancers and promoters regions via chromatin looping have been shown to allow 
single gene and gene cluster activation. This has been shown for example for Myb proto-
oncogene transcription (Stadhouders, Thongjuea et al. 2012) and for the beta-globin locus 
(Tolhuis, Palstra et al. 2002). The looping, in these cases, occurs in the 5’ part of genes 
and over tens or hundreds of kb. The role of these loops is to isolate a chromatin portion 
from surrounding repressive environment (Vogelmann, Valeri et al. 2011). RNA pol II 
seems to be involved in loop formation and maintenance. In fact, another role for 
chromatin loops might be to “help” the RNA pol II to recycle, converting it from the 
elongation form into initiation form and delivering it back to the promoter (Kadauke and 
Blobel 2009). In contrast, the short-range loop observed for CCND1 gene has a 
repressive role. Upon activation, the loop is open, H2A.Z is acetylated by Tip60 and the 
gene can be transcribed. We think that in this case the chromatin loop has a different role. 
We hypothesize that this type of loop helps chromatin compaction but at the same time, 
allows the possibility to activate rapidly gene transcription. This possibility is ensured by 
H2A.Z recruitment to regulatory regions including promoter and enhancer. Previous model 
have shown that H2A.Z containing nucleosomes are more labile and that H2A.Z eviction 
promotes chromatin accessibility (Jin, Zang et al. 2009). 
Interestingly, this process seems to be fundamental to the acetylation of H2A.Z. H2A.Z 
acetylation is the only histone modification that increases (acetylation of the other histones 
remains low and stable) after gene activation in 3’ enhancer region, suggesting that this 
modification specifically regulates 3D organization of genetic loci. 
In a recent study, we use MCF-7 ER-positive cells to investigate the mechanisms that 
characterize the early steps of gene activation. In these cells, CCND1 expression is 
 

estradiol-dependent. The events involved in E2 induction of CCND1 include dynamic 
exchange of a series of cofactors, namely the Tip48 complex and the histone variant 
H2A.Z, Tip60 recruitment and H2A.Z acetylation enabling ER to associate with its target 
sequences. Tip60 can directly interact with ER and its acetyltransferase activity is 
important during transcription initiation once ER binds to the promoters of target genes 
(Jeong, Kim et al. 2011). 
We show that for CCND1 activation in MCF-7, the eviction of H2A.Z performed by Tip48 
(AAA+ family member) as a prerequisite for the ER binding in presence of hormone. 
Tip48 promotes acetylation and exchange of H2A.Z, which triggers the opening of the 
loop between TSS and 3’ enhancer region. This release enables the estrogen receptor to 
bind to the CCND1 promoter. Removal of H2A.Z from CCND1 regulatory elements is 
accompanied by Tip60 recruitment and the change in the ratio of acetylated H2A.Z / total 
H2A.Z. Increase of acetylated H2A.Z amount correlates with transcriptional activation in 
ER-positive breast cancer cells. Looking at the early steps that characterize hormonal 
activation of CCND1 gene, we show that these events depend on Tip48 and H2A.Z 
specific nucleosome conformation. In fact, H2A.Z eviction, acetylation (by Tip60) and the 
loop release depend on Tip48 chromatin remodeling factor and prepare chromatin for the 
estrogen receptor binding. 
All our studies demonstrate that the histone variant H2A.Z has a central role in gene 
regulation. In particular, its acetylation seems to play a fundamental role for gene 
activation. For a long time, several studies focused exclusively on the presence or not of 
this variant. We are first to uncover the importance of the acetylation of H2A.Z. 
Each time that we stimulate gene transcription with HDACi, as in the case of p21 or 
CCND1 in MDA-MB231 cells, or with E2, as in the case of CCND1 in MFC-7 cells, the 
modification that characterizes this activation, is the increase in H2A.Z acetylation. This 
evidence paves the way for different outlooks. 
Our observations are very significant for several reasons. We show an alternative and 
p53-independent pathway to activate p21 in ER-negative breast cancer cells. These cells 
represent a more aggressive and hyper-proliferative tumor. This tumor type is a problem 
because it escapes hormonal therapies. We show that HDACi treatments induce p21 
expression, leading to proliferation arrest, and this activation depends on H2A.Z 
acetylation. This suggests that H2A.Z could have a critical role in tumor aggressiveness. 
In the absence of the possibility to acetylate H2A.Z, we can lose the possibility to activate 
p21 and to stop cell proliferation. The evidence that the increase of H2A.Z acetylation is a 
mark for gene activation opens new potential strategies to arrest cell proliferation, in some 
specific cases, such as breast cancer.  
 
It will be interesting understand how H2A.Z acetylation can recruit the complexes 
necessary to start transcription. Is the acetylation of H2A.Z a specific signal to recruit RNA 
pol II to gene promoters? We could address this question using in vitro studies, which 
allow to create a system with a “constitutively” acetylated form of H2A.Z to understand the 
impact on transcriptional gene control. The same study in vivo is nearly impossible. 
Introducing a constitutively acetylated form of H2A.Z induces genome-wide alteration and 
may change the normal cellular physiology. 
Our studies open new avenues for understanding chromatin organization and its 
impact on the control of gene expression. The existence of a short-range loop that 
represses gene transcription is an exciting finding. We initiated studies to analyze the 
chromatin organization by microscopy in fixed and living cells. We can use FISH 
(Fluorescent In Situ Hybridization) to test loop presence in different conditions. Using two 
probes to visualize the extremities of an expected loop, we are able to see the opening or 
not of the loop in a transcriptional activity dependent manner. In particular, in the case of 
the CCND1 gene, if we use two probes recognizing TSS and 3’ enhancer sequence, we 
can visualize the presence of the loop and its opening after CCND1 activation. The same 
strategy can be used for other genes too, for example, for the estrogen receptor target 
genes. In the future, we would like to perform the similar approaches in living cells using a 
recently implemented and patented chromosome labeling technique (WO/2012/127047). 
In this manner, we could observe loop dynamic step by step during gene activation. 
Moreover, we can use shorter probes. Indeed, small-range loops are difficult to visualize 
using classical FISH probes. Classical probes are long sequences but the sequences 
involved in loop formation are short. Using these probes some problems during spots 
analysis arise due to microscopy resolution. To prevent these problems we can use 
shorter probes, such as fosmide probes, to have more precise signals easier to visualize 
and analyze.  
The role of H2A.Z and cofactors involved in H2A.Z exchange and modification are cell- 
and gene-dependent.  Our findings open new research fields of investigation to 
increase our understanding of breast cancer biology, but also of epigenetic 
mechanisms in general. Our aim is to refine models that approach reality more and 
more, keeping in mind that we will never be able to have all the answers. The “tension” to 
find one answer is enough.  
 
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